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ABSTRACT  
MTMR2 is an active member of the MTM family of inositol lipid phosphatases 
and the physiological substrates for MTMR2 play key roles in endosomal trafficking.  
Additionally, loss of function mutations in MTMR2, have been associated with the 
peripheral neuromuscular disorder CMT4B1.   
In these studies we used mass spectrometry (MS) based methods to identify a 
novel high stoichiometry phosphorylation site at Ser
58
 on MTMR2.  Further analysis has 
illustrated that a phosphorylation deficient MTMR2 (S58A) displayed constitutive 
localization to early endocytic structures.  Moreover, we determined that the subcellular 
targeting of S58A was accompanied by depletion of PI(3)P and an increase in the 
phosphorylation of ERK1/2.  Recently we have used in vitro kinase assays to determine 
that ERK1/2 phosphorylates Ser
58
.  Furthermore, we have recently confirmed a C-
terminal phosphorylation site at Ser
631
 and generated combinatorial mutants which have 
shown to display characteristic localization to a distinct subset of endocytic 
compartments as well as sustained ERK1/2 activation.  
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CHAPTER 1- LITERATURE REVIEW 
 
1.1 Cellular Protein Phosphorylation 
Protein phosphorylation is a critical protein post-translational modification (PTM) 
employed by numerous living systems and has long be viewed as a critical component 
underlying most physiologic processes [1].  Reversible phosphorylation is an integral part 
of all living systems and regulates nearly all aspects of cellular life [2].  Identification of 
protein phosphorylation sites has been extensively studied utilizing complex and unique 
biochemical approaches including in vivo [
32
P] radiolabeling, phosphoamino acid 
analysis, phosphopeptide mapping and MS [3].  Recent technological advances have 
made feasible the detection and quantitation of protein phosphorylation on a widespread 
global scale combining stable isotope labeling by amino acids in cell culture (SILAC), 
strong-cation exchange (SCX) and titanium dioxide chromatography (TiO2) all coupled 
with multistage MS [5].   
Phosphorylation can be a reversible process and primarily occurs on the hydroxyl 
group of threonine, serine and/or tyrosine residues and has been shown to be critical for 
regulating protein function (figure 1) [4].  The reaction is catalyzed by a highly conserved 
family of enzymes called protein kinases which are classified into three major categories 
based on the residue they modify (Ser/Thr, Tyr and dual specific).  The reverse process is 
catalyzed by protein phosphatases in antagonistic actions [3].  It is estimated that there 
are more than 1000 kinases and 500 phosphatases in the human genome, with the Protein 
tyrosine phosphatase (PTP) domain being present in over 100 different proteins [5,6].  It 
is estimated that 3-4% of genes in eukaryotes encode for members of the protein kinase 
family, and that one-third of all proteins contain a covalently attached phosphate group 
 2 
[7,8].  Nearly 30% of all existent proteins are phosphorylated at any given time and 
overall, the readily available amount of ATP in eukaryotic systems has deemed reversible 
phosphorylation as the most general regulatory mechanism in living systems [2].  
Modifications of target protein substrates can increase or decrease enzymatic activities, 
control movement between different subcellular compartments, alter protein-protein 
interactions or affect protein stability [2].   
The addition of a phosphate group to a side chain of a protein is adding two negative 
charges, which can change the characteristics of the protein.  Most commonly, these 
changes are conformational resulting from attractive or repulsive forces [4].  Electrostatic 
interactions can be stabilizing through interaction with positively charged amino acid side 
chain groups, or destabilizing if with negatively charged amino acid groups.  These types 
of interactions are of way of regulating the enzyme in such a way that the enzyme may be 
active in one conformation and inactive in another.  Aberrant and abnormal protein 
phosphorylation has been linked to a number of cancers and human disease implicating 
this as a critical control mechanism that is tightly regulated. 
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Figure 1. Cellular Protein Phosphorylation  
 
Protein kinases facilitate the addition of the gamma phosphate moiety from ATP onto the 
hydroxyl group of Ser/Thr or Tyr residues of the target substrates releasing ADP and 
generating a phosphorylated protein.  The reverse process is catalyzed by protein 
phosphatases that remove the phosphate group releasing inorganic phosphate and 
regenerating the original protein. [figure from reference 4]   
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1.2 Protein Tyrosine Phosphatases 
The Protein Tyrosine Phosphatases (PTPs) are a large group of enzymes whose 
active-site catalytic consensus sequence D...HCX5RS/T is conserved throughout 
evolution from unicellular to multicellular species ranging from yeast-/mouse to human 
[9].  Stringent preservation of this characteristic phosphate binding loop (P-loop) suggests 
that all PTP family members dephosphorylate their targets by a similar catalytic 
mechanism (figure 2).  The nearby Arg (R) residue stabilizes the net negative charge of 
the phosphate group on the target protein shielding it in order for entrance into the active 
site pocket of the enzyme. The invariant Cys (C) residue is critical for PTPase activity 
and performs the nucleophilic attack on the phosphate group of the substrate, resulting in 
the formation of a phospho-enzyme intermediate.  Studies with site-directed mutagenesis 
reveals mutation to a Ser results in complete loss of catalytic activity of the enzyme 
[10,11].  The catalytic acid/base (usually an invariant Asp residue) is located within an 
outer loop of the enzyme that donates a proton to hydrolyze the phosphoprotein substrate 
and release the dephosphorylated target protein, and mutations of this residue results in 
dramatic decrease in enzymatic activity [10].  The same Asp residue now functions also 
as the catalytic base removing a proton from an incoming water molecule thereby 
allowing for nucleophilic attack onto the phospho-enzyme intermediate.  This action 
triggers regeneration of the original enzyme and release of inorganic phosphate for 
utilization and re-incorporation for subsequent ATP generation.   
Protein kinases and protein phosphatases regulate the equal balance between 
protein phosphorylation and dephosphorylation through antagonistic action in order to 
mediate the appropriate duration of signaling throughout living systems.  Protein 
phosphatases remove a phosphate group most commonly from a serine, threonine or 
 5 
tyrosine residue and are classified based on recognition sequences, substrate specificity 
and mechanism of action.  The PTP family is composed of three main classes which are 
further subdivided into smaller families according specifically to their target substrates 
(figure 3): Class I; the classical transmembrane-receptor like tyrosine-specific 
phosphatases (RPTPs), the intracellular-non-receptor tyrosine-specific phosphatase 
(NRPTPs) and the VH1-like DSPs (the Tyr-Ser/Thr dual specificity phosphatases (DSP-
PTP), Class II; the low Mr PTPs (LMPTP) and Class III; the cell division cycle 25 
phosphatases (CDC25) [12].   
The Class I PTPs are the largest family of cysteine-dependent phosphatases based 
on domain architecture and sequence homology between their catalytic domains. They 
are further divided into several subfamilies constituting the most divergent group with 
respect to substrate preference and are represented in the human genome by 38 different 
genes [12].    The VH1-like DSPs were named and sub classed according to their 
sequence homology and structural similarity to the yeast vaccinia virus gene VH1 
encoding the classical DSP [12,13].  Unlike the classical PTPs which solely 
dephosphorylate phosphotyrosine residue from their substrates, the DSPs can act to both 
dephosphorylate phosphoserine and/or phosphotyrosine residues [12].  The extensive 
variations for broad target substrates amongst this group is proposed to be a result of 
additional targeting domains and motifs acquired throughout evolution in order to 
increase rigidity to this regulation as well as they may harbour differences in the depth of 
their active clefts. 
The Class II PTPs is the LMPTPs and is represented in the human genome by a 
single gene, ACP1 [12].  This protein in humans functions as an acid phosphatase and can 
 6 
dephosphorylate several autophosphorylated tyrosine kinases and their substrates in 
addition to protein tyrosine to orthophosphate [12].  The particular regulatory function of 
these PTPs remains unclear, however conservation throughout evolution from bacterial to 
human indicates a critical regulatory function. Markedly, many LMPTP variants have 
been shown to be common in human diseases including rheumatoid arthritis and 
Alzheimer‟s disease implicating their fundamental role in a number of biological 
mechanisms [12].  The Class III PTP is comprised of three cell cycle regulators that 
function to dephosphorylate cyclin-dependent kinases (CDKs) at their Thr-Tyr dually 
phosphorylated motifs thereby resulting in activation and further progression through the 
cell cycle [12].  Presumably, the CDC25 group evolved in conjunction with the 
regulation of CDKs by tyrosine phosphorylation [12].  The Asp-based PTPs are encoded 
by the Eyes absent (Eya) phosphatases that have only recently been explored in upper 
eukaryotic systems in which the phosphatase activity towards phospho-Tyr/Ser residues 
has been shown to be required for regulating genes that encode growth control and 
signaling molecules [12,14].  However the human compliment to these Asp-based PTPs 
has not yet been identified, therefore an accurately based definition and functionality to 
this unique subgroup of PTPs remains to be elucidated.  
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Figure 2. The Mechanism of Dephosphorylation by Protein Tyrosine Phosphatases  
The mechanism of dephosphorylation by PTPs is a two step process that first requires a 
nucleophilic attack by the active-site cysteine onto the electron-deficient center of the 
phosphoprotein substrate generating a thiol-phosphate intermediate. Donation of a proton 
from the catalytic aspartic acid neutralizes the negatively charged oxygen and results in 
release of the dephosphorylated substrate.  The same aspartic residue then acts as a base 
catalyst to remove a proton from an incoming water molecule resulting in nucleophilic 
attack onto the phosphoenzyme intermediate.  This causes release of inorganic phosphate 
and regeneration of the original enzyme and its phosphatase active site.  Throughout this 
mechanism, a nearby arginine residue stabilizes and shields the negative charges of the 
phosphate allowing the substrate to enter into the active site of the enzyme.  The serine 
residue stabilizes the nucleophilic thiolate ion of the catalytic cysteine to lower its pKa 
for increased attack onto the phosphate group of the target substrate.  Additionally, there 
is a nearby Glutamate residue that aids in proper positioning of the incoming water 
molecule. [figure from reference 47]   
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Figure 3. The Classification of Protein Tyrosine Phosphatases 
The protein tyrosine phosphatases can be classified into three major categories: the Class 
I PTPs comprising the classical tyrosine specific PTPs and the VH1-like DSPs which 
make up the largest PTP subfamily, the Class II PTPs harbouring the LMPTP, and the 
Class III PTPs containing the CDC25s.  Within the DPSs is a relatively large family of 
phosphoinositide lipid phosphatases the MTMs, who unlike characteristic PTPs utilize 
lipid substrate rather than phosphoproteins.  Amongst this category is MTMR2 that 
utilizes mainly PI(3)P as its physiological substrate, and is highly important as mutations 
result in CMT-4B1. [figure from reference 42]    
 
 9 
1.3 The Myotubularin Family of Inositol Lipid Phosphatases 
 The Myotubularin (MTM) family of inositol lipid phosphatases is the largest 
superfamily of PTPs that is comprised of 14 members, eight of which are active and 
contain the putative catalytic consensus sequence CSDGWDR and six which are inactive 
and classified as the pseudophosphatases containing mutations within this highly 
conserved catalytic sequence (figure 4) [15].  Myotubularins are ubiquitously expressed 
containing highly conserved protein domains amongst all active/inactive members and 
most have been conserved throughout evolution.  All eukaryotes organisms contain MTM 
and related members, with only 2 active MTMs to date found in the flower plant 
Arabidopsis thaliana, 4 related members in Caenorhabditis elegans (3 active/1 inactive) 
and 1 sole active MTM in Saccharomyces cerevisiae, however no homologues are 
present in prokaryotes and the inactive members are absent in plants [16,17,18].  To date 
it has been proposed that the evolution of the MTMRs occurred at some point and time in 
vertebrates because orthologues are present in distant vertebrate species such as the 
zebrafish in addition to some members of the fungus kingdom [16].  However, there is no 
evolutionary history or answers at present, to explain how the inactive members evolved 
and whether they originated from a single inactive ancestor or as a result of archaic 
intermittent mutational events in higher organisms as a means for implementing striker 
biological regulation of their active counterparts [16].   
 Mutations in two active MTMs (MTM1 and MTMR2) and 1 inactive member 
(MTMR13) have been linked to distinct human disease including x-linked myotubular 
Myopathy (MTM1), CMT4B1 (MTMR2) and CMT4B2 (MTMR13) (figure 5). X-linked 
Myotubular Myopathy (XLMTM) is caused by large deletions and point mutations in the 
MTM1 gene most resulting in severe decrease/loss of catalytic activity and a non-
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functional protein (figure 6). Characteristic clinical features and genetic screenings are 
the primary means by which this disease is diagnosed.  Charcot-Marie Tooth disease 
(CMT) type 4B1 and 4B2 (CMT4B1-CMT4B2) are caused by mutations in the MTMR2 
and MTMR13 genes respectively (figure 6).  Similar to XLMTM, point mutations in 
MTMR2 yield a non-functional protein and diagnosis is done by utilizing NCV tests and 
genetic screenings in addition to clinical features.  CMT4B2 is unique in that the disease 
causing protein is already inactive therefore, considering the similarity in clinical features 
to CM4B1; diagnosis is confirmed by NCV tests and genetic screenings.  It is proposed 
that mutations result in the inability of MTMR13 to effectively regulate MTMR2 as 
mutations result in a truncated protein lacking important interaction motifs [19].  
Moreover, this is the first human disease that has been shown to be caused by mutations 
in an inactive phosphatase thereby implicating the importance of the inactive MTM 
members [19].  Considering that MTMR13 loss of function mutations cannot be 
complimented or rescued by MTMR5 and that early onset glaucoma is a highlighted 
distinctive feature from CMT4B2 suggests a potential role in the visual system [19].  
Collectively, the linkage of MTM mutations to human disorders will only fully be 
understood once the specific roles of these proteins are elucidated.        
All MTMs members contain four of the following highly conserved domains: an 
RID (Rac-induced recruitment domain), an N-terminal PH-GRAM (Pleckstrin 
Homology-Glucosyl transferases, Rab-like GTPase activators and Myotubularins) 
domain, a central phosphatase domain (PTP/DSP), an SID (SET-interacting domain) 
[15,16].  Some members additionally contain predicted C-terminal coiled-coil  (CC) 
regions [15,16].  The RID domain has previously been reported to be important for the 
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recruitment of MTM members to the plasma membrane and potentially represents the 
region that mediates protein-protein interactions among specified homologue members 
(i.e. MTMR2 with NF-L) [16].  The PH-GRAM domain is proposed to be the site of 
allosteric activation by PI(5)P in a positive feedback loop, in addition to playing a role in 
mediating correct protein-protein and protein-lipid interactions [15].  A number of 
disease-causing mutations are located within the PH-GRAM domains and it has been 
proposed to be a result of reduced responsiveness to activation and disruption of 
subcellular translocation to the site where the substrates reside.  The phosphatase domain 
contains the active catalytic sequence CSDGWDR (CX5R) which forms a P-loop at the 
base of the substrate binding pocket and is much larger than classical PTPs in order to 
accommodate the large hydrophilic lipid substrates.  Classical PTPs contain an additional 
WPD loop near their active site, which is absent in MTMs [15].  In 2003, Bergley et.al 
[20] proposed that the additional Asp acid within the P-loop, likely contributes to the 
general acid-base catalytic step in substrate dephosphorylation in order to accommodate 
for absence of the WPD loop. The SID domain has methyltransferase activity and is 
composed of amphipatic helices and was initially proposed to be the region mediating 
heterodimerization with inactive partners [16].  The PDZ-binding motif is present in 
several active and inactive MTMs and has been suggested to be important in governing 
protein-protein interactions with other PDZ containing proteins that are involved in 
transmembrane anchoring and signaling [21].  Considering the evidence that most MTM 
members are cytosolic proteins, there have been reports of nuclear localization in a minor 
number of studies.  However there has been no evidence to date indicating that MTMs 
play roles in transcription or anywhere in the nucleus for that matter.  In 2001, Firestein 
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et.al [22] discovered that deletion of MTMR5 DENN domain resulted in nuclear 
translocalization and attainment of transforming properties.  Therefore, it can be 
proposed that MTMs could potentially play a role in chromatin remodelling as a result of 
their particular nuclear subcellular localization under specific cellular conditions.  The 
CC region has been identified in effectively mediating interactions with the inactive 
partners which has been shown to largely enhance enzymatic activity (Kim et.al 2003 
[19]), in addition to mediating self-association to form homodimers [15].  
 The exact role of MTMs is very discrete and to date only proposed mechanisms of 
involvement in the endocytic pathway have been developed.  MTMs substrate lipids are 
key secondary signaling molecules and accumulate to identify specific organelle 
compartments.  It has been suggested that the role of MTMs is to co-ordinately maintain 
the precise concentrations of lipids at the correct subcellular compartment [15,20,23].  
Most MTMs are not found on endosomal structures under native conditions and are often 
cytosolic, however  Laporte et.al (2002) have shown partial association of select MTMs 
with plasma membrane ruffles and occasionally the golgi complex [23].  Tsujita et.al. 
have reported that EGF stimulation results in translocation of MTMR2 to EGFR 
containing endosomes resulting in the blockade of receptor degradation at the late 
endosomes [24].  In addition, Berger et.al have shown MTMR2 to translocate to vacuolar 
structures following hypoosmotic shock [25].  Therefore, there must be some mechanism 
that governs the strict regulation in order to target these phosphatases to the sites where 
their substrates reside.   
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Figure 4. The Myotubularin family and conserved protein domains 
Depicted are scaled representations of conserved domains amongst human MTM family 
members.  All members both active and inactive contain a PH-GRAM domain, an RID 
domain, a PTP/DSP phosphatase homology domain even amongst inactive members, and 
a SID domain.  The C-terminal coiled-coil domain is present in nearly all members with 
some additionally displaying a distant PDZ-binding motif. The catalytically active MTMs 
all contain the putative catalytic consensus sequence VHCSDGWDRT with divergent 
amino acids in the inactive members highlighted in red. [figure from reference 16] 
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Figure 5. The Myotubularin family of phosphoinositide phosphatases and family 
members with linked genetic mutation and corresponding human diseases  
The Myotubularin family is a large subfamily of the PTPs and in the human genome is 
composed of 14 members; 8 of which are catalytically active and 6 which bear mutations 
in their catalytic domain rendering them inactive.  Homologues containing the conserved 
domains are found amongst all eukaryotes.  Mutations in MTM1 result in X-linked 
myotubular Myopathy, germline mutations in MTMR2 results in CMT4B1, and 
MTMR13 in CMT4B2. [figure from reference 33] 
 
 
 
 15 
Protein Disease Genetic Mutations Clinical Features 
MTM1
1
 
Active 
X-linked Myotubular 
Myopathy 
(XLMTM) 
 
-200 point mutations  
(3 large deletions) 
 
- 26% are within completely 
conserved domains 
 
E17X, R24X, R37X, 
K47del, fs48, R69C, 
L70F, L87P, fs100, 
fs133, L154X, 
N189S, fs198, 
P205L, fs217, 
R222X, R224X, 
S229P, R241C, 
S376N, G378R, 
Y397C, G402A, 
420insFIQ, R421Q, 
D431, D433N, 
H469P, R474X  etc.. 
-Congenital myopathy 
-Hypotrophic myofibres 
with central nuclei 
-Infancy/early childhood 
-Death in infancy 
common 
-Not progressive 
-Hypotonia and muscle 
weakness 
-Respiratory difficulties 
-Usually require aid with 
a ventilator 
MTMR2
2
 
Active 
CMT4B1 
 
- 5 point mutations 
(1 large deletion) 
 
-autosomal recessive 
G103E, E276Q, 
R283W, Q426X, , 
E482X, F494-
E531del , Y579fs 
-Degeneration of the 
peripheral nerves 
-Reduced NCV (<40m/s) 
-Myelin outfoldings 
-Early onset with 
progressive distal 
weakness and sensory 
loss in outer extremities 
-Muscle atrophy, Pev 
cavus 
MTMR13
3
 
Inactive 
CMT4B2 
 
2missense 
(1 small deletion) 
 
-autosomal recessive 
Q956Stop, 
R1196stop, L351-
E432del 
- Similar characteristic 
features as CMT4B1  
- Optic atrophy 
- Early onset glaucoma  
del: deletion, fs: frameshift, ins: insert, NCV: nerve conduction velocities 
*Mutations underlined are severe and within conserved domains 
 
Figure 6. Mutations in myotubularins and genetic diseases 
The Myotubularin family is a subgroup of the classical PTPs and is composed of lipid 
phosphatases of which 14 members have been identified in humans, and three of which 
when mutated results in human genetic diseases.  Point mutations are predominant and 
primarily result in a non-functional protein or truncations that are both due to mutations 
within highly conserved domains.  Distinctive characteristic features and genetic 
screening aid in defining and differentiated between these diseases.       
                                                          
1
 MTM1 mutations: Laporte et.al. Human mutation.15:393-409(2000), Laporte et.al. Human molecular 
genetics.6;9:1505-1511(1997). MTM1 genecard  
2
 Houlden et.al. Brain.124;5:907-915(2001), Bolino.et.al.JBC.167;4:711-721(2004). MTMR2 genecard. 
3
 MTMR13 mutations: Robinson.et.al.JBC.280;36:31699-31717(2005),Robinson.et.al PNAS.105:12;4916-
4921(2008). MTMR13/Sbf2 genecard. 
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1.3.1 Myotubularin-Related Protein 2 
 Myotubularin-Related protein 2 (MTMR2) is a 73kDa catalytically active 
member of the large family of MTM lipid phosphatases.  It is ubiquitously expressed in 
vivo in myelin forming and non-myelin forming Schwann cells with high preferential 
expression at the onset of myelination [15,21].  Additionally, it is found in Schwann cell 
axons and is abundantly expressed in neurons of the peripheral nervous system [15,21].  
It is only slightly active on proteins in vitro and its main substrates are PI(3)P in vivo and 
PI(3,5)P2 in vitro where both are dephosphorylated at the D3 position of the inositol ring 
[15].  Canhong et.al. have shown that abolishment in MTMR2 phosphatase activity 
results in elevation of cellular PI(3)P levels [26].  Phosphatase activity is enhanced by 
association with inactive members MTMR5 and MTMR13, the later of which when 
mutated results in CMT4B2, a disease highly resembling CMT4B1 [15].  The particular 
role of interactions with these pseudophosphatases remains unclear, however the 
excessive large nature of these inactive proteins implicates that they could serve as 
molecular scaffolds or interaction modules [19,23].   
Many active members have been shown to associate in a hetero-oligomerization 
fashion with these inactive members, suggesting that they may be important in regulating 
subcellular localization and activity [18].  Recently, MTMR2 has been found to interact 
with neurofilament light (NF-L) chain in the peripheral nerves and post synaptic density 
protein-95 (PSD-95) in central neurons the former of which is important in intermediate 
filament (IF) assembly, and the later in membrane remodelling during myelination 
[24,25,28].  Also, Bolis et.al have identified that MTMR2 specifically interacts with Disk 
large 1 (Dlg1; also known as synapse-associated protein 97 (SAP97) in Schwann cells 
and negatively regulates membrane formation [25]. Disruption in this interaction results 
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in altered Dlg1 localization [25].  Loss of negative control in membrane addition due to 
impaired Dlg1 localization, results in the generation of myelin outfoldings at Schwann 
cell paranodes suggesting relevancy of this interaction to CMT4B1 pathogenesis [25]. 
 MTMR2 contains two important phosphorylation sites both with similar Proline-
directed protein kinase (PDPK) recognition sequences located at N-terminal Ser
58
 (SP) 
and C-terminal Ser
631
 (SSP) (figure 7). These sites are highly conserved throughout 
evolution yet intriguingly, neither the kinase(s) nor phosphatase(s) have been identified 
(figure 8.A,B).  Importantly to note that there are sequence variances amongst the Ser
58
 
phosphorylation site between MTMR2 and MTMR1 the later lacking the MAPK 
recognition site (S/T-P), yet the C-terminal region is highly conserved even amongst 
distant orthologues including the carpenter ant.  Additionally, multiple sequence 
alignment of the MTMR2.Ser
58
 phosphorylation site shows conservation even amongst 
the sole S.cerevisiae MTM homologue ymr1p, which has been shown to have activity 
towards PI(3)P and function in PI(3)P-dependent signaling pathways [29].  Knock-out 
models of ymr1p do not yield any definitive phenotypes, potentially due to the functional 
overlap of phosphoinositide phosphatases in yeast which allows for compensation by the 
synaptojanin-like phosphatase (Sjl3p) whereas only double knock-out models result in 
increased cellular levels of PI(3)P [29].  
The largest group of PDPKs are the mitogen-activated protein (MAP) kinases 
which recognize the optimal recognition sequence PX(S/T)P and a minimal dipeptide 
sequence motif S/T-P on non-phosphorylated proteins, making these two phosphorylation 
sites of MTMR2 potential MAPK targets [30].  The role and regulation surrounding 
phosphorylation sites for MTMR2 remain unidentified to date. It has been suggested that 
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Ser
58
 may play a role in regulating substrate targeting considering its close proximity to 
the PH-GRAM domain and Ser
631
 could be involved mediating oligomerization with 
inactive members due to the concurrence to the conserved CC region and SID domain.  In 
addition, Ser
631
 resides near the PDZ-binding motif and could potentially function as a 
protein interaction motif [31].  Multiple sequence alignment of the N-terminal 
phosphorylation sites of both MTM1 and MTMR2 show low sequence homology of Ser
58
 
in the S/T-P motif yet the Ser is highly conserved throughout multiple species, supporting 
the notion of important biological relevancy and differential regulation.  The common 
primary sequence position for both sites are in close proximity and ~11 amino acids 
upstream of the start of the PH-GRAM domain yet their actual sequences vary leading 
one to propose regulation by different protein kinases (figure 8.A).  
Furthermore, this could explain the puzzling findings that MTM1 and MTMR2 
cause distinct diseases despite their high overall sequence homology, common substrates 
and similar tissue expression pattern, which prompts the hypothesis that they utilize 
unique cellular lipid pools.  Both MTM1 and MTMR2 contain potential phosphorylation 
sites in their C-terminal regions however; MTM1 has the preferred MAPK recognition 
sequence (PSSP) whereas MTMR2 contains the minimal (SSP) (figure 8.B).  This 
suggests that they may be regulated by different MAPKs resulting in distinct subcellular 
targeting and specific cellular substrate pools.   
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Figure 7. Schematic of MTMR2 phosphorylation sites and conserved MTM domains 
 
The conserved domains amongst MTM members are depicted and represented in the 
MTMR2 protein diagram: N-terminal PH-GRAM domain, consensus CX5R catalytic 
phosphatase domain and the C-terminal CC region.  MTMR2 has two in vivo identified 
phosphorylation sites located N-terminal and in close proximity to the PH-GRAM at 
Ser
58
 and within the distant C-terminal region at Ser
631
, with both sites containing the 
minimal PDPK recognition sequence for MAPKs (S/T-P). [figure modified from 
reference 27]  
 
 
 
 
 
PH Catalytic Domain 
41
SASVVSSDSISTSADNFS
58
PDLR
62
  
404
DKVESGKTSVVVHC
417
SDGWDR
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CC SID PDZ 
622TSSSERASS631PAQCVTPVQTVV643  
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A 
MTMR2_Human    SSDSISTSADNFSPDLRVLRES--NK 
MTMR2_Sumatran Orangutan SSDSISTSADNFSPDLRVLRES--NK 
MTMR2_Bovine   SSDSISTSAENFSPDLRVLRES--NK 
MTMR2_Dog    SSDSISTSADNFSPDLRVLRES--NK 
MTMR2_Mouse    SSDSISTSADNFSPDLRVLREA--NK 
MTMR2_Rat    SSDSISTSADNFSPDLRVLRES--NK 
MTMR2_Pufferfish   SSDSVSTSTE-LSPELRVKPQAVNK 
MTMR2_Atlantic Salmon  SSDNVSTSTE-FSPELRGRPKAV--K 
MTMR1_Human    -QISGSVTSENVSRDYKALRDGNK 
MTMR1_Mouse    -QISGSVTSENVSRDYKALRDGNK 
MTM1_Human    -SKYNSHSLENESIK-RTSRDGVN-- 
MTM1_Bovine    -SKYNSHSLENESIK-RTSRDGVN-- 
MTM1_Dog     -SKYNSHSLENESIK-RTSRDGVN-- 
Ymr1p_s.cerevisiae  TTHHLIFESPQLSTE FWFP------ 
 
B 
MTMR2_Human    RSTSSSERASSPAQCVTPVQTVV 
MTMR2_Sumatran Orangutan RSTSSSERASSPAQCVTPVQTVV 
MTMR2_Bovine   RSTSSSERAGSPAQCVTPVQTVV 
MTMR2_Mouse    RSTSSSERASSPAQCVTPVQTVV 
MTMR2_Rat    RSTSSSERASSPAQCVTPVQTVV  
MTMR2_Red Junglefowl  RSTSSSERAGSPAQCVTPVQTVV 
MTMR2_Atlantic Salmon  RSASSTERAGSPTRSITPVQTFV-  
MTMR2_Zebrafish   TASSSSERAGSPTRSITPVQTFV- 
MTMR2_Carpenter Ant  ASRA-NRSVTSPAPPRIHSPVHT- 
MTMR1_Human    RSTSSSERASSPAQCVTPVQTVV 
MTMR1_Mouse    TISSSSERGSSPTHSATPVHTSV- 
MTM1_Human    KLSDPPTSPSSPSQMMPHVQTHF 
MTM1_Bovine    KLSDPSASPSSPSQMMPHVQTHF 
MTMR6_Human    NDALRTIEGSSPADNRYSEYAEE 
MTMR4_Human    SHSGRPSATSSPDGPSRSHLDDD  
Ymr1p_S.cerevisiae  -----SEKEKFQQNLPNKTKSVW 
 
Figure 8. Multiple sequence alignments of the N-terminal (Ser
58
) and C-terminal 
(Ser
631
) phosphorylation sites on MTMR2 
 
(A) Multiple sequence alignment (NCBI BLAST: Similarity and Homology) showing 
conservation of the N-terminal Ser
58
 phosphorylation site within MAPK consensus 
sequence S/T-P. This site is also conserved even amongst and including the distant 
orthologue the Atlantic salmon that has lower yet significant full length sequence identity 
(79%). Also shown is the sole S.cerevisiae MTM homologue ymr1p that displays 
conservation of Ser
58
 yet with low full length sequence identity (28%) (B) Multiple 
sequence alignment showing conservation of the C-terminal Ser
631
 phosphorylation site 
also contained within MAPK recognition sequence.  Conservation is present even 
amongst distant orthologues including the Zebrafish and Carpenter ant that have lower 
full length sequence identities (73% and 60% respectively).  Also included are MTMR6, 
MTMR4 and MTMR1 which display conservation of the C-terminal phosphorylation.  
MTM1 contains the optimal MAPK recognition sequence (PxS/T-P) with significant full 
length sequence identity to MTMR2 (70%). The yeast ymr1p lacks the conserved C-
terminal phosphorylation site with amino acids underlined.   
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1.3.2 Myotubularin-Related Protein 5 
 Myotubularin-Related protein 5 (MTMR5; sbf1) is a large 208kDa cytoplasmic 
protein and is a catalytically inactive member of the MTM family [32].  
Pseudophosphatases display extensive sequence similarities to their active counterparts 
however lack important amino acids in their catalytic sequences, due to germline 
substitutions thereby rendering them catalytically inactive.  The consensus sequence 
CX5R in the catalytic domain amongst most active members is CSDGWDR, while 
MTMR5 has the sequence LEDGWDI (figure 9) [33].  Features for the most part have 
been conserved throughout evolution and six inactive members within the MTM family 
have been identified [33].  The inactive MTMs contain an N-terminal DENN 
(Differentially expressed in neoplastic versus normal cells) domain, a central 
myotubularin domain, a PH/PH-GRAM domain in addition to a C-terminal coil-coiled 
(CC) region, PDZ-binding motif and SID (SET interacting)-domain (figure 4) [19].  The 
functions of DENN domains are not fully understood yet several proteins containing this 
domain have been shown to associate with Rab GTPases and are thought to play a 
functional role in membrane trafficking [33].   
The active-site phosphatase sequence is conserved amongst both inactive and 
active MTM members with the pocket sufficiently preserved to bind phosphorylated 
substrates, even amongst the inactive members [35].  Several researchers propose that 
they might function as naturally occurring substrate trapping mutants, whose purpose is 
to oppose the action of active members thereby by contributing to regulation of cellular 
lipid pools [35,36].  Firestein et.al have shown MTMR5 to be linked to cellular growth 
and oncogenic transformation in vitro and that deletion of the PH domain or mutations 
which restore catalytic activity abrogates its ability to modulate cellular growth in NIH 
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3T3 fibroblast cells [36].  Robinson et.al have identified that the pseudophosphatase 
domain alone was sufficient for membrane targeting of inactive members [33].  MTMR5 
interacts directly with MTMR2 but not MTM1 through their CC domains and mutations 
in either MTMR2 or MTMR5 can abolish this interaction (figure 10.A) [2].  The exact 
role of this interaction is still unclear, but it is proposed that MTMR5 may regulate the 
enzymatic activity and subcellular localization of MTMR2 [19].  Firestein et.al have 
suggested that MTMR5 may be important in spermatogenesis and germ cell 
differentiation based on his finding that MTMR5 mutations in mice resulted in infertility 
and decreased spermatogenesis [35].   
PDZ-binding motifs have been shown to play important roles in protein anchoring 
to the cytoskeleton and holding together signaling complexes through interactions with 
other proteins containing PDZ domains [36,38].  Deletion of this motif in MTMR5 has no 
effect on interaction with MTMR2 implicating that this region may play a larger role 
potentially with associations with key trafficking proteins [33,36,38].  The CC region of 
both MTMR13 and MTMR5 mediates direct association with MTMR2 and deletion of 
this region results in abolished interaction (figure 10.B) [19,33].  Ciu et.al (1998) have 
implied that the SID domain in the inactive MTM members may link the epigenetic 
regulatory machinery with signaling pathways that are involved in growth and 
differentiation [35]. This may partially explain the consequences of deletions and 
resultant in vivo oncogenic transformations observed with MTMR5 and NIH 3T3 
fibroblast [35].  Nevertheless, the specific role of inactive members in regulating their 
active partners is not fully understood and may function through a yet to be identified 
unrelated mechanisms to which these issues warrant further investigations.  
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Figure 9. Schematic of MTMR5 conserved domains 
The conserved domains amongst inactive MTM members are depicted and represented in 
the MTMR5 protein diagram: N-terminal DENN domain (former uDENN and latter 
dDENN domains enclosed in black boxes), PH-GRAM domain, the central catalytically 
inactive phosphatase domain with the putative cysteine and argenine residues mutated 
(bold faced and consensus active site amongst active members underlined), the C-
terminal CC region, SID and PH domains.  Interaction with the active MTM partner 
MTMR2 is mediated through the coiled-coil domain and shown here is the relative 
proximity to the distant PH domain which has been proposed that abolishment results in 
increased cellular proliferation, which may be a result of inability to regulate MTMR2 
function.  MTMR5 has a number potential Proline directed phosphorylation sites located 
throughout the protein however they have yet to be identified in vivo or in vitro.  
 
 
 
 
 
 
DENN Inactive Phosphatase Domain CC PH-GRAM 
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A 
MTMR2 WSYINSQLEDFTNPLYGSYSNHVLYPVASMRHLELWVGYYIRWNPRMKPQEP--IHNRYK 598 
MTM1 WSLINSNKEKFKNPFYTKEINRVLYPVASMRHLELWVNYYIRWNPRIKQQQPNPVEQRYM 558 
 ** ***: *.*.**:* .  *:***************.********:* *:*  :.:**  
 
MTMR2  ELLAKRAELQKKVEELQREISNRSTSSSERASSPAQCVTPVQTVV 643 
MTM1 ELLALRDEYIKRLEELQLANSAKLSDPPTSPSSPSQMMPHVQTHF 603 
 **** * *  *::****   * : :...  .***:* :. *** . 
    
 
             
B 
MTMR5 LAQGPPEPPEE-ERSDGGAPQSRRRVVWPCYDSCPRAQPDAISRLLEELQRLETELGQP 1667 
MTMR13 MLTPKHFPSEDSDLAGEAGPRSQRRTVWPCYDDVSCTQPDALTSLFSEIEKLEHKLNQA 1656 
 :      *.*: : :. ..*:*:**.******. . :****:: *:.*:::** :*.*. 
 
MTMR5 AERWKDTWDRVKAAQRLEGRPDGRGTPSSLLVSTAPHHRRSLGVYLQEGPVGSTLSLSL 1726 
MTMR13 PEKWQQLWERVTVDLKEEPRTDR----SQRHLSRSPGIVSTNLPSYQKRSLLHLPDSSM 1711 
 .*:*:: *:**..  : * *.*     *.  :* :*    :     *: .:    . *: 
 
 
Figure 10. Pairwise alignments of the regions of MTMR2 interaction with the 
inactive MTM family members MTMR5 and MTMR13  
Multiple sequence alignments (ClustalW2) showing partial sequence conservation of 
amino acids within the proposed regions of MTMR2 interactions.  (A) The region of 
MTMR2  CC domain is highlighted and underlined in addition to the predicted  CC 
region of MTM1, displaying only partial sequence similarity (*) to MTMR2 with 
significant full length sequence identity (66.8%) implicating a probable method of 
selection for MTMR5/MTMR13 as opposed to MTMR12 (inactive MTM1 partner).  
Additionally shown in red is the proximity to the C-terminal phosphorylation site(s) on 
both MTM1 and MTMR2 displaying sequence similarity with reported MTM1 
phosphorylation site underlined.  (B) The high sequence similarity between MTMR5 and 
MTMR13 (74.5%) yet low full length sequence identity (59.1%) implicates possible 
mechanism of selection of MTMR2 for either of its inactive partner.  The reported 
regions of MTMR13 interaction underlined and proposed region of interaction of the CC 
region of MTMR5 underlined.  Coiled-coil domain boundaries of MTM1 and MTMR5 
were obtained from COILS [2,5].   
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1.4 Charcot-Marie-Tooth Disease 
Charcot-Marie-Tooth disease (CMT) is a genetically heterogeneous disease 
consisting of motor and sensory deficits which represent the larger portion of hereditary 
peripheral neuropathies [39]. Genetically, more than 35 genes have been identified and 
associated with the demyelinating forms CMT-types 1,3,4 (CMT1, CMT3, CMT4) and 
the axonal form CMT-types 2 (CMT2).  These groups are further divided into many 
subtypes based on chromosome linkage analysis, genetic screenings, and NCV tests.  The 
most prevalent form of demyelinating CMT is CMT1A which is caused by a 1.5Mbp 
duplication on chromosome 17p12 harbouring the causative gene PMP22 [40].  In 2010 
Huang et.al [40] identified that copy number variants (CNV) are the underlying cause 
and importance for CMT1A manifestations.  Genetic testing for CMT is generally based 
on direct sequencing, and to date, no other disease-causing CNVs have been identified to 
result in other forms of CMT, and all others are nearly exclusively caused by point 
mutations.  There have been implications that CNVs affecting several coding exons or 
larger introns may be excluded by conventional methods, and therefore potentially could 
be present amongst the genomic regions of the heterogeneous populations of CMT 
harbouring genes. 
CMT4B1 is a hereditary autosomal recessive demyelinating motor and sensory 
neuropathy (HMSN) characterized by focally folded myelin sheaths in the peripheral 
nerves, slow NCV tests (<40m/s) and decreased Schwann cell proliferation [41]. 
Currently incurable, it is the most commonly inherited neurological disorder in the 
United States affecting approximately 1:2500 individuals [42].  Clinical features of 
CMT4B1 include progressive muscle atrophy, distal sensory loss and weakness in the 
outer extremities with typical age of onset in childhood years.  Characteristic phenotypes 
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in all affected individuals displayed prominent weakness beginning in the lower limbs 
and spreading proximally to the upper limbs in later years [16,17,41,44,46].  However, 
additional features have been described including weakness in upper facial muscles with 
this data being suggestive that varying phenotypes are dependent on the severity of 
mutations [34].  Bolino et.al. (1996/2000) localized the gene responsible for CMT4B1 to 
chromosome 11q22 and mapped the critical interval to a 2Mb region by haplotype 
sharing using two unrelated CMT4B1 pedigrees [41,43].  This disease is distinguished 
from CMT4B2 which was localized to chromosome 11p15 coding for the gene SET-
binding factor 2 (SBF2/MTMR13) only by direct sequencing considering it resembles 
CMT4B1 both clinically and pathologically [44].  In addition, they demonstrated that 21 
different transcripts along with 3 identified genes reside in this critical region.  In 
particular, they identified two expressed sequence tags (EST) belonging to the same 
transcript were contained within the sequence-tagged site (STS) markers for the critical 
CMT4B interval, those coding for the MTMR2 gene. Most known CMT causing genes 
encode myelin structural proteins in Schwann cells (MPZ: Myelin Protein Zero), regulate 
expression of other myelin proteins, or have some involvement in Schwann cell 
metabolism (PMP-22: Peripheral myelin protein 22). Because the exact functional role of 
MTMR2 remains unclear, this implicates a critical importance of this protein to have 
involvement in some form of Schwann cell-related mechanism; whether be those listed 
above or cell signalling/ trafficking. It has been suggested that the lack of protein may 
result in uncontrolled phosphorylation events leading to Schwann cell proliferation and 
myelin overgrowth, which is observed in the peripheral nerves of CMT4B1 patients [41].       
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Researchers have identified at least 10 different base pair mutations in the MTMR2 gene 
associated with causing CMT4B1 resulting in frameshift readings to yield a truncated 
protein or point mutations, both rendering the protein inactive.  Alterations in protein 
structure most likely affect the ability of MTMR2 to modify its substrate which in turn, 
could disrupt key trafficking and signaling events sensitive to correct lipid levels.   
In addition, Schwann cells rely on efficient Ras/Raf/ERK signaling at different 
thresholds with respect to the particular stage of myelination.  Transient activation of 
ERK is associated with proliferation whereas high levels of activation have been 
associated with promoting differentiation in a number of cells [45]. Harrisingh et.al. 
(2004) recently discovered that the ERK pathway is responsible for driving 
dedifferentiation [45].  Inhibition had no effect on the differentiation processes which are 
mediated by upstream Ras/Raf in Schwann cells [45].  Axon-derived signals are the 
driving force in Schwann cell myelination and rely on signal transduction through the 
Ras/Raf/ERK pathway to initiate differentiation.  They also determined that Raf/ERK 
activation in Dorsal-Root ganglion (DRG)-Schwann cell co-cultures, induced 
demyelination and breakdown of the myelin sheath [45].   
Schwann cells divide irregularly particularly following precise cellular demands 
and are also regenerative, meaning that they myelinate axons in response to specific 
axon-derived signals, dedifferentiate in response to nerve damage, and can redifferentiate 
during the axonal repair process [45].  Axon/nerve damage results in strong activation of 
the ERK pathway leading to sustained signal transmission which triggers myelin 
breakdown.  Ultimately, through efficient and tightly regulated ERK activation, Schwann 
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cells dedifferentiate and proliferate, then are triggered to re-enter the cell cycle resulting 
in remyelination of the damaged axon as part of the efficient nerve repair process [45,46]. 
Signal transduction and membrane trafficking of the axonal signal and key 
secondary signaling molecules such as phosphoinositides, must be coordinately 
maintained at precise cellular levels for efficient signal transport. Therefore, proteins that 
are involved in regulation of cellular lipid levels in primary/early signaling stages such as 
MTMR2, may ultimately be involved in regulating a subset of Schwann cell processes.  
Inability of MTMR2 to maintain the correct lipid levels may result in impaired ERK 
activation, therefore, disrupting the efficient nerve repair processes and myelin 
development.  In 2007, Chojnowski et.al. [46] determined that loss of functional MTMR2 
resulted in decreased Schwann cell proliferation, implicating a role in the primary stages 
of Schwann cell myelination.  Myelin outfoldings and decreased Schwann cell 
proliferation are characteristic features of CMT4B1, thereby implicating that correct 
MTMR2 regulation is required for proficient Schwann cell processes.    
1.5 The Dynamic Role of Phosphoinositide Phosphatases 
 Phosphoinositide (PI) synthesis, degradation and inactivation are important 
biological processes that are co-ordinately regulated by lipid kinases and lipid 
phosphatases respectively [26,48].  The influence of numerous phosphoinositide 
phosphatases in membrane trafficking, cell survival, cell growth and signal transduction 
has largely been underrepresented as most research primarily has focused on kinases as 
being the key players in various physiological systems.  Only within the last decade has 
there been more aim focused on studying the critical aspects of phosphoinositide 
phosphatase regulation as it has become more apparent that dysregulation triggers 
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aberrant phosphoinositide signaling which often results in a number of human cancers 
and disease in addition to type-2 diabetes mellitus [3].   
 The phosphatase and tensin homologue deleted from chromosome 10 (PTEN) is a 
tumour suppressor gene that has been found to be deleted in a number of human cancers 
and characteristically results in invasive phenotypes [50,51].   Somatic and germline 
mutations in PTEN are found to be predominantly the cause of carcinomas, gliomas and 
relatable to other genetic disorders including Cowden disease and Lhermitte-Duclos 
syndrome in addition disruption in expression has also been implicated in cardiovascular 
disease [51].  Unlike MTMR2 and MTM1, PTEN utilizes PI(3,4,5)P3 rather than PI(3)P 
or PI(3,5)P2  as its physiological substrate, implicating its activity to be dependent and 
antagonistic towards PI3K signaling in addition to PI(3)P effector proteins such as Akt 
[51].  Akt is responsible for governing key signaling pathways that control growth, cell-
cycle and apoptosis, and it has been proposed that the tumour development as a result of 
loss in PTEN activity, triggers metastatic tumour growth through defects in an Akt-
mediated fashion [51].  Loss of phosphatase activity results in the inability of PTEN to 
act as a tumour suppressor thereby resulting in increased levels of PI(3,4,5)P3 and 
overactive Akt signaling which stimulates tumour cell proliferation [26,50,51].  Studies 
by Birle et.al. [52] and Xu et.al. [53] demonstrated that phosphorylation of PTEN 
triggers conformational changes that elicit a closed conformation resulting in greater 
protein stability yet catalytically inactive.  As a result, these changes impact PTENs 
ability to interact with membrane targeting binding factors thereby culminating in 
inaccessibility to its phosphoinositide substrates [52,53].   
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Conversely, dephosphorylation of PTEN results in an open conformation, allowing for 
targeting to the plasma membrane and access to its substrate [53].   
1.6 Endocytosis and Constitutive Membrane Trafficking 
 
The process of endocytosis involves a complex organization of membrane-bound 
receptors and intracellular vesicles that mediate the efficient internalization of molecules 
and correct endocytic sorting.  Endocytosis is crucial for an array of cellular functions 
and can occur through several distinct morphologically and biochemically diverse 
mechanisms with the capacity to internalize both small molecules to entire cells [54].  
Adequate regulation ensures the precise maintenance of important cellular functions and 
organelle targeting, whereas aberrant disruption in these processes in addition to incorrect 
post-endocytic sorting, often results in diseases [55,56].   
The most common and well characterized mechanism for the intracellular entry of 
molecules is via complementary cell-surface receptors, initially resulting in formation of 
clathrin-coated pits and subsequently commencing in receptor-mediated endocytosis 
(RME) (figure 11) [56].  Internalized receptors contain specific signals composed of short 
tyrosine-based sequence motifs (-YXXZ-/-NXXZ-) in their cytoplasmic domains (in 
which X is variable and Z is a large bulky hydrophobic group i.e Phe, Trp) permitting 
recognition by adaptor proteins (AP) [54,56,7].  The functional activation of the APs and 
receptor membrane targeting is closely coupled to direct clathrin membrane recruitment 
and coated pit assembly [55,57].  Clathrin binding to the region of ligand-bound receptor 
on the inner surface of the plasma membrane, triggers pit invagination and bud formation 
[58,59].  The newly formed clathrin-coated vesicles must then effectively be “pinched-
off” from the plasma membrane to complete the initial stages of endocytosis and 
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commence in vesicular trafficking.  The clathrin coat must then be rapidly removed in 
order to enable the vesicle to fuse with its target membrane, ultimately recycling the coat 
components back to the cell membrane surface for further use and targeting of the newly 
formed vesicle to the initial molecular sorting stations at the early endosomes [60].       
Collectively, this leads to long held classical view of endocytosis that following 
extracellular ligand-receptor binding, the complexes are internalized via fission and 
consumed within the newly formed clathrin-coated vesicles (figure 11) [55].  Progression 
through the endocytic pathway is subsequently characterized by the shedding of clathrin 
wherein the cargo-containing vesicles proceed inwards and fuse with the early endosomes 
[55].  These organelles are responsible for directing the internalized vesicles to their 
proceeding pathway, consequently; the Endocytic Recycling Compartment (ERC) for 
redirection towards the plasma membrane, towards the trans-Golgi Network (TGN) for 
packaging prior to trafficking to its destined subcellular compartment, or they may be 
targeted to the late endosomes/lysosomes (Multivesicular bodies; MVB) for degradation 
[61,62].  Regulation of the endosomal sorting system that ultimately directs active 
receptor tyrosine kinases (RTK) to the lysosomes can be prolonged and affect the 
duration of the stimulus and hence, perpetuate the length of signaling events [63].  The 
complex functionality of these subcellular compartments can be defined and enhanced by 
particular marker proteins in addition to specific subdomains within these organelles [55].  
The Rab family of small GTP binding proteins is known to regulate vesicular trafficking 
processes and they are markedly established proteins for distinct endocytic compartments 
[64].  Highly modulated exchanges of GDP/GTP aid in the correct regulation of 
constitutive endocytosis, which in turn can ultimately be modified by extracellular stimuli 
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[65].  The small GTPases Rab5 in particular, is a key regulator of trafficking events such 
as vesicle formation, docking, and fusion from the cell membrane into and between the 
early endosomes [65,66].  Rab5 associates with endosomes in its active GTP bound form 
which is co-ordinately mediated by the endosomal Guanine exchange factor (GEF) 
RABX-5.  Notably, RABX-5 maintains Rab5 activation on endosomes and is spatially 
modulated by the endosomal protein SAND-1/Mon1 (Monensin sensitivity protein 1) in a 
PI(3)P dependent fashion [67].  It is therefore highly conceivable that the adequate 
regulation of Rab5-dependent trafficking events that are sensitive to PI(3)P, could be 
modulated by proteins and/or events that alter specific cellular pools of PI(3)P.   
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Figure 11. Subcellular localization of phosphoinositides in the endocytic pathway 
and cellular translocation of binding components of the endocytic machinery  
The processes along the endocytic pathway are regulated in such a manner that particular 
steps can be identified by specific organelle subdomains and marker proteins.  Various 
phosphorylated forms of PIs are located along different regions of the pathway and 
represent key components of early-late endosomal compartments.  Correspondingly, the 
small Rab GTP-binding proteins are proficient in their ability to recruit further 
components required for homotryptic fusion (EEA-1), retrograde transport (SNX-1/4) and 
ESCRT machinery binding (Hrs) [61].  [figure from reference 61] 
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1.6.1 The Early Endosomes and Late Endosomes 
 
The canonical early endosomes are characterized by the presence of Rab5, in 
addition to its effectors Rabenosyn-5, Early Endosomal Antigen 1 (EEA1) and the lipid 
PI(3)P [55,64].  The efficient recruitment of Rab5 effector complexes regulate endosomal 
vesicle tethering and is coupled to membrane fusion events which are mediated by 
SNARE (soluble N-ethylmaleimide–sensitive factor (NSF) attachment protein receptor) 
proteins [66,68].  Highly coordinated events of SNARE functions coupled with 
membrane tethering, effectively organizes membrane subdomains on early endosomes 
[65,66,68].  Morphological studies have shown that Rab5 occupies a distinct domain on 
endosomes thereby recruiting the PI3-kinase isoform hVPS34, and generating localized 
production of PI(3)P [68].  The complementary presence of Rab5 and PI(3)P is a 
necessary element for the proficient recruitment of the Rab5 effector complex EEA1 
[55,64,68].   
In mammalian systems, the levels of PI(3)P are typically low and only ~0.2% are 
phosphorylated at the D3 position however, the direct localization to early endosomes 
implies a highly specialized role of this phosphoinositide in membrane trafficking [69].  
EEA1 binds PI(3)P though a specialized zinc finger FYVE (Fab1p, YOTB, Vac1p and 
EEA1) domain thereby effectively allowing for docking of this membrane tethering 
molecule [68,69].  Interactions of basic side chains in highly conserved FYVE finger 
domain motifs (R(R/K)HHCR and RVC) form a coordination shell with the 3-phosphate 
[68].  Additional side chains with a third conserved motif (WxxD) interact with the 4-/5-
/6- hydroxyl groups of the inositol head group thereby preventing interactions with 
alternative phosphoinositides and implicating the ligand specificity of FYVE fingers for 
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PI(3)P [68].  In addition, proteins containing FYVE domains which are located on 
endosomes have been shown to function in endocytosis and growth factor signaling, and 
those located on the plasma membrane assist in the regulation of the actin cytoskeleton 
[61,70].  Moreover, researchers have adequately devised a method for locating specific 
PIPs within the cell, in which fusion of the lipid binding modules definitive for a PI 
species such as the FYVE domain to green fluorescent protein (GFP) as a means of 
specifically identifying regions rich in the desired PI [61,72]. Collectively, strict 
regulation in the turnover of PIPs managed by the complex enzymology governing 
phosphoinositide synthesis, degradation and homeostatic control can be directly 
associated with phosphoinositide phosphatase deficiencies linked to a number of human 
diseases [61].     
The presence of Rab5 on early endosomes allows for the efficient recruitment of 
effector complexes that are essential for correct maturation of endosomal organelles [55].  
Zoncu et.al. (2009) have recently identified that the membrane adaptor protein APPL1 
(Adaptor protein, Phosphotyrosine interaction, PH domain and Leucine zipper containing 
1) directly binds Rab5 and is considerably distinct from classical early endosome marked 
by EEA1 [55,64,73].  At the very early stages of endocytosis, APPL1 vesicles are formed 
immediately following fission of endocytic vesicles [74].  The loss of APPL1 as vesicles 
moved centrally from the plasma membrane coincides with the recruitment of EEA1 and 
subsequently maturation into the canonical PI(3)P positive endosomes, and in turn further 
recruitment of Rab5 [74].  APPL1 directly binds Rab5 and portions of the lipid bilayer 
via a Bin–Amphiphysin–Rvs (BAR) and a PH domain, in addition to the cytoplasmic 
portion of a subset of membrane receptors (i.e. EGFR) [74].  This subpopulation of 
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endosomes positive for APPL1, is presumed to precede the canonical Rab5 and EEA1, 
with a known functional role in assembly of signaling complexes for MAPK and Akt 
pathways [55,73]. Therefore, the presence of APPL1 profoundly impacts Akt and MAPK 
signaling and recent advances have indicated a lack of APPL1 endosomes is linked to 
increased apoptosis during development as a result of decrease in key growth factor 
related signaling pathways [74].  Recent work has shown that increased levels of PI(3)P 
acts as a molecular switch to turn off growth factor signaling [74].   
Furthermore, select specialized phosphoinositide molecules such as PI(3)P, 
PI(3,4)P2, and PI(3,5)P2 also play fundamental roles as molecular tags along the 
endocytic pathway [55].  The transition between early and late endosomes could be 
mediated by the simultaneous loss of Rab5 from an endosome which occurs 
concomitantly with the acquisition of Rab7 [67].  The physiological importance of 
signalling from endosomes post-internalization requires further understanding and more 
detailed delineation, in order to fully comprehend the complexities associated with 
examination of endosome signal in intact mammalian systems. 
1.6.2 Linking Receptor Internalization to Signaling Pathways 
 
The corresponding signaling cascades following receptor internalization are 
activated promptly after receptor ligation provoking signal transduction and initiation of 
endocytic trafficking.  The most sought about and characterized forms of cellular 
response to stimuli coupled with internalization and intracellular trafficking is the RME 
and Epidermal Growth Factor Receptor (EGFR) signaling pathway [56,75].  Haugh et.al. 
(1999) discovered that receptor tyrosine kinases (RTKs) are capable of signaling 
following activation by EGF and internalization as a result of autophosphorylation and 
activation of the intracellular kinase domains of the receptors [76].  In particular, they 
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along with others have determined a crucial downstream event following receptor 
complex formation directly linked to the EGFR pathway that is the activation of the 
ERK/MAP kinase cascade [76,77].  It is proposed to be a result of recruitment of the AP-
s2 and RTK substrate Eps15 that mediates the growth factor responses in eukaryotic 
systems [75,77].  Notably, Barbieri et.al (2000) showed that EGF stimulation under 
serum conditions triggered Rab5 GTP loading (activation) and as a result, enhanced the 
effects of ligand induced endocytosis and ultimately signal transduction [75]. 
Furthermore, they showed that total cellular PI(3)P depletion resulted in the blockade of 
the EGF effects on endocytosis and hence, prevention of EGF induced endocytosis [75].  
Profound evidence has now shown that aberrant EGFR trafficking is associated with 
uncontrolled signaling events and may be ultimately a result of abnormal initial 
trafficking events that may be dependent on the activity of phosphoinositide 
phosphatases.              
The functional regulation of rapid endocytosis of activated receptors is one of the 
most highly conserved processes in multicellular systems, and is a means of correctly 
mediating receptor signaling from the plasma membrane [80]. Eukaryotic organisms have 
adequately devised a mechanism for turning off signals generated as a result of ligand-
induced activation of receptors, as a means of mediating precise signal transduction 
levels.  The long held concept underlying endocytosis is that the molecular mechanisms 
are presumably for receptor down-regulation and reducing the number of available 
ligands, mediated through recruitment of ubiquitin ligases following receptor activation 
to ubiquitin-binding platforms that direct receptor sorting [61,78,79].  Accordingly, the 
number of active cell surface receptors is controlled via constitutive internalization and 
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prompted to recycling back to the plasma membrane surface as a means of controlling the 
number of available cell surface receptor comparative to appended ligands.  The spatial 
and temporal regulation of receptor endocytosis is required in order to maintain and 
control signalling and to elicit the appropriate biological responses.   
The small GTPases protein Ras is an additional factor that can contribute to 
cellular signal transduction cascades which is located at the plasma membrane and has 
also been shown to be present on intracellular membranes of endosomes [82].  Ras-
GTPases have crucial roles in RTK signaling and activation, in which the GTP-bound 
state is presumed to be crucial for the activation of an array of signaling pathways [79].  
Ras localization to endosomal vesicles is presumed to in part be mediated by association 
with the Rab5 GEF RABX-5, which promotes the ubiquitination of Ras concomitantly 
with GTP Rab5 activation thereby promoting endosome maturation ultimately leading to 
the suppression of ERK activation [79,82,83].  Defects in the mechanisms of receptor 
internalization and degradation results in RTKs acquiring oncogenic properties ultimately 
associated with defective endocytosis and prolonged amplitude/duration of biochemical 
growth factor signals (i.e. enhanced proliferation).  As a result, the functional aspects of 
the endocytic pathway have long been viewed as a means of receptor down regulation 
and attenuation of growth factor signals.  Irrespective of evidence indicating signaling 
following endocytosis, the ultimate fate of activated RTKs is targeting for degradation in 
the lysosomes [63].  
1.7 The Essential Roles of Phosphoinositides in the Endocytic Pathway 
Phosphorylated forms of phosphatidylinositols are referred to as 
phosphoinositides (PIs) which are ubiquitous components of eukaryotic cell membranes 
and key secondary signaling molecules in vesicular trafficking (figure 11) [84].  The 
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spatially segregated generation of PIs within the cell reflects the significance of 
maintaining a precise balance between the activities of kinases and phosphatases at 
distinctive cellular locations in response to extracellular cues, in addition to intracellular 
cargo transport between various compartments.  Of the seven known species of phospho-
PIs in the cell which are generated as a result of versatile and differential phosphorylation 
of the inositol headgroup, there are four well established and characterized PIs that play 
key roles in the endocytic pathway.  The recruitment of endocytic proteins to the plasma 
membrane is governed by PI(4,5)P2 which predominates on the plasma membrane, 
resulting in sequential endocytic protein invagination and subsequent vesicule formation 
[85].  Activation of the PI(5) kinase-1  which in turn phosphorylates the D5 position of 
PI(4)P to generate PI(4,5)P2 following growth-factor receptor binding, and can 
additionally lead to increased localized production to the site of subsequent coated-pit 
formation and receptor internalization [79]. The question arises as to what factors 
regulate the local synthesis of PI(4,5)P2 and restriction to the plasma membrane.  PI-
binding effectors are likely to play a major contribution in sequestration of the pre-
formed PI pools at the plasma membrane, which in part is tightly correlated with the 
myrisotoylated alanine-rich C-kinase substrate (MARCKS) association [86].  Association 
is mediated through basic amino acid stretches thereby keeping PI(4,5)P2 restricted to the 
plasma membrane and requires release initiation by reversible phosphorylation by protein 
kinase C (PKC) and calmodulin (CAM) binding following triggering of action by specific 
extracellular stimuli (i.e. EGF, NGF) [86].  Cellular growth factor stimulation leads to 
activation of two distinct PI3Ks, PI3K  and Vps34, which transiently phosphorylates the 
D3 position of the inositol ring of PI(4,5)P2 resulting in generation of PI(3,4,5)P3, with the 
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latter phosphorylating only at the early endosomes.  This PI is responsible for binding to 
the PH-GRAM domain of the AGC (named from: cAMP-dependent protein kinase A, 
cGMP-dependent protein kinase G, and phospholipids-dependent protein kinase C) 
family protein kinases thereby recruiting them to the plasma membrane commencing in 
allosteric activation and consecutive regulation of growth, proliferation and survival [84]. 
The small GTPase Rab5 can cycle between endosomal membrane bound and 
cytoplasmic, based on its association with the guanine nucleotide dissociation inhibitor, 
(GDI) [87].  The direct complex formation of Rab5-GDI is responsible for govering Rab5 
localization and ultimately the direct interaction with Vsp34 and PI3K  leading to 
controlled generation of PI(3)P [87].  Sequentially, PI(3,4,5)P3 is dephosphorylated by 
inositol polyphosphate 5-phosphatases (PIPP,SKIP,ORCL) and the 4-phosphatases (Type 
I,II) to generate PI(3)P which is the major phosphoinositide on early endosomes.  
Additionally, it has been shown that Rab5 directly interacts and stimulates the activity of 
PI3K , 4- and 5-phosphatases.  Therefore, Rab5 can be implicated in being involved in 
the enzymatic turnover of PIs from the plasma membrane to the early endosomes.  
Concomitantly it presumably functions with PI3K  and the 4-, 5-phosphatases which 
function as Rab5 effectors, leading to PI(3)P synthesis, efficient endocytosis and signal 
transduction [87].   
Recently, Clague et.al (2009) made a critical observation indicating a major role 
of 3-phosphoinositides in homotryptic early endosomal fusion in which inhibition of the 
PI3K by wortmanin, subsequently could inhibit the trafficking of a number of growth 
factor receptors [88].  Additionally, PI(3)P is a precursor for the generation of PI(3,5)P2 
in which the FYVE domain containing PI5-kinase, PIKfyve, is recruited to the early 
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endosomes leading to the phosphorylation at the D5 position of the inositol head group 
allowing for further maturation into late endocytic organelles marked by PI(3,5)P2 
[70,86].  Association of Rab5 with early or Rab7 with late endosomes is not affected by 
PI3K inhibition with wortmanin and therefore, localization of these distinct 
compartmental membrane proteins is not dependent on the endosomal levels of PI(3)P 
[67].  However, a positive feedback loop involving the GEF RABX-5 in turn, is disrupted 
by the regulator SAND-1/Mon1 that is dependent on recruitment to the early endosomes 
based on the age and accumulation of PI(3)P within early endosomes [67].  In turn, this 
results in the subsequent displacement RABX-5 for recruitment of Rab7 and is proposed 
to be a result of interactions through the Rab7 GEF Class C Vps/HOPS complex [67].  
Loss or disruption in the ability of SAND-1/Mon1 to consummate conversion to Rab7 
endosomes, results in a large accumulation of Rab5 protein and enlarged Rab5 positive 
endosomes, unable to undergo homotryptic fusion [67].  Therefore, the likelihood that 
proteins whose function is to regulate early endosomal PI(3)P levels, could potentially 
contribute to the mechanistic control of Rab5 dependent trafficking and maturation into 
late endosomes. 
1.7 The Mitogen-Activated Protein Kinase Signaling Pathway 
 The Mitogen Activated Protein Kinase (MAPK) signaling cascade controls a vast 
array of complex biological functions and plays key roles in mediating signal 
transduction of extracellular signals to elicit the appropriate cellular response.  The 
function and regulation is tightly controlled mechanism which has been conserved 
throughout evolution from unicellular to multicellular organisms [89,91,94].  In 
mammalian systems, there have been three well characterized MAPK families: the 
 42 
classical Extracellular regulated kinases (ERK), c-Jun N-terminal kinase/Stress activated 
protein kinases (JNK/SAPK) and p38 kinases (figure 12) [89].  Only recently, has there 
been identified a fourth MAPK, ERK5 which responds to oxidative stress and growth 
factors in addition to stimuli similar to ERK1/2 however unlike ERK1/2, ERK5  has key 
roles in cardiovascular development and neural differentiation [90].   
All MAPK cascades operate on a three-tiered system of enzymes that are activated in 
series (MAPKKK-MAPKK-MAPK) ultimately leading to the amplification and 
activation of downstream targets in response to cellular signals [89].  Activation of 
MAPKKK by upstream signals triggers the dual phosphorylation of downstream 
MAPKKs at two Ser/Thr residues in which selectivity is conferred by distinct motifs in 
their sequence and with respect to different stimuli responses [91,94]. The 
phosphorylated MAPKKs are dual specificity kinases that then act to phosphorylate the 
downstream MAPKs at Thr/Tyr residues, such as ERK1/2 Thr-Glu-Tyr (TEY) motif 
[92].  MAPKs are a subgroup of the proline-directed Ser/Thr kinases because they share 
the partial sequence recognition of PDPKs (P-X-S/T-P-X-Z), whereby Z is a basic amino 
acid (H, K or R) and X is any amino acid [93].  The activated MAPKs then act to 
phosphorylate target substrates based on their specificity. MAPKs have the recognition 
X-S/T-P, with the similarity to PDPKs being the Proline preceding the phosphorylated 
Ser/Thr residue [92]. The reverse is catalyzed by MAPK phosphatases that 
dephosphorylate MAPKs to return them to their original inactivated state and it is the 
rapid and reciprocal actions that allows for cells to quickly respond to changes in their 
external environment [94].   
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One of the best and well characterized MAPK cascade is the Ras-Raf-MEK-ERK 
pathway which plays a critical role in the regulation of cell proliferation in response to 
cytokines and growth factors, in addition to the regulation of G1/S cell cycle progression 
[89].  Sequentially, binding of extracellular stimuli such as EGF to the corresponding 
RTK, leads to receptor autophosphorylation/activation which provokes further 
downstream activation of the MAPKs in a multistep process [89].  Ultimately, 
phosphorylation of ERK1/2 by MEK1/2 triggers activation and increased enzymatic 
activity leading to phosphorylation of target substrates and partial ERK1/2 nuclear 
translocation, resulting in transactivation of specific transcription factors thereby 
producing effects on growth, gene expression and differentiation [89].  Loss of control in 
MAPK cascades ultimately leads to impaired cellular signaling and transduction resulting 
in defective growth and development [89].  In addition, MAPK pathways have been 
shown to be involved in many pathological human disease and cancer [89].  In particular, 
the proto-oncogene Ras is found upstream of Raf and leads to its activation [90].  
However Ras mutations that result in Ras acquiring oncogenic properties  results in 
persistent activation of ERK1/2 pathways contributing to the overactive growth rate of 
tumour cells, implicating that pathways surrounding and governing ERK1/2 activation 
need to be tightly controlled [90].     
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Figure 12. The Mitogen Activated Protein Kinase signaling cascade
4
 
 
The MAPK pathway is a signaling cascade that is activated in response to inflammatory 
cytokines, stress and growth factors.  The MAPKKK are activated in response to effector 
molecules that bind to either RTKs or G-protein coupled receptors.  The downstream 
MAPKs are activated by phosphorylation of Thr and Tyr residues in the activation loop 
by the upstream dual specific kinases, the MAPKKs.  The activated MAPKs are Ser/Thr 
kinases that phosphorylate specific targets including transcription factors, regulators and 
cytoplasmic proteins. 
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1.8 Utilization of Mass Spectrometry to Identify Protein Phosphorylation 
 Mass spectrometry (MS) is used as a site mapping tool for the quantification of 
protein post-translational modifications.  Protein phosphorylation is a central mechanism 
used by all eukaryotic systems as a means for precise regulation and controlling cellular 
signaling.  Protein kinases and phosphatases govern reversible phosphorylation events 
and it is estimated that one-third of all proteins are phosphorylated at any given time, 
implicating the importance of correct regulation [81].  The detection of covalent 
modifications and monitoring changes is a key feature of MS.  More specifically, MS 
utilizes mass-to-charge (m/z) ratio to detect a mass increase of +80 m/z for singly 
phosphorylated peptides (HPO3) in addition to changes as a result of the neutral loss of a 
phosphate group from an amino acid residues of -98 m/z (H3PO4) following gas-phase 
fragmentation (MS/MS) of phosphopeptides [81].  This neutral species (H3PO4) is lost as 
a result of cleavage of the phosphodiester bond from phosphorylated serine or threonine 
residues.  Generally, phosphopeptides are rarely detected in total trypic digest pools, 
primarily owing to their low stoichiometry and inefficient ionization in MS therefore, 
usually will require further purification and/or enrichment steps.  Covalent coupling to 
chemical tags and affinity purification steps such as immobilized metal affinity 
chromatography (IMAC), TiO2, and zirconium dioxide (ZrO2) are widely used as a 
means for enrichment of phosphoanalytes [81].   
Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) - MS is 
a common technique utilized for the detection of modifications on larger molecules such 
as proteins [71].  The purpose of MALDI is to decrease the amount of direct energy 
transfer to the analyte molecules in order is avoid excess decomposition and 
fragmentation [71].  The digested samples are pre-mix with an absorbing matrix such as 
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α-cyano-4-hydroxycinnamic acid (CHCA) in combination with highly purified water 
(milliQ), acetonitrile (ACN) and a low percentage of trifluoroacetic acid (TFA) then 
spotted onto a MALDI plate [71,81].  The solution vaporizes and results in the formation 
of co-crystals containing the absorbing matrix and the analyte.  Once the sample is 
allowed to dry, it is placed into the mass spectrometer under high vacuum and the laser is 
fired which ionizes the matrix allowing for efficient energy transfer to the analyte 
molecules thereby avoiding the harsh direct energy transfer.  The TOF analyzer measures 
ions in the gas phase which travel through an energy free region known as the “flight-
tube” or “drift region” based on their m/z, meaning that larger molecules will travel 
slower than smaller ones [71].  MALDI generally produces singly charged protonated  
ions [MH
+
], which in MALDI-linear mode, represents the parent ion of the fragmented 
peptide as a peptide mass fingerprint [71,78].  Dominant peptide peaks are then chosen 
for further fragmentation in MS/MS mode or post-source-decay (PSD) in order to obtain 
the primary peptide sequence which allows for greater accuracy in the identification of 
post-translational modifications [37,71]. The MALDI-PSD spectra are then utilized to 
search large protein data bases in order to match the corresponding peptide 
fragmentations and identify the amino acid sequence, ultimately assisting in the 
identification of phosphorylated residues [37].    
1.9 Research Objectives 
The focus of this research is to gain further understanding and insight into the 
critical biological aspects of MTMR2 regulation by reversible phosphorylation.  
Although several studies have implicated MTMRs to be involved in vesicular trafficking, 
lack of profound evidence yields misunderstanding into the particular role that these PIP 
phosphatases play.  In addition, the definitive biological consequences related to 
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alterations in MTMR2 phosphorylation have yet to be identified.  Particular emphasis of 
this research will be placed on determining the cellular responses associated with 
MTMR2 phosphorylation as well as the biological relevancy particularly with respect to 
the endocytic pathway.   
The specific aims are as follows: 
(i) To evaluate the effects of Ser
58
 phospho-mutants on the stability of interaction with 
MTMR5 in vivo in addition to its lipid phosphatase activity in vitro and will be carried 
out as follows: 
a. Investigate the extent of interaction upon co-expression of MTMR2 and 
phospho-variants with MTMR5 in cell culture followed by co-
immunoprecipitation   
b. Purify recombinant MTMR2 proteins and examine the lipid phosphatase 
activity in vitro using water soluble phosphorylated-phosphoinositol lipid 
substrates.  The phosphorylated form of MTMR2 (S58E) will be represented and 
function as a phosphorylation-mimic and investigate if activity is enhanced by 
phosphorylation. 
(ii) Identification of kinase(s) involved in regulation of Ser
58
 phosphorylation 
a. Purify recombinant wild-type MTMR2 protein and examine phosphorylation by 
several MAPKs using pSer
58
 antibody. 
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b. If MTMR2 is determined to be phosphorylated by a specific kinase, inhibitor 
treatments will be applied in cell culture to monitor the effects on subcellular 
localization and Ser
58
 phosphorylation in vivo using pSer
58
 antibody.   
 (iii) Characterization of MTMR2 subcellular targeting and signal transduction through 
regulation by phosphorylation 
a. Generated single and combinatorial phosphorylation mutants for the Ser
58
 and 
Ser
631
 phosphorylation sites and monitor potential alterations in their subcellular 
localization using endogenous endosomal marker proteins. 
b. Investigate the relationship to the endocytic pathway by monitoring lipid 
substrate localization and relatable signaling pathways.  
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CHAPTER 2  
 
Endosomal Targeting of the Phosphoinositide 3-Phosphatase MTMR2 Is Regulated 
by an N-terminal Phosphorylation Site 
 
This Chapter incorporates the outcome of joint research undertaken in 
collaboration with Dr. Gregory S. Taylor, Department of Biochemistry and Molecular 
Biology, University of Nebraska.  In all cases, the key ideas, primary contributions, 
experimental designs, data analysis and interpretation, were performed by the authors and 
the contribution of co-authors was through the provision of experimental assistance, 
analysis and data interpretation.; Dr. Gregory S. Taylor and Dr. Panayiotis Vacratsis 
performed the [
32
P] orthophosphate labelling and the MALDI-TOF-MS analysis for the 
identification of the phosphorylation site Ser
58
 on FLAG-MTMR2.  Dr. Gregory S. 
Taylor provided all of the original wild-type pCNF-FLAG-MTMR2 and pET-MTMR2-
His6 constructs.  My contribution to this manuscript was preparation of the MS samples 
from immunoprecipitated mammalian cells that were utilized in the studies for the 
identification of Ser
58
 stoichiometry by MS, protein purification for in vitro phosphatase 
assays, co-immunoprecipitation experiments, localization experiments and 
characterization of the phenotype, as well as cell signaling analysis. 
These results were published:  Norah E. Franklin, Gregory S. Taylor, and 
Panayiotis O. Vacratsis (2011). Endosomal Targeting of the Phosphoinositide-3-
Phosphatase MTMR2 Is Regulated by an N-terminal Phosphorylation Site. JBC 286, 
15841–15853  
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INTRODUCTION 
The protein-tyrosine phosphatase superfamily can be divided into distinct 
subfamilies, which include the receptor tyrosine phosphatases, the intracellular tyrosine 
phosphatases, and the dual specificity phosphatases, which dephosphorylate 
phosphoserine/threonine residues, as well as phosphotyrosine residues [1-3]. All protein-
tyrosine phosphatase family members possess the invariant catalytic sequence C(X)5R 
and use a thiol phosphate intermediate as a catalytic mechanism [4]. In recent years, other 
protein-tyrosine phosphatase families have been identified that dephosphorylate 
phosphatidylinositol phosphates (PIPs) as their physiologic substrates [3]. These inositol 
lipid phosphatases include the phosphatase and tensin homolog deleted on chromosome 
10 (PTEN) and the myotubularin-related (MTMR) subgroups [5,6]. PTEN has been 
widely characterized as a tumor suppressor protein [7,8], and mutations in three MTMR 
genes have been identified in distinct human neuromuscular diseases, signifying their 
importance in fundamental biological processes [9–12]. 
Phosphatidylinositol is an abundant membrane lipid that is phosphorylated by PI 
kinases on positions 3, 4, and 5, of the inositol head group in response to various 
extracellular signals, yielding seven unique PIPs [13,14]. These unique PIPs function to 
recruit target proteins containing the appropriate PIP binding domains [15] to discrete 
membrane locations where they can properly respond to extracellular stimuli. These 
highly specific lipid-protein interactions are subsequently regulated through the 
phosphorylation/dephosphorylation of the PIPs. 
Active MTMRs dephosphorylate the lipid second messengers PI(3)P and 
PI(3,5)P2 [16-18]. These phosphoinositides play key roles in membrane targeting, 
 59 
vesicular trafficking, and regulation of signal transduction pathways [19]. In particular, 
the presence of PI(3)P on early endosomes has recently been shown to facilitate 
endosome maturation and attenuate growth factor receptor signaling from endocytic 
structures, indicating that regulators of endosomal PI(3)P levels can directly impact the 
rate of endocytosis and duration of growth factor signaling [20]. 
Although the PIP substrates for MTMRs are constituents of membrane bilayers in 
structures such as endosomes, numerous groups have observed that MTMRs, including 
MTMR2, do not extensively localize to suborganellar structures containing its lipid 
substrates [21-23]. In this study, we have used MS to identify a high stoichiometry 
phosphorylation site on MTMR2 that regulates targeting to endocytic structures.  An 
MTMR2 phosphorylation-deficient mutant (S58A) exhibited strong localization to early 
endocytic structures, where it efficiently depleted PI(3)P. In contrast, wild-type MTMR2 
was highly phosphorylated at this site and did not localize to these structures. 
Furthermore, a phosphomimetic MTMR2 mutant (S58E) exhibited localization identical 
to that of wild-type MTMR2. Our findings suggest that MTMR2 phosphorylation at Ser
58
 
regulates its targeting to endosomal membranes and access to phosphoinositide 
substrates. The significance of this effect was underscored by the fact that signaling 
through pathways known to be sensitive to endosomal PI(3)P levels were dramatically 
altered in cells expressing the MTMR2 S58A mutant. 
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MATERIALS AND METHODS 
2.1 Cloning Expression and Plasmid Constructs  
The mammalian expression vector for N-terminally FLAG-tagged MTMR2 
protein was created by inserting cDNA fragments containing the complete MTMR2 open 
reading frame into the 5_-NheI/3_-KpnI of pCDNA3.1-NF as previously described [24]. 
Vectors for the expression of bacterial recombinant His6-tagged MTMR2 were created 
using the pET21a vector (Stratagene, La Jolla, CA). The pET-MTMR2 construct was 
created by inserting a DNA fragment containing the MTMR2 open reading frame without 
a stop codon into the 5_-NheI and 3_-NotI sites of pET21a in-frame with the six-histidine 
tag as previously described [24]. 
 The synthesis of pCDNA3.1-NF and pET21a vectors containing wild type 
MTMR2 have been previously described [24]. Plasmids were harvested from a 5 mL 
overnight Luria Broth (LB)-Ampicilin (100 µg/ml) culture as described by the 
manufacturer using GenElute Plasmid Miniprep Kit (Sigma-Aldrich, Inc.). Site-directed 
mutagenesis reaction mixtures were as follows: 5 µl of 10x reaction buffer, 100 ng 
template DNA, 1.5 µl dNTPs, 125ng each of forward and reverse primers, 1 µl MgSO4 
and 1 µl of Cloned Pfu DNA Polymerase (600154; Stratagene). To generate pCDNA3.1-
NF and pET21a with point mutations of S58A and S58E to mimic the nonphosphorylated 
and phosphorylated version of the protein respectively, PCR-based site directed 
mutagenesis was performed on purified pCDNA3.1-NF or pET21a plasmids containing 
the wild type MTMR2 insert. Oligonucleotide primers (synthesized by Invitrogen Corp.) 
were designed to carry out the N-terminal phosphorylation site mutations of 
Ser58Ala(S58A), Ser58Glu(S58E) and to generate the catalytically inactive mutant 
Cys417Ser(C417S). The forward primer for the generation of S58A used was 5‟-
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CTGCCGACAACTTTGCTCCTGATTTGAGGGTC-3‟ while the reverse primer was 5‟-
GACCCTCAAATCAGGAGCAAAGTTGTCGGCAG-3‟.  The forward primer for the 
generation of S58E used was 5‟-
CTTCTGCCGACAACTTTGAGCCTGATTTGAGGGTCC-3‟ while the reverse primer 
was 5‟-GGACCCTCAAATCAGGCTCAAAGTTGTCGGCAGAAG-3‟.  The forward 
primer for the generation of C417S used was 5‟- 
CTGTGGTAGTGCATAGCAGTCATGGTTGGG-3‟ while the reverse primer was 5‟-
CCCAACCATCACTGCTATGCACTACCACAG-3‟.  Oligonucleotide primers were 
designed to carry out the C-terminal phosphorylation site mutations of 
Ser631Ala(S631A) and Ser631Glu(S631E). The forward primer for the generation of 
S631A used was 5‟-GAGAGAGCCAGCGCTCCTGCACAGTG-3‟ while the reverse 
primer was 5‟-CACTGTGCAGGAGCGCTGGCTCTCTC-3‟.  The forward primer for 
the generation of S631E used was 5‟-
CAGAGAGAGCCAGCGAGCCTGCACAGTGTGTC-3‟ while the reverse primer was 
5‟-GACACACTGTGCAGGCTCGCTGGCTCTCTCTG-3‟.  Following PCR, the 
products were subjected to DpnI (Invitrogen Corp.) digestion for 1 h at 37°C to degrade 
template DNA. Highly competent DH5α cells were then transformed with PCR products 
(proceeding DpnI digestion) as described below. Plasmids were harvested using 
GeneElute Plasmid Miniprep kit (Sigma-Aldrich) and plasmids verified by agarose gel 
electrophoresis and automated DNA sequencing (ACGT Corp. and Bio Basic Inc.). 
Transformation of plasmid constructs was carried out using 90 μl of highly 
competent DH5α cells that were thawed on ice, and ~500 ng of DNA was added.  The 
E.coli/DNA mixtures were then incubated for 30 min on ice, followed by a 42°C water 
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bath heat shock for 45 seconds, then cold shocked for 2 min on ice.  500 μl of autoclaved 
LB was then added to the tubes and incubated at 37°C with constant shaking (225 rpm) 
for 1 h.  The cells were pelleted at 12,000 rpm at room temperature for 1 min.  All but 
100 μl of liquid was removed, and the pellet was resuspended in the remaining LB liquid.  
The resuspended pellet was then plated onto a LB-ampicillin (AMP) or LB-Kanamycin 
(pEGFP-2xFYVE) agar plates and incubated inverted at 37°C overnight.  An individual 
transformed colony (per plate) was then selected and resuspended in 150 ml of 
autoclaved LB and incubated at 37°C with constant shaking (225 rpm) overnight.  DNA 
from the cells was then purified using QIAGEN HiSpeed plasmid maxi-prep kit 
according to manufacturer‟s instructions.  Agarose gel electrophoresis was then used in 
order to confirm the correct DNA purification, based on migration in relation to the 
number of base pairs.  DNA concentrations were then determined by measuring A260 in 
μg/μl and verifying the purity of DNA by the 260/230 and 260/280 ratios (range of 2.0-
2.2 and ~1.8 respectively). 
2.2 Cell Culture, Transfection and Cell Lysis 
 
HeLa cells and HEK293 cells were obtained from the American Type Tissue 
Culture Collection (ATCC; Manassas, VA).  HeLa cells and HEK293 cells were grown 
as a monolayer and maintained at 37°C with 5% CO2 in Dulbecco‟s Modified Eagles 
Medium/Nutrient (DMEM: Sigma-Aldrich; D6421) Ham F-12 containing 10% fetal 
bovine serum, 2 mM L-glutamine, and supplemented with antibiotics (100 units/mL 
Penicillin, 100 μg/mL streptomycin).  Cells were seeded 24 h prior to transfection and 
were approximately 60-70% confluent at the time of transfection.  Cells grown on 100 
mm culture dishes were transiently transfected with 10 µg plasmid DNA using either the 
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Polyethylenimine (PEI) reagent (100 mm dishes: Sigma-Aldrich - St Louis, 
MO;Cat.No.408727) or 5 µg using FuGENE® HD (100 mm dishes for signalling studies: 
Roche Diagnostics; Cat.No.04 709 705 001) according to the manufacturer‟s instructions.  
PEI transfections were carried out as follows: 50 µl of a 150 mM sterile NaCl solution 
was mixed and incubated with 10 µg plasmid DNA while simultaneously 50 µl of 150 
mM NaCl was mixed with 15 µl of a 1 mg/ml solution of PEI reagent (pH 7.4) for 10 min 
at room temperature.  The solutions were then mixed and incubated for an additional 10 
min, then added drop wise to the culture plates, gently mixed, then incubated at 37ºC.  
Fresh media was replaced 4 h following transfection, and then the culture plates were 
returned to 37ºC for 24-42 h incubation.  HeLa cells cultured on treated slides were 
transfected with 0.5 µg pCNF: FLAG-wild-type, S58A and S58E MTMR2 constructs in 
addition to 0.25 µg of pEGFP-2xFYVE ( a generous gift from Harald Stenmark, Oslo 
University and Norwegian Radium Hospital, Norway) [26,50] where indicated, at a 3:1 
ratio of FuGENE® HD:DNA respectively.  At 42 h post-transfection, cells were washed 
with ice-cold phosphate-buffered saline (PBS) and lysed in 0.5 ml (100 mm dish) of ice-
cold lysis buffer (50 mM Tris-HCl, pH.7.4, 1% Triton-X 100, 150 mM NaCl, 0.1% SDS) 
containing protease inhibitors (17.4 mg/ml Phenylmethylsulfonyl fluoride: 1 mg/ml 
Aprotinin).  Lysates were vortexed and cleared by centrifugation (15,000 g for 20 min at 
4°C).  The supernatant was then subjected to Bradford analysis or immunoprecipitation 
(as indicated) and stored at -20°C until analyzed by SDS-PAGE. 
2.3 Immunofluorescence Analysis 
HeLa cells were seeded on four-chamber Polystyrene vessel tissue culture treated glass 
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slides (BD Falcon – BD biosciences) in DMEM and cultured as described above.  After 
attachment (~24 h following seeding), cells were then transiently transfected by using 
FuGENE® HD transfection reagent (Roche Diagnostics; Cat.No.04 709 705 001) as 
previously described and according to manufacturer‟s instructions. 42 h post-transfection, 
coverslips/cells used for pEGFP-2xFYVE intracellular translocation assays for 
comparative control with S58A, were treated with the class III specific PI3K inhibitor 
wortmanin (LC Laboratories; W-2990) for 1 h at a final concentration of 1 µM (pEGFP-
2xFYVE alone as control).  All coverslips/cells (treated and untreated) were washed 
twice with PBS (pH 7.4) and fixed with 3.7% PFA in PBS (pH 7.3) for 10 min at room 
temperature. Where indicated, cells were initially treated with 0.01% saponin (Sigma; 
100902805) in PBS for 2 min room temperature prior to fixation. The cells were then 
washed with Tris-buffered saline (TBS) and permeabilized with 0.15% Triton X-
100/TBS for 2 min. For immunostaining, cells were pre-treated for 60 min with 5% 
BSA/PBS as a blocking agent. Then, cells were incubated with 1.0% BSA/PBS 
containing affinity purified monoclonal mouse-anti-FLAG® M2 antibody at a 1:500 
dilution (Sigma-Aldrich; F1804), in conjunction with a rabbit polyclonal antibody raised 
against the amino acids 614-709 of the endogenous human APPL1 (Santa Cruz 
Biotechnology; H-96:sc-67402) at a 1:80 dilution, a rabbit polyclonal antibody raised 
against the amino acids 1-215 of the full length Rab5A  of human origin (Santa Cruz 
Biotechnology; FL-215:sc-28570) at a 1:80 dilution, a rabbit affinity isolated antibody 
raised against the amino acids 163-177 of human Rab7 (Sigma-Aldrich; R4779) at a 1:80 
dilution, a rabbit polyclonal raised within 350 residues of the C-terminus of human 
LAMP1 (Abcam; ab24170) and rabbit polyclonal antibody raised against a peptide 
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mapping at the C-terminus of human EGFR (Santa Cruz Biotechnology; 1005:sc-03) at a 
1:50 dilution.  Cells were then washed with PBS three times 5 min and incubated with 
Alexa Fluor
®
 568  goat anti-mouse secondary antibody (Invitrogen – Molecular Probes; 
A11004) at a 1:500 dilution for anti-Flag visualization and affinity purified Fluorescein-
conjugated goat-anti-rabbit IgG (Vector Laboratories; FI1000) or Alexa Fluor® 568  goat 
anti-rabbit secondary antibody (Invitrogen – Molecular Probes; A11011) where indicated,  
in 1.0% BSA/PBS for 60 min. The cells were then washed as previously and incubated 
with Hoechst 33342 stain (0.5 mg/ml in PBS; Invitrogen – molecular probes) for 2 min at 
room temperature for DNA visualization (Fluorescence excitation 350 nm and emission 
461nm).  Coverslips were then washed with PBS, and incubated in equilibration buffer 
(Invitrogen – molecular probes) for 5 min then mounted with S2828 Slow-fade antifade 
in glycerol/PBS (Invitrogen – molecular probes) with 22 mm microscope glass covers 
(Fisher Scientific).  Fluorescence analyses were performed using a Leica DM IRB 
inverted fluorescent microscope equipped with FITC/TRITC/DAPI filter cubes and HCX 
PL S-APO 40x/0.75 objective with a 1300i FAST Cooled mono 12-bit camera (Qimaging 
Retiga).  Additionally, a Zeiss Axiovert 200M inverted fluorescent microscope with 
FITC/TRITC/DAPI filter cubes and LD Plan-APO-Neofluar 63x/0.75 or EC Plan-
Neofluar 40x/1.3oil objectives equipped with 1030x1300 monochrome CCD camera 
(Axiovision MRM) was also used.  Captured pictures from both microscopes were 
processed with Northern Eclipse software 6.0 (Empix, Mississauga, ON) with 
contrast/brightness and exposure image corrections performed using program processing 
application software in addition to Adobe Photoshop 7.0.  The criteria for cells that were 
included in the size quantification analysis had to be individual in order for discrepancies 
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and isolation amongst clustered cells and approximately circular in geometry.  All 
vesicles meeting these criteria were included for analysis and the vesicle areas for 
quantification were measured from 8-10 cells in three independent experiments for each 
with APPL1: wt_+U+SP, S58A_+SP, S58A/S631A, S58A/C417S/S631A. The area of 
each vesicle was measured using Image-J software (National Institutes of Health, 
Bethesda, MD) as described previous (Colliver et al.2000) with an analyze set scale of 15 
µm according to image magnification.   
2.4 Immunoblotting  
Following cellular lysis, protein concentrations were determined using the BioRad 
Protein Assay reagent (Cat No.500-0006) and standard BSA at 2.0 μg/μl diluted to 
desired concentrations. A standard curve was generated by reading absorbance values at 
λ595nm on the Ultrospec 31 2100 pro UV/Visible spectrophotometer, followed by 
absorbance readings of samples. These absorbance values were used to determine the 
volume (μl) of samples required in order to obtain the same protein concentrations (μg). 
Equal amounts of total protein were loaded onto polyacrylamide gels (gel percentages as 
indicated) and separated by SDS-PAGE.  Proteins were transferred to a Polyvinylidene 
fluoride (PVDF) membrane (Millipore), and blocked with 5% skim milk solution in 1X 
TBST (TBS with tween 20) or 5%BSA/TBST (pSer
58
.MTMR2, Pathscan®, pJNK1 and 
pEGFR.Tyr1173).  For co-immunoprecipitaion experiments, both lysates and IP samples 
were then incubated with mouse monoclonal anti-FLAG® clone M2 antibody (Sigma; 
F3165) in 1% skim milk at a 1:3000 dilution for 1 h at room temperature or overnight at 
4°C with constant shaking. The membrane was washed three times in 1X TBST and 
incubated with anti-mouse IgG HRP conjugate (W4021; Promega) in 1% skim milk at a 
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1:5000 dilution for 45 min room temperature with gentle agitation. The secondary 
antibody was removed, washing steps performed as previously described, and then 
imaging was performed using the Alpha Innotech Imager and the chemilmager v5.5 
software with chemiluminescence filter. Bound antibodies were visualized using Super 
Signal® West Femto maximum sensitivity substrate (34095; Thermo scientific). 
2.5 Protein Expression and Purification  
Highly competent Escherichia coli BL21 (DE3) Codon Plus cells (Stratagene) 
were transformed (80 µl cells) with 500 ng of a bacterial recombinant pETvector 
containing C-terminally His6-tagged fusion proteins of either wild-type MTMR2 or 
phospho-mutants (S58A,S58E), plated onto LB-ampicillin+chloramphenicol (100 
µg/mL,30 µg/mL) agar plates and incubated inverted overnight at 37ºC.  A 5 mL solution 
of 2xYT containing 100 µg/mL:30 µg/mL ampicillin:chloramphenicol  was inoculated 
with a single bacterial colony and incubated at 37
o
C overnight with shaking at 225 rpm. 
This entire 5 mL culture was then used to inoculate 500 mL of 2xYT media 
supplemented with 100 µg/mL:30 µg/mL ampicillin:chloramphenicol.  The large scale 
culture was incubated at 37
o
C with 225 rpm shaking for approximately 2.5 h, until 
reaching an optical density of 0.6 at a wavelength of 600 nm.  Expression of the 
recombinant His6-tagged fusion proteins was induced by the addition of isopropyl-β-D-
thiogalactopyranoside (IPTG) to a final concentration of 0.8 mM and shaken at 240 rpm 
at room temperature for 16 h.  Following incubation, cultures were pelleted by 
centrifugation at 6000 rpm for 15 min at 4
o
C.  The supernatant was discarded and the 
pellets were fully resuspended in lysis buffer (50 mM Tris, 300 mM NaCl, 20 mM 
Imidazole, 0.5% Triton X-100, 1 mM PMSF, 0.05% β-mercaptoethanol, pH 8.0 with 
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phosphatase and protease inhibitors; 17.4 mg/ml PMSF: 1 mg/ml Apr).  The suspended 
cells were sonicated at 4ºC in ice, for 3 min followed by centrifugation at 2,000g for 15 
min at 4ºC.  HIS-select Ni
2+
-affinity resin (Sigma-Aldrich; P-6611) was  equilibrated 
with 10 ml of lysis buffer, centrifuged in a swinging bucket rotor at 1600 g for 2 min at 
4ºC, and the buffer solution discarded prior to sample loading.  The supernatant lysates 
were added to 1 mL of pre-equilibrated HIS-select Ni
2+
-affinity resin and incubated for 2 
h at 4ºC.  The resultant was centrifuged at 2,000 g for 5 min at 4ºC and the supernatant 
was discarded.  The resin was washed three times with lysis buffer containing 0.5% 
Triton X-100, then an additional three times in lysis buffer without detergent (no Triton 
X-100).  The HIS-tagged fusion proteins were eluted from the resin for 3 x 30 min with 
0.5 ml of elution buffer (50 mM Tris, 50 mM NaCl, 300 mM imidazole, 0.1% v/v β-
mercaptoethanol  pH 8.0) containing protease inhibitors (17.4 mg/ml PMSF: 1 mg/ml 
Apr) and filtered through a 0.2 µm syringe filter.  The purified proteins were stored in 
10% glycerol, 1 mM DTT, 1 mM PMSF and retained at -80°C until further use. Protein 
concentrations were determined by the Bradford assay using BSA as a standard as 
described previously. Protein purification was determined by SDS-PAGE followed by 
Coomassie staining.  
2.6 EGF Treatments and Signaling Pathway Analysis  
Cells were transiently transfected with pCNF-FLAG MTMR2 constructs (wild-
type, S58A, S58E, and S58A/S631A) as previously described, were incubated in serum 
free medium (DMEM Ham-F12 supplemented with glutamine and antibiotics as 
previous) at 37°C for 30 min.  Subsequently, an equal volume of serum free medium 
containing EGF used at final concentration of 5 ng/ml (Sigma-Aldrich; E4127) was 
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added to the dishes and incubated at 37°C.  At the indicated time points, cells were 
washed in cold PBS and lysed in lysis buffer prior to immunoblotting analysis as 
previously described. The antibodies used for signal detection are as follows: rabbit 
PathScan® Multiplex Western Cocktail I (5301; Cell signalling technology) at a 1:200 
dilution in 5% BSA/TBST overnight at 4°C with secondary anti-rabbit HRP used at a 
1:2000 dilution in 1% skim milk (Bio-Rad; cat.no.170-6515) with all subsequent 
secondary antibody dilution at 1:5000, rabbit anti-MAPK antibody (M 56701; Sigma) at 
1:10,000 dilution, rabbit anti-EGFR (1005.sc-03; Santa cruz biotechnology) at a 1:3000 
dilution, rabbit-phospho-EGFR (Tyr1173) at a 1:200 dilution in 2.5%BSA/TST with 
secondary anti-rabbit at 1:2000 in 2.5% BSA/TBST and affinity isolated rabbit anti-actin 
(Sigma-Aldrich: A2066) at a 1:3000 dilution. 
2.7 Immunoprecipitation 
HEK293 cells co-transfected with pCNF-FLAG-MTMR2 constructs (as 
indicated) and pCNF-FLAG-MTMR5-FRI (a generous gift from Fred Robinson, 
University of San Diego, CA) [25] were immunoprecipitated using goat anti-MTMR5 (I-
13.sc-51135; Santa Cruz biotechnology) at 1 µg antibody/20µl Protein A-agarose 
(Invitrogen; cat.no.15918-014 ) for co-immunoprecipitation studies (as indicated), or 
with anti-flag-M2 affinity gel as indicated (Sigma).  Immunoprecipitations were 
incubated for 3 h at 4 °C and subsequently washed with 0.5 ml of IP wash buffer (50 mM 
Tris-HCl, pH 7.4, 0.1% Triton-X 100, 150 mM NaCl, 0.1% SDS) three times. 
Immunoprecipitates were suspended in 2X SDS sample buffer (0.12 M Tris-HCl pH 6.8, 
4% SDS, 0.3% β-mercaptoethanol, 10% glycerol, 0.004% bromophenol blue, 3% DTT) 
boiled at 95°C for 5 min, vortexed, and centrifuged at 15,000 rpm for 2 min. All 
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immunoprecipitates and lysates were resolved in 8 (for MTMR5 co-
immunoprecipitation), 10 or 12% Ployacrylamide (BioRad laboratories) gels, transferred 
to polyvinylidene difluoride (PVDF) membranes (Millipore), and analyzed by 
immunoblotting.  Immunoprecipitated samples preparation for gel excision for MS 
analysis were isolated using anti-FLAG-M2 affinity gel (Sigma) 
2.8 Sample Preparation for MALDI MS 
Immunoprecipitated FLAG-tagged proteins were first separated on a 10% 
polyacrylamide gel and the proteins of interest were excised and subjected to in-gel 
trypsin digestion.   The excise bands of interest were initially destained 3x 25 min at 37°C 
225 rpm with 50% acetonitrile:50% ammonium bicarbonate.  The gel pieces were 
dehydrated with 100% ACN, centrifuged at 5,000 rpm for 30 sec, with this process 
repeated twice, each removing the supernatant.  The gel pieces were dried in a speed 
vacuum for 20 min and the resultant was re-hydrated with 13 ng/ml trypsin (in 50 mM 
ammonium bicarbonate) and incubated at 37°C 225 rpm for 2 h.  A 2 µl “pre-extract” 
sample was aliquoted with the addition of formic acid ([ ]F = 1%), then stored at -20°C 
until further analysis.  The gel/trypsin sample was returned to the 37°C incubator for 
overnight digestion.  The “extract” sample was obtained following overnight digestion 
with the addition of peptide extraction solution (60% ACN, 39% ddH2O, 1% formic acid) 
and incubation at 37°C for 45 min (repeated 2x).  The resultant supernatants were stored 
in a siliconized micro centrifuge tube containing formic acid ([ ]F = 5%) at -20°C until 
further analysis.  The resulting solutions containing proteolytic fragments were spotted (1 
μL) on a MALDI sample plate followed by 1 μL of a freshly prepared solution of a UV 
absorbing matrix (1% α-cyano-4-hydroxycinnamic acid (Sigma), 60% ACN (HPLC 
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grade, Burdick and Jackson), 0.01% formic acid. Peptide fragments were analyzed by 
MALDI-TOF-MS in linear mode using Voyager DE Pro Biospectrometry Workstation 
(Applied BioSystems). 
2.9 In Vitro Phosphoinositide Phosphatase Assays 
All phosphatidylinositol polyphosphate substrates used in this work were obtained 
from Echelon Research Laboratories (Salt Lake City, UT). Phosphatase assays were 
carried out using  50 ng of bacterial recombinant purified MTMR2-His6 proteins in 
reaction buffer (50 mM Tris, 150 mM NaCl, 50 mM Bis-Tris and 5 mM DTT, pH 7.0) 
containing 100 µM of nonfluorescent di-C8- phosphatidylinositol phosphate derivatives 
(Echelon;D8-myo-Phosphatidylinositol lipid substrates [PI(3)P, PI(3,4)P2,PI(3,5)P2, 
PI(3,4,5)P3, PI(5)P] reconstituted in autoclaved sterile milliQ H2O at final concentration 
of 1 mg/ml.  Reactions were carried out at 30 °C for 5 min and terminated using equal 
volume of 20 mM Sodium Orthovanadate (pH 10.0. Sigma-Aldrich; S6508), and 
phosphate release was determined using a malachite green-based assay system (Echelon; 
K-1500) for detecting inorganic phosphate as described [25].  The absorbance 
measurements at wavelengths 620nm/660nm were measured using a Victor
3
TM wallac 
1420 multilabel counter (Perkin Elmer) and Workout 2.0 program applications with free 
phosphate release determined using non-linear regression analysis [(specific activity 
reported in terms of mol·min
-1
·mol
-1
(mol inorganic phosphate released/min·mol 
enzyme)]. 
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RESULTS 
 
2.1 The N-terminus of MTMR2 Posses a High Stoichiometry Phosphorylation Site  
In order to examine if MTMR2 is modified by phosphorylation, wild-type FLAG-
MTMR2 was immunoprecipitated from HEK293 cells and protein samples resolved by 
SDS-PAGE.  The protein band corresponding to MTMR2 was excised and subjected to 
in-gel trypsin digestion for analysis by MS (Supplemental figure 1).  Phosphorylated 
proteins are rarely detected in unfractionated trypsin digests primarily owing to their low 
stoichiometry and poor ionization therefore will generally require some form of 
purification and/or phosphopeptide enrichment step.  Interestingly, when a „pre-
extraction‟ aliquot was analyzed by MALDI-TOF, we detected a prominent peptide peak 
at m/z 2322 which corresponds to a phosphorylated N-terminal peptide containing a 
single phosphate moiety (figure 1).  Additionally, we observed a prominent peptide peak 
at m/z 2242 corresponding to the same peptide lacking the phosphate moiety (figure 1).  
Reproducible scans in independent experiments yielded these two peptides are present at 
relative equal intensities. Taken together, these results support the notion that the 
stoichiometry of phosphorylation at Ser
58
 on MTMR2 is at least or greater than 50% 
implicating that MTMR2 is highly phosphorylated at this site under the cellular 
conditions used in this study.     
2.2 Identification of Ser
58
 as the N-terminal Phosphorylation Site  
Considering the results implicating high levels of MTMR2 phosphorylation under 
normal cellular conditions, previous work performed by Dr. Otis Vacratsis and Dr. 
Gregory Taylor were aimed at precisely identifying the site of phosphorylation within the 
phosphorylated N-terminal peptide (m/z 2322).  In order to elucidate and identify the 
particular site of MTMR2 phosphorylation, FLAG-MTMR2 was immunoprecipitated  
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Figure 1. MTMR2 possesses a high stoichiometry phosphorylation site within its N-
terminus 
 
FLAG-tagged MTMR2 was isolated from HEK293 cells by immunoprecipitation and 
separated by SDS/PAGE. The MTMR2 band was excised from the gel and subjected to 
in-gel digestion with trypsin. Displayed is the MALDI-TOF linear spectrum of the total 
pool of MTMR2 tryptic peptides. The m/z values corresponding to the unphosphorylated 
(m/z 2242) and phosphorylated (m/z 2322) forms of peptide Ser41-Arg62 are boxed. This 
region is also shown as an expanded view.  
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Figure 2. Mapping the N-terminal phosphorylation site using MALDI-CAF-MS 
 
MTMR2 tryptic peptides were fractionated by reverse phase HPLC. (A) The HPLC 
fraction containing the phosphopeptide of interest was further analyzed by MALDI-TOF 
MS/MS. The neutral loss of the phosphate moiety (-98m/z) is indicated. (B) The same 
HPLC fraction was subjected to CAF labeling and re-analyzed by MALDI-TOF MS/MS. 
The fragment ions whose m/z value corresponds to y or b ions with the loss of a 
phosphate group are indicated. The observed fragment ions are labeled on the spectrum 
and peptide sequence (phosphorylated Ser
58
 is underlined and in bold text).  
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from HEK293 cells that were radiolabeled with [
32
P] orthophosphate, resolved by SDS-
PAGE and analyzed by autoradiography.  Correspondingly, results revealed that the 
FLAG-MTMR2 immunoprecipitated protein was highly phosphorylated.  In attempts for 
further purification, the proteins were separated by SDS-PAGE and the band of interest 
was excise and subjected to in-gel trypsin digestion.  The total tryptic peptide pool was 
then separated using reverse phase HPLC and the phosphorylated peptide of interest was 
identified in HPLC fraction 68 that was further analyzed by MALDI-MS/MS.  The parent 
ion at m/z 2322 was readily detected in MALDI-linear mode, and further fragmentation 
(MALDI-PSD) yielded an intense peak at m/z 2224 corresponding to the same N-
terminal peptide with a neutral loss of the phosphate group (figure 2.A).  However, this 
peptide exhibited no additional fragmentation and recognizing that there were a total of 
eight potential phosphorylation sites within this N-terminal peptide, additional steps were 
required for precise identification.  To improve the MS/MS spectrum, the tryptic peptides 
were further subjected to Chemically-Assisted Fragmentation (CAF) analysis which 
successfully increased fragmentation along the peptide backbone [26].  Precise analysis 
of the fragmented ion series allowed for unambiguous identification of phosphorylation 
to Ser
58
 (figure 2.B). 
2.3 MTMR2 Ser
58
 Phosphovariants Retain Catalytic Competence and MTMR5 
Binding Activity 
 
The most prevalent form of cellular PTMs is reversible phosphorylation which 
has largely been thought of as a means to induce conformational changes in enzymes that 
causes alterations in their catalytic activity.  The N-terminal phosphorylation site on 
MTMR2 resides in close proximity to the PH-GRAM domain, which has been proposed 
to be important in mediating correct lipid substrate interaction.  To test whether the N-
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terminal site has an effect on catalytic activity, phosphovariants were generated by site 
directed mutagenesis to produce a phosphorylation mimetic (S58E) and phosphorylation-
deficient (S58A) MTMR2 mutant proteins. We purified recombinant MTMR2 proteins 
from BL21 Escherichia coli lysates (Supplemental figure 2) and compared their in vitro 
phosphoinositide phosphatase activity against water soluble physiological substrates di-
C8-PI(3)P and -PI(3,5)P2 (D8-myo-Phosphatidylinositol lipids).  A darker protein band at 
73kDa in the induced lanes represents successful induction with IPTG and the large thick 
band in the elution lane indicates purification of the protein of interest.  We determined 
the pH optimum and most favourable incubation period for activity to be pH 7.0 and 10 
min at 30°C, parallel to recently published data on MTMR6 [27].  Three independent 
trials were performed and the average phosphatase activity represented as pmol of 
phosphate released using the Malachite-Green based assay system, were then compared 
by statistical analysis and relative phosphatase activities were determined (figure 3A).  
MTMR2 and phosphovariants retained full catalytic activity towards their known 
physiological substrates PI(3)P and PI(3,5)P2 and did not demonstrate and significant 
differences in activity with comparison to wild-type MTMR2.  Moreover, there was no 
significant activity towards other control phosphoionositols indicating that point 
mutations at Ser
58
 do not have any effects on the phosphatase activity of MTMR2.   
Previously, it has been demonstrated that MTMR2 interacts with the catalytically 
inactive MTMR proteins; MTMR5 and MTMR13 and that deletion of the critical C-
terminal CC region of MTMR2 results in loss of heterocomplex formation and abolishes 
this interaction [28].  In addition, it has been shown that the closely related  
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Figure 3. Lipid phosphatase activity and MTMR5 association is unaffected by the 
phosphorylation status of Ser
58
  
 
(A) Phosphatase assays using purified recombinant MTMR2 proteins were carried out at 
30 °C for 10 min with 50 ng of enzyme (■ wild-type; ■ S58A; ■ S58E) and 100µM of 
the indicated phosphoinositide substrates as described under “Materials and Methods.” 
Phosphate release was measured using a malachite green-based assay for inorganic 
phosphate. The relative amount of phosphate released by recombinant MTMR2 proteins 
in these assays is shown in picomoles and represents the mean of triplicate 
determinations ±S.D. (n=3). (B) Immunoprecipitation of overexpressed FLAG-tagged 
MTMR5 (lane 2) and co-expression with MTMR2 proteins (lanes 3-5) from HEK293 
cells. At 42 h post-transfection, cell lysates were prepared and subjected to 
immunoprecipitation (IP) using anti-MTMR5 antibody conjugated to Protein A-agarose 
beads. Following SDS-PAGE, immunoprecipitated proteins were detected by 
immunoblotting (IB) using anti-FLAG antibody.  Whole cell lysates were probed for 
MTMR5 and MTMR2 to verify protein expression.  
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family member MTMR6, interacts with the catalytically inactive MTMR9 resulting in 
increased 3-phosphatase activity of MTMR6 [27].  Collectively, this implicates an 
important role with respect to the correct biological modulation of their corresponding 
active partners.  We therefore sought to examine the in vivo effect of the N-terminal Ser
58
 
phosphorylation site mutations on the binding capability towards MTMR5 by transiently 
co-expressing both FLAG-MTMR2 and phospho-variants with FLAG-MTMR5 in 
HEK293 cells.  Following 42 h transfection, cells were lysed and co-immunoprecipitation 
was performed.  Following co-immunoprecipitation, the samples were then separated by 
8% SDS-PAGE and probed for both of the overexpressed FLAG proteins. The 
association affinity towards MTMR5 was not affected upon point mutations at Ser
58
 
(figure 3B) implicating the unambiguous association primarily to be through the C-
terminal coiled-coil region as previously described [27].  Thus, the imposing interaction 
of MTMR2 and MTMR5 is not modulated by N-terminal phosphorylation and may 
collectively be influenced by alternative biological signals.  Taken together, these results 
demonstrate that phosphorylation of Ser
58
 does not affect the lipid phosphatase activity of 
MTMR2 or its ability to interact with inactive MTMR proteins. 
2.4 Phosphorylation of Ser
58
 regulates MTMR2 Subcellular Localization 
The overexpression of MTM1 and MTMR2 has been previously shown to result 
in decreased cellular pools of PI(3)P, and that siRNA mediated MTM depletion resulted 
in a striking accumulation of both PI(3)P and PI(3,5)P2 [30].  Predominant cytosolic 
staining with greater intensity in the perinuclear region for wild-type MTMR2 has been 
formerly reported in COS-1 cells and HEK293 cells [28,30,31].  Additionally, there was 
no detectable localization of overexpressed wild-type or endogenous MTMR2 with any 
particular subcellular organelle(s) or membrane compartment in these systems [28,30]. 
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More recent studies have shown that the closely related family member, MTM1 localizes 
to Rab5 positive endosomes and to a lesser extent with Rab7 [30].   
MTMR2 contains an N-terminal PH-GRAM domain which has been proposed to 
be important in MTMR2 localization and function as a PIP binding module [32].  It is 
plausible that protein modifications and/or mutations that affect PH-GRAM function, 
may also affect localization as previously shown with MTMR2 in COS-cells, in which 
mutations within this domain, prevented its localization to vacuole membranes following 
hypoosmotic shock [32].  Considering that the N-terminal phosphorylation site of 
MTMR2 resides approximately 11 amino acids upstream of the PH-GRAM domain, we 
therefore investigated its potential involvement in regulating MTMR2 subcellular 
localization.  As a primary step to understanding the functional differences between wt-
MTMR2 and mutations, localization patterns of phosphorylation site mutants were 
compared (figure 4).  In order to study the potential involvement of MTMR2 in the 
endocytic pathway, HeLa cells were transfected with FLAG-wild-type, S58A or S58E 
then fixed, permeabilized and incubated with mouse monoclonal M2-α-FLAG antibody 
with corresponding α-mouse Alexa Fluor® 568 secondary antibody and analyzed by 
immunofluorescence as previously described under “Materials and Methods”.  We 
observed that wild-type MTMR2 displayed dispersed localization predominantly in the 
cytoplasmic region of FLAG transfected HeLa cells, with greater fluorescence intensity 
in the perinuclear region as previously reported (figure.4.A) [28,30].  Saponin prior to 
fixation and immunostaining has been shown to deplete soluble cytoplasmic proteins, and 
permit visualization of membrane-localized proteins [33].  When HeLa cells over 
expressing wild-type MTMR2 were treated with saponin there was greatly reduced  
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Figure 4. MTMR2 S58A localizes to punctate structures 
 
HeLa cells were transfected with FLAG-MTMR2 phosphorylation mutants: wild-type (A 
and B), S58A (C and D), S58E (E and F). Following fixation, the cells were 
immunostained with anti-FLAG monoclonal antibody to localize FLAG-MTMR2 
proteins. Saponin treatment (right panels) (0.01%) was used to enhance detection of 
membrane-localized proteins via depletion of cytosolic contents. Images were collected 
using 63x and 40x HD objectives. The scale bar represents 15 µm (10 µm in expanded 
views).   
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fluorescence intensity observed, suggesting that wild-type staining was predominantly 
cytoplasmic (figure 4.B).  Intriguingly, the phosphorylation mimetic mutant S58E, also 
displayed an identical characteristic localization phenotype within the cytosolic region 
and complete loss of fluorescence staining following saponin treatment (figure.4.E,F).  
These results imply and are coincident with the stoichiometric MS data implying that 
wild-type MTMR2 is highly and differentially phosphorylated at Ser
58
.  
Furthermore, our phosphorylation-deficient mutant S58A displayed an opposite 
and unique phenotype with distinct punctate localization staining indicative of endosome 
localization (figure 4.C).  Accompanying treatment with saponin revealed a larger portion 
S58A fluorescence remained in a punctate staining pattern, implying direct localization to 
intact subcellular organelles (figure.4.D). Additionally, expression of empty-vector 
FLAG alone did not reveal any punctate localization as a comparative control and was 
mainly observed as nuclear staining with moderate observance in the cytoplasmic region 
(figure 4.G-H).  This is the first report of MTM regulation by phosphorylation and may 
be the link surrounding involvement in the endosomal pathway with efficient and correct 
substrate targeting.  Collectively, these results strongly suggest that phosphorylation of 
Ser
58
 thus regulates MTMR2 subcellular localization whereby phosphorylation sequester 
MTMR2 in the cytoplasm and preventing its targeting to endocytic membranes. These 
findings are also highly suggestive that only once MTMR2 is dephosphorylated will it 
then preferentially localize to endocytic-like vesicles. 
2.5 MTMR2 Phosphorylation Deficient Mutant Localizes to Early Endosomes 
On the basis of distinct localization changes and known functions of MTMR2 in  
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PI(3)P regulation, we next sought to examine into the particular subcellular compartment 
to which S58A may be localized.  Considering that formation of the physiological 
substrates of MTMR2 are differentially regulated by the small GTPases Rab5 and Rab7, 
respectively, and have been previously demonstrated to play a pivotal role in PI(3)P 
degradation, we initially examined these compartments for the primary target(s) [30].  
Additionally, these GTPases have been well characterized to associate with early/late 
endosomes where they facilitate endosome maturation and trafficking processes [34].  To 
test whether FLAG-MTMR2 proteins localized to Rab5 positive vesicles, we 
overexpressed MTMR2 in HeLa cells and performed immunofluorescence probing for 
the endogenous early endosomal protein Rab5.  Wild-type MTMR2 displayed no co-
localization with Rab5, with the absence of any punctate distribution within the cytosolic 
region as previously shown here and also formerly reported (Supplemental figure 3.A-C) 
[28,30,31].  Additionally, S58E displayed an identical pattern to wild-type MTMR2 
displaying dispersed cytosolic staining and lack of any co-localization with Rab5 
(Supplemental figure 3.G-I).  However, when S58A was overexpressed in HeLa cells and 
probed for Rab5, there were to a significant extent a subset of vesicles displaying co-
localization with Rab5 within the punctate patterns of the cytosolic region as displayed 
within the enlarged sections (figure 5.A-C).  Notably following saponin treatment, there 
was significant Rab5 and S58A immunostaining that were found on neighboring vesicles 
or opposite sides of the same vesicle (figure 5.D-F). Moreover, saponin treatment 
revealed to a greater extent that these coalesced regions lie directly on subcellular 
organelles and a greater percentage of co-localized regions remained.  In contrast, we did 
not detect significant co-localization of wild-type MTMR2, S58A or S58E with Rab7 
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Figure 5. Co-localization of MTMR2 S58A with the early endosomal protein Rab5  
 
HeLa cells were transiently transfected with FLAG-MTMR2 S58A for 42 h and analyzed 
by immunofluorescence microscopy without saponin treatment (A–C), or with saponin 
treatment (D–F). Cells were probed for endogenous Rab5 (green) (A and D) and FLAG-
MTMR2 S58A (red) (B and E). Merged images are shown to indicate partial co-
localization (yellow) (C and F). Arrowheads indicate regions of interest and are presented 
in expanded views. Images were collected using 63x (top panel) and 40x oil (lower 
panel) objectives. The scale bar represents 15 µm (10 µm in expanded views). 
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(Supplemental figure 4.A-C, D-F, G-I). 
Acknowledging only partial staining of MTMR2.S58A and Rab5, we considered 
that this may be attributed to the phosphatase activity of MTMR2.  Progression of 
endocytosed vesicles to Rab5 positive early endosomes in addition to Rab5 dependent 
trafficking events, are tightly regulated by the association of PI(3)P binding proteins, 
implicating these events may be sensitive to changes in PI(3)P levels.  Therefore, in order 
to precisely define the compartment to which S58A localized, we generated a 
catalytically inactive MTMR2 phosphorylation-deficient mutant (S58A/C417S) and 
performed co-immunofluorescence analysis with various endocytic markers (figure 6).  
Following immunostaining for our overexpressed protein S58A/C417S and endogenous 
markers, we observed a strong degree of co-localization with Rab5 in addition to the 
PI(3)P marker EGFP-2xFYVE (figure 6.top two panels).  However, when this inactive 
mutant was overexpressed and probed for endogenous markers of late endosomes, we did 
not observed any regions of co-localization with Rab7 or LAMP1 (figure 6. bottom two 
panels).  These results are highly suggestive that dephosphorylation of MTMR2 results in 
subcellular targeting particular to early endosomes that are rich in its physiological 
substrate PI(3)P. 
2.6 Endocytic Localization of S58A Greatly Enhances Endocytic PI(3)P Depletion 
 
In addition to Rab GTPases, levels of PI(3)P are indicative of actively maturing 
endosomes. The MTMR2.S58A mutant contained lipid phosphatase activity that was 
comparable with that of the wild-type enzyme.  Considering the evidence determined in 
this study, we were interested in further distinguishing and examining if S58A 
localization to early endosomes resulted in targeted PI(3)P depletion. More specifically, 
wild-type MTMR2 did not display any localization to endosomal structure however our 
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Figure 6.Co-localization of catalytically inactive MTMR2 S58A.C417S with early 
endosome markers  
HeLa cells were transiently transfected with FLAG MTMR2 S58A.C417S alone or co-
transfected with EGFP-2xFYVE (upper panel) for 42 h and analyzed by 
immunofluorescence microscopy with saponin treatment. Cells were probed for FLAG-
MTMR2 S58A (red) and endogenous Rab5, Rab7, or LAMP1 (green). Merged images 
are shown on the right panels with yellow indicative of co-localization. Boxes indicate 
regions of interest and are presented in expanded views. Images were collected using 63x 
objectives. The scale bar represents 15 µm (10 µm in expanded views).  
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S58A did exhibit marked localization predominantly to early endosomes. Therefore, we 
were interested in determining whether S58A affected PI(3)P levels on the surface of 
these vesicles.  Early endocytic vesicle fusion requires EEA1 which in turn is localized to 
early endosomes via the C-terminal FYVE finger and PI(3)P [53].  The construct 
comprises two FYVE domains with C-terminal EGFP fusion, supporting specific PI(3)P 
binding and localization to early endosomes.  The results displayed are punctate 
structures within the cytoplasm of cells with binding being dependent upon PI3K activity 
in order to generate the PI(3)P product from phosphorylation of  PIs.  
 HeLa cells were co-transfected with FLAG-MTMR2 proteins and EGFP-
2xFYVE, a marker used for the detection of PI(3)P rich endosomes which was also 
useful for monitoring translocation effects such as through indirect immunofluorescence 
[8].  The subcellular localization of EGFP and endogenous MTMR2 has been previously 
reported in HEK293 cells showing global GFP fluorescence for empty vector-EGFP 
constructs and cytoplasmic localization for both endogenous and overexpressed wild-type 
MTMR2 respectively [28,30,31,36].  Specific proteins bind to the PI(3)P lipid head 
groups through Phox homology (PX) domains or cysteine rich double zinc FYVE-fingers 
[35].  Depletion of the PI(3)P through PI3K inhibition with wortmanin has been 
demonstrated to result in marker re-distribution as a result of EGFP-2xFYVE dissociation 
from early endosomes (figure 7.D-F) [35].  The Phosphoinositide PI(3)P is crucial for 
correct endocytic membrane trafficking, and as a result, excessive endosome depletion 
could disrupt the recruitment of proteins to specific membrane compartments such as 
Rab5 [35].  We identified that co-transfection of EGFP-2xFYVE with wild-type MTMR2 
displayed the observed cytoplasmic phenotype, and had no effect on the distribution 
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pattern of the FYVE domain marker, with characteristic punctate staining (figure7.J-L).  
Moreover, the phosphomimetic S58E mutant displayed a similar phenotype of 
cytoplasmic localization with no overall translocation effects on the EGFP-2xFYVE 
marker (figure 7.M-O).  Intriguingly, HeLa cells that were positively co-transfected with 
S58A resulted in cytoplasmic dispersion of the marker following endosomal targeting as 
displayed by the punctate fluorescence staining pattern of S58A (figure 7.G-I).  The 
intracellular translocation of the marker implies that PI(3)P rich endosomes are depleted 
therefore rendering absence of the FYVE finger to bind to the phospholipid ligands.  
Also, the catalytically inactive dephosphorylated MTMR2 (S58A,C417S) did not 
disperse the EGFP-2xFYVE PI(3)P marker (figure. 6. top panel) in contrast to the 
catalytically active dephosphorylated MTMR2 (S58A) indicating that the observed 
depletion of PI(3)P does require the phosphatase activity of MTMR2.  Taken together, 
these results indicate that phosphorylation deficient MTMR2 preferentially localizes to 
early endosomal vesicles, where it effectively targets and depletes PI(3)P.  These results 
further suggest that the localization of MTMR2 is mediated by reversible 
phosphorylation, and ultimately regulates localization to early endosome in addition to 
the levels of PI(3)P at these regions. 
2.7 MTMR2 Phosphorylation Site Mutant Augments EGF Signaling  
 
The overexpression of wild-type MTMR2 has been previously elucidated to have 
a total cellular effect on PI(3)P pools resulting in large reduction of lipid levels [29].  
However, the particular function of MTMR2 in the endocytic pathway has yet to be 
elucidated [32,37].  There have been implications regarding the importance of MTM lipid 
phosphatases in regulation of PI(3)P and PI(3,5)P2, yet it has not been determined the  
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Figure 7. MTMR2 S58A expression depletes PI(3)P from endosomes 
 
HeLa cells were co-transfected with EGFP-2xFYVE and FLAG-MTMR2 
phosphorylation mutants. After fixation, the cells were immunostained with anti-FLAG 
and Alexa Fluor
®
 568 anti-mouse secondary to detect MTMR2 proteins. Localization of 
the PI(3)P sensor EGFP-2xFYVE (right panels) on endosomes was detected as a punctate 
pattern. The punctate pattern is seen in control cells (A–C), and cells expressing wild-type 
MTMR2 (J–L) and S58E (M–O). The altered localization of the EGFP-2xFYVE marker 
was observed in both wortmanin-treated cells (D–F) and in cells expressing MTMR2 
S58A (G–I). Images were collected using 63x and 40x HD objectives. The scale bar 
represents 15 µm. 
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particular link to endosomal PI levels [29].  Recent work has shown that recruitment of 
the catalytically active MTM1 to Rab5 endosomes resulted in targeted PI(3)P depletion, 
which emanated in enhanced and prolonged Erk1/2 phosphorylation in addition to 
increased phosphorylation of Akt substrates [28].  In order to address the potential effects 
of MTMR2 endosomal targeting on subsequent signaling pathways, HeLa cells were 
transiently transfected with FLAG-MTMR2 and S58A, lysed and the phosphorylation of 
EGFR effectors was monitored over several times periods following low dose EGF 
(5ng/ml) stimulation (figure 8).  Our own work showed that MTMR2 is recruited to early 
endosomes induced by dephosphorylation of the N- terminal Ser
58
 site resulting in 
depletion of PI(3)P (figure.7).  We therefore examined whether several early EGFR 
effector pathways were induced, by monitoring two different mammalian cell lines.  An 
intense increase in the phosphorylation of Erk1/2 was observed with S58A compared to 
wild-type transfected cells (figure 8A) predominantly in the earlier treatment time periods 
(3-5 min).  Quantification by densitometry analysis revealed an ~2-fold increase in 
Erk1/2 phosphorylation observed with S58A versus wild-type at the early time periods of 
3 min and 5 min respectively (figure 8B).  An obvious difference in phosphorylation of 
Akt (Ser473), S6 Ribosomal Protein (Ser235/236) and 90 Ribosomal S6 Kinase (Ser380) 
was also observed, however with a less discrete difference, possibly a result of early 
activation and signal diminishment.  
We then determined and compared the relative strength of the enhanced signaling 
activity by comparing two independent mammalian cells lines concentrated at the earlier 
5 min time period; HEK293 and HeLa cells (figure 9).  The strength and increase in 
Erk1/2 phosphorylation was distinctively observed with S58A in comparison to untransf- 
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Figure 8. Phosphorylation-deficient MTMR2 increases activation of EGF signaling 
(A) HeLa cells transfected with wt FLAG-MTMR2 and S58A were serum starved for 30 
min and treated with 5 ng/ml of EGF for the indicated times. Lysates were 
immunoblotted (IB) for proteins phosphorylated in response to EGF treatment using the 
Pathscan
®
 Multiplex antibody to detect phosphorylated proteins. Loading controls 
included total ERK1/2 and actin. FLAG-MTMR2 was immunostained with anti-FLAG to 
confirm equal MTMR2 expression levels in each of the samples. (B) ERK1/2 
phosphorylation levels were quantified by densitometry using Image J, and normalized to 
total ERK1/2 levels. The values indicate the mean ±S.D. (n =3). 
 
 
 91 
 
 
Figure 9. ERK1/2 activation enhanced by phosphorylation deficient MTMR2 
 
(A) HeLa and HEK293 cells were transfected with FLAG-MTMR2 expression vectors 
for 42 h. The cells were serum starved for 30 min and treated with 5 ng/ml of EGF for 5 
min at 37 °C. ERK1/2 phosphorylation was determined by immunoblotting. Total 
ERK1/2 and actin levels served as loading controls. FLAG-MTMR2 immunoblotting was 
used to confirm equal transfection between samples. (B) ERK1/2 phosphorylation was 
quantified by densitometry using the Image J program and normalized to total ERK1/2 
levels (■HeLa;■HEK293). The values are shown as fold-change from control ±SD (n=3). 
 
 
 
 92 
-ected cells, wild-type MTMR2 and phospho-mutant S58E (figure 9A).  Quantification 
by densitometry revealed a striking difference with nearly a ~2-fold increase in ERK1/2 
phosphorylation with S58A in both HEK293 and HeLa cells, with values normalized to 
total ERK1/2 expression levels (figure 9B). Additionally, the observable increased 
signaling of phospho-90RSK could be a result of downstream ERK1/2 activation and 
appears that there may be variation within different systems considering a larger was 
contrast observed with HEK293 cells in comparison to HeLa cells.  Interestingly, there 
was also observed a large increase in phospho-Akt which suggest that the affect of 
MTMR2 N-terminal dephosphorylation (as represented by S58A) may represent 
alternative effects on signaling pathways and may not only be specific to EGFR effectors.  
These findings provide a biological consequence of MTMR2 N-terminal 
dephosphorylation and present evidence of the important role of MTMR2 in the 
regulation and trafficking of not only growth factor receptors, but within the regulation of 
the early endocytic pathway.   
We also sought to address any potential effects on EGF-receptor activation and 
localization under these same conditions.  HeLa cells were transfected with MTMR2- 
S58A and stimulated with EGF (5 ng/mL) particularly at 5 min stimulations and analyzed 
by immunofluorescence.  Under these conditions, we observed strong regions of co-
localization with endogenous EGFR indicating that dephosphorylation of MTMR2.Ser
58
 
results in receptor interaction in the early endocytic stages (figure 10).  Additionally, we 
examined direct receptor activation of EGFR at Tyr1173, which is a known site of 
activation by phosphorylation that is linked to ERK1/2 signaling events.  HEK293 cells 
were transfected with FLAG-MTMR2 and phospho-variants for 42 h then stimulated 
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with EGF (5 ng/mL) for 5 min (figure 11).  We observed a modest yet reproducible 
increase in EGFR-Tyr1173 phosphorylation with S58A compared to wild-type, S58E and 
untransfected cells.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
Figure 10. Co-localization of MTMR2 S58A with EGFR  
 
HeLa cells were transiently transfected with FLAG-MTMR2 S58A for 42 h and analyzed 
by immunofluorescence microscopy.  Cells were probed for endogenous EGFR (red) and 
FLAG-MTMR2 S58A (green). Merged images are shown to indicate partial co- 
localization (yellow). Boxed areas indicate regions of interest and are presented in 
expanded views. Images were collected using 63x objectives. The scale bar represents 15 
μm. 
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Figure 11. EGFR phosphorylation at Tyr1173 is enhanced by phosphorylation 
deficient MTMR2  
 
HEK293 cells were transfected with FLAG-MTMR2 expression vectors for 42 h.  The 
cells were serum starved for 30 min and treated with 5 ng/ml EGF for 5 min at 37°C.  
EGFR phosphorylation at position Tyr1173 was determined by immunoblotting.  Total 
EGFR and actin levels served as loading controls.  FLAG-MTMR2 immunoblotting was 
used to confirm equal transfection between samples (n=3). 
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DISCUSSION 
The results of this study demonstrate that reversible phosphorylation represents a 
critical mechanism for regulating the subcellular localization of MTMR2. The finding 
that an MTMR2 phosphorylation-deficient mutant preferentially localized to endocytic 
structures where it depleted PI(3)P suggests a mechanism by which phosphorylation of 
Ser
58
 impairs the localization of MTMR2 to compartments containing one of its 
physiological substrates, PI(3)P. Because the stoichiometry of MTMR2 Ser
58
 
phosphorylation under normal cell culture conditions was quite high, we hypothesize that 
extracellular signals are required to induce Ser
58
 dephosphorylation (figure.12). By 
analogy, attenuation of signals that activate the kinase(s) responsible for phosphorylating 
MTMR2 at Ser
58
 would also result in an unphosphorylated MTMR2 and allow its  
localization to endocytic structures, including those containing PI(3)P.  Following 
depletion of PI(3)P by MTMR2, phosphorylation of Ser
58
 may be required to dissociate 
MTMR2 from the vesicle to attenuate signal(s) generated by MTMR2-dependent PI(3)P 
dephosphorylation. In light of the highly dynamic role of PI(3)P in endocytic processes, 
the balance between MTMR2 Ser
58
 phosphorylation and dephosphorylation is likely to 
contribute to the maturation and signaling capacity of a distinct set of endosomes.   
One of the most striking aspects of the Ser
58
 phosphorylation site was the 
apparent high stoichiometry determined by MS. Phosphopeptides are rarely detected in 
unfractionated trypsin digests primarily due to their low stoichiometry, making them 
underrepresented in a complex mixture and thus subject to suppression by other 
unphosphorylated peptides present [30]. However, the phospho-Ser
58
 peptide was readily 
detected in the complex peptide pool, along with the unphosphorylated peptide. These 
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cognate peptides were reproducibly detected at approximately equal intensities. Taking 
into consideration the widely held view that phosphate addition reduces peptide 
ionization, we can safely conclude that the stoichiometry of phosphorylation is at least 
50% and is likely to be considerably higher under the conditions used in the study.  This 
conclusion is further supported by subcellular localization studies and PI(3)P depletion 
experiments, where localization of wild-type MTMR2 and endocytic PI(3)P depletion 
were indistinguishable from the MTMR2 S58E phosphomimetic mutant. In contrast, the 
unphosphorylatable MTMR2.S58A mutant displayed striking endosomal localization and 
caused a marked depletion of endosomal PI(3)P. These findings further substantiate our 
working model that MTMR2 exists in a constitutively phosphorylated state, where it is 
sequestered away from its physiological substrate until the appropriate signal leads to its 
dephosphorylation and subsequent targeting to endocytic vesicles, where PI(3)P is 
localized. It must be taken into consideration that we utilized MTMR2 overexpression 
throughout these studies. However, during the course of elucidating the functional 
relevance of the Ser
58
 phosphorylation site, three independent phosphoproteomic 
screening studies reported phosphorylation at Ser
58
 of endogenous MTMR2, thus 
validating the results obtained in our overexpression studies [34-36].  Ongoing efforts of 
developing a Ser
58
 phosphospecific antibody will help determine the relative 
stoichiometry of phosphorylation at Ser
58
 on endogenous MTMR2 under various 
conditions.   
Inhibitory phosphorylation events that affect membrane binding have been shown 
to be critical for other inositol lipid phosphatases, including PTEN. Several lines of 
evidence suggest that phosphorylation of PTEN by casein kinase II and other kinases can 
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inhibit its cleavage by caspase 3 and increase its stability [37,38]. Phosphorylated PTEN 
also exhibits decreased lipid phosphatase activity and is unable to interact with binding 
factors that target it to the inner surface of the plasma membrane [39-41].  Collectively, 
these findings have led to a model by which phosphorylation of PTEN induces a closed 
conformation that is stable, but inactive. PTEN dephosphorylation induces an open 
conformation that allows PTEN to localize to membrane compartments and act on its 
lipid substrate, PI(3,4,5)P3. The membrane-associated (unphosphorylated) form of PTEN 
is more susceptible to proteolytic cleavage, which functions to allow down-regulation of 
PTEN signaling.   
The exact mechanism of MTMR2 phosphorylation remains to be elucidated. 
However, the sequences surrounding the phosphorylation site can often offer clues to the 
kinases involved.  Ser
58
 resides in a so-called SP motif, suggesting that MTMR2 is 
regulated by proline-directed kinases such as members of the MAPK family. Although 
numerous proline-directed kinases are encoded in the human genome, which represent 
potential MTMR2.Ser
58
 kinases, a wide array of chemical inhibitors and proteomic tools 
are available that will aid in our ongoing efforts to identify the specific kinase(s) that 
phosphorylate MTMR2 at Ser
58
.  
At this time it is uncertain what extracellular stimuli may be responsible for 
regulating MTMR2 reversible phosphorylation.  However, Berger et al. (2003) reported 
that hypo-osmotic stress in COS-1 cells caused translocation of MTMR2 to membrane 
vacuoles rich in PI(3,5)P2 [21]. Furthermore, a CMT4B disease-associated point 
mutation in the PH-GRAM domain greatly reduced binding to these vacuoles. We now 
present compelling data that phosphorylation of a site in close proximity to the  
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Figure 12. Phosphorylation Regulates Endosomal Targeting of MTMR2 
 
Inhibition of MTMR2 Ser
58
 phosphorylation results in subcellular targeting to PI(3)P-
positive endosomes, which leads to PI(3)P depletion and increased growth factor receptor 
signaling via endosomal pathways. Phosphorylation of Ser
58
 by a proline-directed kinase 
sequesters MTMR2 in the cytoplasm, thus preserving the levels of PI(3)P and promoting 
endosomal maturation/trafficking. 
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PHGRAM domain regulates endosomal membrane targeting. Because hypo-osmotic 
stress is known to regulate proline-directed kinases, including MAPK members [42,43], it 
is plausible that the localization of MTMR2 to vacuolar structures in response to osmotic 
stress may involve dephosphorylation of MTMR2 at Ser
58
. We are currently exploring 
this possibility as well as systematically identifying regulatory signals that can regulate 
Ser
58
 phosphorylation. 
Several studies have demonstrated that active MTMRs are positively regulated by 
inactive MTMR binding partners [22,25,44,45].  MTMR2 has been shown to interact 
with two highly homologous members within the inactive MTMR subtypes, MTMR5 and 
MTMR13. The mode of interaction between active and inactive MTMRs is thought to be 
mediated by the coiled-coil domains found in the C termini of the active and inactive 
binding partners [22,25]. These associations have been suggested to be important for 
MTMR2 localization. Because we detected no significant difference in the ability of 
MTMR2 phosphorylation site mutants to interact with MTMR5, and overexpression of 
MTMR5 did not alter the phosphorylation levels of MTMR2 (data not shown), we 
conclude that MTMR2 Ser
58
 phosphorylation is unlikely to regulate its interaction with 
MTMR5 or MTMR13.  Because MTMR13 mutations are also associated with type 4B 
CMT disease, it will be important to conduct similar experiments focused on MTMR13 
to determine whether MTMR2 Ser
58
 phosphorylation might affect its interaction with 
MTMR13. 
Another interesting observation was the co-localization of MTMR2.S58A and 
Rab5.  We observed a subset of Rab5 positive endosomes that were also positive for 
catalytically active MTMR2 S58A, suggesting that unphosphorylated MTMR2 is targeted 
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to endocytic like vesicles. However, a considerable amount of MTMR2 S58A positive 
vesicles were Rab5 negative but often directly adjacent to Rab5 positive endosomes 
(figure. 5).  This perhaps signifies that targeting of MTMR2 S58A to endocytic structures 
could affect Rab5 function. Moreover, this putative function would require phosphatase 
activity as the catalytically inactive variant (MTMR2 S58A,C417S) displayed strong co-
localization with Rab5 (figure. 6).  Notably, Rab5 endosomal activities have been linked 
to PI(3)P levels [33, 46]. For example, the critical endosomal effectors Rabenosyn-5 and 
early endosomal antigen 1 require association with Rab5 and PI(3)P simultaneously to 
localize to early endosomes [47–49].  Furthermore, Rab5 associates with endosomes in 
its GTP bound form, which is maintained by endosomal guanine exchange factors such as 
RABX-5. Poteryaev et al. (2010) have recently discovered that the endosomal protein 
Mon1/SAND-1 removes RABX-5 (and subsequently Rab5) from endosomes in a PI(3)P-
dependent manner [46]. Therefore, based on our co-localization results and the ability of 
MTMR2 S58A to effectively deplete endosomal PI(3P), it is conceivable that reversible 
phosphorylation of MTMR2 could regulate Rab5-dependent trafficking events that are 
sensitive to PI(3)P. Moreover, the observed co-localization between MTMR2 S58A and 
EGFR and the MTMR2 S58A-mediated increase in EGF signaling is consistent with a 
model whereby phosphorylation deficient MTMR2 disrupts the ability of Rab5 to 
modulate EGFR endocytosis resulting in prolonged receptor signaling. 
In conclusion, we have identified a novel mechanism through which the 
endosomal targeting of MTMR2 is regulated by reversible phosphorylation at Ser
58
. This 
discovery provides critical insight into how MTMR2 activity toward its lipid substrates 
can be spatially and temporally controlled. Furthermore, differential phosphorylation of 
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other MTMR family members may represent a specific means for targeting these 
enzymes to distinct pools of PI(3)P and PI(3,5)P2. Likewise, understanding the 
mechanistic details of MTMR phosphorylation may help to clarify how similar gene 
products (MTM1 and MTMR2) can cause distinct human disorders. Thus, it is of great 
interest to further investigate whether other MTMR members are phosphorylated and 
how these modifications regulate their activities. 
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CHAPTER 3 – INTRODUCTION  
Within the N-terminus of MTMR2 resides a high stoichiometry phosphorylation 
site (Ser
58
) that is contained within the minimal MAPK recognition sequence.  
Previously, we have shown that phosphorylation-deficient Ser
58
 (S58A) results in early 
endosomal targeting of MTMR2 with a subsequent depletion of PI(3)P and an increase in 
ERK1/2 signaling events [17].   
In mammalian systems, the MAPK signaling cascades consists of three well 
characterized members: ERK1/2, JNK/SAPK and p38 kinases [4,50].  MAPKs are a 
subgroup of the proline-directed Ser/Thr kinases in which they recognize and 
phosphorylate the consensus sequence (P-X-S/T-P-X-Z) on their substrate targets [5].  
These kinase cascades mediate the transmission of extracellular signals to various 
intracellular targets including transcription factors, facilitating the appropriate changes in 
gene expression to respond to the extracellular stimuli [4,50].  The binding of 
extracellular ligands to the corresponding RTK, leads to receptor 
autophosphorylation/activation provoking further downstream activation of the MAPKs 
in a multistep process [4,6].  Aberrant MAPK activation ultimately leads to impaired 
cellular signaling resulting in defective growth and development [4].   
Activation of each MAPK cascade results in biological responses that are most 
often regulated and transmitted through RME [50].  More recently it has been shown that 
endosomes rich in the adaptor protein APPL1 function as the regulatory switch mediating 
the initial stages of endosome maturation coupled to the strength of MAPK signaling 
[1,53].   In addition, the APPL proteins function as Rab5 effectors and are suggested to 
play an important role in signaling events rather than the general housekeeping of 
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endocytosis [51].  The loss of APPL1 as vesicles move centrally coincides with the 
recruitment of EEA1 and subsequent maturation into the canonical PI(3)P-Rab5 positive 
endosomes [1,52].  APPL1 vesicles are known to play a functional role in the assembly 
of signaling complexes for MAPK and Akt pathways therefore, the presence of APPL1 
profoundly impacts Akt and MAPK signaling [1-3,51,53].  Recent work has shown that 
increased levels of PI(3)P acts as a molecular switch to turn off growth factor signaling 
through the simultaneous loss of APPL1 on these endosomes [1].   Here, we present the 
novel finding that the targeting of MTMR2 to these newly defined APPL1 endosome 
subpopulations is mediated by dephosphorylation of MTMR2 at two phosphorylation 
sites (Ser
58
/Ser
631
 - S58A/S631A) and may present a mechanism through which MTMR2 
shuttles between endosome compartments to target different pools of PI(3)P.  
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MATERIALS AND METHODS 
3.1 Cell Treatment with Kinase Inhibitors 
HEK293 cells (immunoblotting) or HeLa (immunofluorescence) cells were 
treated with a JNK inhibitor (SP600125: LC laboratories; Woburn,MA), a highly specific 
p38 inhibitor (SB203580: LC laboratories; Woburn,MA) or a potent MEK1/2 inhibitor 
(U1026: LC laboratories; Woburn,MA) prior to cell lysis or immunofluorescence 
analysis as indicated.  Cells were treated for 30 min with SB203580 at a final 
concentration of 20 μM; for 1 hr with SP600125 at a final concentration of 40 μM; or for 
1 hr with U1026 at a final concentration of 50 μM.  Following cell lysis as previously 
described, samples were purified by FLAG-IP, separated on 12% acrylamide gel, and 
subjected to immunoblotting analysis as described (Chapter 2 – pg.66). For inhibition 
controls, cells were first serum starved for 30 min followed by preincubation with U0126 
as previous, then stimulated with 5 ng/ml EGF for 5 min and subsequently lysed and 
analyzed by immunoblotting to determine extent the of ERK1/2 inhibition using primary 
antibodies ERK1/2 and Pathscan® as previous and phosphorylation changes at 
Ser
58
MTMR2 using chicken-anti-pSer
58
.MTMR2 (Christopher Bonham) at a 1:1500 
dilution in 2.5% BSA/TBST at 4ºC overnight followed by incubation with donkey-anti-
chicken HRP (DAIgY-HRP: Gallus Immnotech Inc.) at 1:3000 dilution in 2.5% 
BSA/TBST for 1 h room temperature.  For detection of JNK1 inhibition, cells were 
serum starved for 60 min and pre-incubated with SP600125 as previous then subjected to 
hypoosmostic shock by incubation in hypotonic medium (0.25x serum free medium plus 
antibiotics in sterile DIUF H2O) for 30 min at 37°C or hyperosmotic shock by incubation 
in hypertonic medium (150mM NaCl in serum-free medium plus antibiotics) for 30 min 
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at 37°C.  Cells were lysed, immunoblotted and probed for total JNK1 using rabbit-anti-
JNK1 (C-17: sc-474 Santa cruz Biotechnology) at a 1:1000 dilution in 2.5% BSA/TBST 
overnight 4°C with secondary dilutions as previous, and mouse-phospho-JNK1 (G-7: sc-
6254; Santa Cruz biotechnology) at a 1:1000 dilution in 2.5% BSA/TBST overnight at 
4°C, ERK1/2, pERK1/2 (Pathscan®), FLAG, and actin as previous and goat-anti-mouse 
HRP, goat-anti rabbit HRP as previously described.    
3.2 In Vitro Kinase Assay 
Kinase assays were carried out using  5 µg of bacterial recombinant purified 
MTMR-His6 proteins in reaction buffer (Assay  dilution buffer (ADB) sterile filtered: 25 
mM HEPES, pH 7.2, 12.5 mM β-glycerol phosphate, 25 mM MgCl2, 5 mM EGTA, 2 
mM EDTA, 0.25 mM DTT) with 200 µM ATP reconstituted in ADB and 100 ng 
activated kinase in ADB (total reaction vol = 50 µl).  Reaction mixtures were incubated 
at 30°C for 30 min with gentle shaking and the reaction was terminated by the addition of 
30 µl 2x SDS, boiled for 5 min and centrifuged at 15,000 rpm for 2 min for elution (final 
reaction vol = 80 µl).  Samples were separated on a 10% polyacrylamide gel and the 
following amounts of reaction mixtures were analyzed: 20 ng using anti-pSer
58
MTMR2 
as previously described, 20 ng of reaction mixture to probe for ERK1 and ERK2 at 
dilutions previously described, p38α using rabbit-anti-p38 MAPK antibody 
(Thr180/Tyr182; #9211S: Cell signalling) at a 1:1000 dilution in 5% BSA/TBST 
overnight 4°C with secondary antibody goat-anti-rabbit HRP at a 1:5000 dilution in 2.5% 
BSA/TBST, JNK1 as previous,  total MTMR2 using mouse-anti-MTMR2 (I-15:sc-
100398; Santa Cruz Biotechnology) at a 1:1000 dilution in 1% skim milk and secondary 
goat-anti-mouse IgG HRP conjugate (W4021; Promega) at a 1:5000 dilution in 1% skim 
milk and 1 µg was used for Coomassie staining to detect total protein levels. 
 112 
RESULTS 
 
PART I) Identification of the Kinase Governing MTMR2.Ser58 Phosphorylation 
 
3.3 Phosphorylation of MTMR2 Ser
58
 is regulated by ERK1/2  
 
ERK1 and ERK2 are MAPKs with over 160 known substrates including other 
kinases/phosphatases, proteins involved in membrane trafficking/signaling, transcription 
factors and membrane receptors [7,8].  The primary recognition sequence for MAPKs 
and in particular ERK1/2 is P-X-S/T-P however, they have been shown to phosphorylate 
several substrates containing the minimal dipeptide sequence X-S/T-P including Protein 
Kinase C-alpha (PKCA) at Thr 638 (PVLTPP) and MAPK phosphatase-1 (MKP-1) on 
Serine 359/Serine 364 (YLQSPI/ITTSPS) ultimately leading to complete protein 
activation, greater protein stability and resultant effects on receptor-mediated signaling 
[9,10].  Considering that Ser
58
 on MTMR2 resides within a similar MAPK recognition 
sequence (DNFSPD) we first examined the potential for phosphorylation by several of 
the well known and characterized MAPKs: ERK1, ERK2, p38α and JNK1.   
Recombinant wt MTMR2 was purified from BL21 E.coli cell lysates and in vitro 
kinase assays were performed.  Substrate and kinase concentrations were determined 
from titration trials and the optimal amounts were utilized for the kinase assays.  
Following the in vitro kinase assay, the reaction mixture was then analyzed by 
immunoblotting.  To ensure that the same amount of protein was utilized for each 
reaction, 20 ng of purified wt MTMR2 protein from each of the reaction mixtures (totvol= 
5 µg/80 µl ~ 62.5 ng/µl → 16 µl = 1 µg: therefore samples were diluted to 0.001 µg/µl → 
20 µl analyzed) was separated on a 10% SDS-PAGE gel and probed with α-MTMR2 
antibody to detect total protein levels (figure 1).  As an additional control 1µg of the same  
 113 
 
 
Figure 1.  In vitro phosphorylation of recombinant wt MTMR2 by ERK1/2 
Purified His6-tagged recombinant wt MTM2 was the substrate in the in vitro MAPK 
kinase assay.  (A) Each reaction contained 5 µg of recombinant wt-MTMR2, each 100 ng 
of kinase and 200 µM ATP and reactions were incubated at 30°C for 30 min.  The 
phosphorylation of MTMR2 at position Ser
58
 was detected using a phospho-specific 
antibody (pSer
58
MTMR2) and total MTMR2 levels determined by immunoblotting with 
α-MTMR2 antibody and Coomassie staining..  (B) Reactions were probed for  kinase 
levels which served as additional controls (ERK2 68kDa, ERK1 42 kDa, p38α 67kDa, 
JNK1 70 kDa).   
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samples were also stained with Coomassie.  For the detection of MTMR2 
phosphorylation at Ser
58
, Christopher Bonham from our lab generated a chicken-α-
pSer
58
.MTMR2 phospho-specific antibody to allow for the unambiguous identification of 
phosphorylation definitively at this site.  It was determined that both ERK1 and ERK2 
phosphorylated MTMR2 at Ser
58
 at relatively the same intensities in vitro (figure 1 (A) 
upper panels).   
For the detection of all activated kinases utilized in these studies, 20 ng each were 
analyzed by immunoblotting.  The detection of ERK1 and ERK2 indicated ERK1 was 
present at the respective 42kDa however ERK2 was detected at 68kDa due to the 
recombinant GST-tag.  Furthermore, the GST-p38α and GST-JNK1 were detected by 
immunoblotting at their respective masses of 67kDa and 70kDa.   
3.4 Inhibition of ERK1/2 alters MTMR2 subcellular localization 
 
Selective MAPK inhibition is a widely utilized method to detect changes in 
cellular systems and mechanisms as a result of targeted „shut-down‟ of kinase 
phosphorylation events.  The inhibitors utilized in this study are competitive and specific 
MAPK inhibitors that have been widely characterized and used in a number of biological 
systems [13-15].          
In order to examine the effects of MAPK inhibition in vivo, HeLa cells were 
transfected with FLAG-S58A or FLAG-MTMR2, then subsequently treated with 
MEK1/2, p38 or JNK1 MAPK inhibitors and analyzed by immunofluorescence as 
described under “Materials and Methods”.  As an inhibitor control, HEK293 cells were 
transfected with wt MTMR2 and subsequently simulated under various conditions that 
are known to activate the JNK1 pathway (figure 2).  Stimulation by hypoosmotic shock 
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Figure 2.  In vivo inhibition of JNK1 
HEK293 cells were transiently transfected with wt FLAG-MTMR2 for 42 h.  Cells were 
serum starved for 1 h then subjected to hypoosmotic shock (0.25x medium) or 
hyperosmotic shock [54] (150 mM NaCl) for 30 min at 37°C. Where indicated, 
SP600125 was added at final concentration of 40 µM as a 1 h pretreatment. Lysates were 
probed for total JNK1, actin and FLAG levels which served as loading controls and to 
confirm equal transfection between samples.  Activation of ERK1/2 with hypoosmotic 
shock was not affected by JNK1 inhibitor treatment. 
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resulted in activation of both the JNK1 and ERK1/2 pathways as detected by 
immunoblotting of HEK293 lysates to detect JNK1 (figure 2 – 2nd panel lanes 3,4) and 
ERK1/2 phosphorylation (figure 2 - 4
th
 panel lane 3) .  Moreover, hyperosmotic stress 
was shown to only activate JNK1 thereby allowing for comparative controls for 
inhibition studies (figure 2 – 2nd panel lane 4). Following pre-incubation with the JNK1 
inhibitor (SP600125: +SP), it was observed that only JNK1 activation was selectively 
inhibited (figure 2 – 2nd panel lanes 7,8) under both stimulation conditions whereas 
ERK1/2 was still activated by phosphorylation (figure 2 – 4th panel lane 7).  The 
displayed selective inhibition prompted us to examine the potential effects on the 
subcellular localization of wt-MTMR2 in vivo following MAPK inhibitor treatments.   
Under normal untreated conditions S58A displayed the unique punctate 
localization and wild-type MTMR2 displayed the characteristic cytoplasmic staining 
pattern as previously observed (figure 3.A-B,I-J).  Moreover, following inhibition of 
either p38 or JNK1, we did not detect any significant difference in subcellular 
localization compared to that of wild-type wherein the transfected cells displayed the 
dispersed cytoplasmic staining (figure 3.E-F,G-H).  Interestingly, following treatment of 
HeLa cells overexpressing wild-type with a MEK1/2 (ERK1/2) inhibitor resulted in loss 
of MTMR2 cytoplasmic staining and a distinct punctate localization similar to that which 
was observed with FLAG-S58A, and is highly indicative of unique vesicular and intact 
subcellular organelle localization (figure 3.C-D).  These results indicate that inhibition of 
ERK1/2 in vivo elevates MTMR2 endosomal targeting potentially by preventing Ser
58
 
phosphorylation.   
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Figure 3. ERK1/2 inhibition triggers targeting of MTMR2 to punctate regions 
 
HeLa cells were transiently transfected with FLAG-MTMR2 or FLAG-MTMR2 S58A (A 
and B) for 42 h and analyzed by immunofluorescence microscopy.  Cells were left 
untreated (I and J) or treated with various inhibitors; U0126 (MEK1/2) at 50 µM for 1 h 
(C and D), SB203580 (p38) at 20 µM for 30 min (E and F), and SP600125 (JNK) at 40 
µM for 1 h (G and H).  Cells were then probed for FLAG-MTMR2 or FLAG-MTMR2 
S58A using Alexa Fluor
®
 568. Boxes indicate regions of interest and are presented in 
expanded views.  Images were collected using 63x objectives. The scale bar represents 15 
μm. 
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3.5 Ser
58
 Phosphorylation is greatly reduced following ERK1/2 inhibition 
 
In response to various stimuli including heat shock, hypoosmotic stress and 
growth factors, ERK1/2 becomes activated by phosphorylation which in turns leads to the 
downstream activation and/or inhibition of the target substrates [1,10,13].  Interestingly, 
ERK1/2 activation by growth factors such as EGF are normally transient, but in some 
circumstances sustained activation of upstream kinases leads to prolonged ERK1/2 
activation and differential effects on target proteins.  Inhibition of ERK1/2 on the other 
hand, has been shown to alter receptor signaling [10,13].  Consequently, there are effects 
on proliferation, growth and differentiation leading to altered cellular mechanisms that 
are important for survival.  Therefore, in an effort to examine the regulation and/or 
changes of MTMR2.Ser
58
 phosphorylation in vivo, we utilized a very well known and 
characterized inhibitor U0126 which functions by inhibiting the upstream MEK1/2 kinase 
that mediates ERK1/2 phosphorylation.   
HEK293 cells were transiently transfected with wild-type MTMR2 and examined 
for the effects on Ser
58
 phosphorylation following ERK1/2 inhibition (figure 4).  
Untreated transfected samples functioned as the control in order to monitor Ser
58
 
phosphorylation under normal resting state conditions.  Under untreated conditions, 
MTMR2.Ser
58
 displayed high levels of phosphorylation which dramatically decreased 
following a 30 min serum starvation (figure 4.A).  Serum deprivation has been shown to 
reduce the basal activity of ERK1/2 under moderate starvation conditions (~ 30 min-120 
min) [16].  Most generally, ERK1/2 displays modest activity under resting state 
conditions however; in some cell lines it can remain undetected potentially as a result of 
culture conditions [16].  Following a 30 min serum starvation period, low dose EGF 
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stimulation (5 ng/ml) was used to monitor ERK1/2 activation (pERK1/2) and the 
subsequent phosphorylation of Ser
58
.  After 5 min and 30 min stimulation with EGF, 
ERK1/2 was transiently activated and we also observed activation of a downstream 
ERK1/2 substrate phospho-S6 kinase (pS6K) which was monitored as a control.  
Moreover, MTMR2 Ser
58
 phosphorylation levels also increased relative to the untreated 
samples. In comparison to serum starved conditions, a nearly 60% increase in Ser
58
 
phosphorylation following ERK1/2 activation was detected (figure 4.B).  A slight 
decrease in Ser
58
 phosphorylation was observed following a longer stimulation period at 
30 min.  However, following serum starvation cells were pre-incubated for 1hr with an 
ERK1/2 inhibitor (+U0126) that resulted in the lack of Ser
58
 phosphorylation following 
the same EGF stimulation conditions.  The MEK1/2 inhibitor, U0126 inhibited EGF-
stimulated ERK1/2 activity and MTMR2.Ser
58
 phosphorylation in parallel wherein 
pERK1/2 levels were undetected and Ser
58
 phosphorylation levels were ~80% lower 
compared to untreated conditions (figure 4.B).  Also, pS6K phosphorylation was 
diminished indicating that inhibition of ERK1/2 activation prevented the phosphorylation 
of downstream substrates (figure 4.A).  Collectively, these results indicate that inhibition 
of ERK1/2 prevents Ser
58
 phosphorylation and the aforementioned changes in MTMR2 
subcellular localization is a result of lack in Ser
58
 phosphorylation. 
3.6 Inhibition of JNK1 and ERK1/2 results in enlarged APPL1 endosomes  
  
Formerly, we have determined evidence implicating that ERK1/2 inhibition 
resulted in MTMR2 targeting to vesicular-like structures primarily as a result of Ser
58
 
dephosphorylation and therefore, our next task was to address and identify these 
subcellular compartments.  Initially we began by examining localization with endogenous  
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Figure 4.  In vivo inhibition of ERK1/2 results in decrease of Ser
58
 MTMR2 
phosphorylation 
 
(A) HEK293 cells were transiently transfected with wt FLAG-MTMR2 for 42 h.  Cells 
were serum starved for 30 min then treated with 50 µM of U0126 (MEK1/2) for 1 h 
(where indicated), followed by the addition of 5 ng/mL EGF for 5 and 30 min at 37°C.  
Cells were then lysed and FLAG immunoprecipitated, then subsequently probed for 
phosphorylation of MTMR2 at Ser
58
. FLAG-MTMR2 immunoblotting from FLAG-IP 
was used to confirm equal transfection between samples. Total ERK, actin and Flag 
levels from lysates served as loading controls and pERK indicates inhibition of the 
activated kinase (ERK1/2:Thr202/Tyr204) with U0126 treatment. Decrease in the 
phosphorylation of a downstream ERK1/2 substrate phospho-S6 (Ser235/236) served as 
an additional control. (B) ERK1/2 and MTMR2 Ser
58
  phosphorylation levels were 
quantified by densitometry using Image J, and normalized to total ERK1/2 or FLAG (IP) 
levels (■ wt MTMR2;■ERK1/2) The values are shown as fold-change to control (n=3). 
Error bars ± SD  
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Rab5 utilizing the same MAPK inhibitors as previous and additionally combined 
treatments with the ERK1/2 inhibitor considering that only this inhibitor had any effect 
on MTMR2 localization.  HeLa cells were transfected with wild-type MTMR2 and 
examined by immunofluorescence (figure 5).  Untreated, wild-type MTMR2 displayed 
the characteristic cytoplasmic staining pattern with greater intensity in the perinuclear 
region and lack of any Rab5 localization (figure 5. top row).  Intriguingly however, when 
cells were treated with the MEK1/2 inhibitor U0126, MTMR2 displayed a punctate 
pattern with a subset of vesicles that were positive for both MTMR2 and Rab5 (figure 5. 
second row and expanded view).  These results are similar to that observed with S58A 
and Rab5 where the colocalized staining seem to be directly adjacent or on opposite sides 
of the same vesicle.  Inhibition of MEK1/2 results in lack of ERK1/2 activation, and 
considering that our wild-type MTMR2 was still active, this pattern could be a result of 
endosomal PI(3)P levels.  Alternatively, combined treatment of U0126 with the p38 
inhibitor (+U+SB) resulted in the same punctate pattern however absence of any Rab5 
colocalized vesicles (figure 5. third row).  Combined inhibition of ERK1/2 and JNK1 
(+U+SP) displayed a more pronounced punctate pattern and these vesicles did appear 
enlarged yet lacking any Rab5 co-localization (figure 5. bottom row). 
To investigate whether these inhibitor treatment were causing localization to a 
distinct subpopulation of endosomes, HeLa cells were transfected with wild-type 
MTMR2 and also immunostained for endogenous APPL1 (figure 6).  As previously 
observed, untreated wild-type MTMR2 was cytoplasmic and did not show any APPL1 
co-localization (figure 6. top row).  Inhibition of ERK1/2 (+U)  or ERK1/2 + p38 
(+U+SB) resulted in a punctate staining pattern that was devoid of APPL1 co-staining  
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Figure 5. ERK1/2 inhibition results in MTMR2 localization to Rab5 positive vesicles 
 
HeLa cells were transiently transfected with FLAG-MTMR2 phosphovariants for 42 h 
and analyzed by immunofluorescence microscopy. Cells were treated with various 
inhibitors; U0126 (+U) at 50 µM for 1 h, or combined with SB203580 (+SB) at 20 µM 
for 30 min, and SP600125 (+SP) at 40  µM for 1 h where indicated. Cells were probed 
for endogenous Rab5 (green) and FLAG-MTMR2 (red).  Merged images are shown to 
indicate co-localization. White arrows indicate direct regions of co-localization and 
purple arrows represent vesicles lacking co-localization.  Regions of interest are 
presented in expanded views. Images were collected using 63x objectives. The scale bar 
represents 15 μm. 
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(figure 6. second/third rows).  In contrast, double inhibitor treatments of ERK1/2 and 
JNK1 (+U+SP) resulted in a large number of vesicles that were positive for both 
MTMR2 and APPL1 and were enlarged (figure 6. bottom row and expanded view). Size 
measurement quantifications revealed colocalized vesicles to have an average area of 
1.84µm
2
 (±0.4) and those only positive for APPL1 were determined to have an average 
area of 0.57µm
2
 (±0.12) (Appendix 2. Table 1).    
Most recently, Zoncu et.al identified that APPL1 vesicles defined an early 
transient endosome subpopulation that reside downstream of clathrin-coated pits in RME 
that are en route to PI(3)P positive early endosomes [1].  In this study it was also 
determined that direct PI(3)P depletion at the early endosomes resulted in reversion of 
PI(3)P/Rab5 endosomes, back to their preceding APPL1 endosomes with accompanying 
vesicles enlargement [1].  As a comparative control to our inhibitor studies, we utilized 
our MTMR2 phosphorylation-deficient mutant S58A in order to eliminate the use of 
ERK1/2 inhibitor.  To examine this, HeLa cells were transfected with MTMR2 S58A and 
probed for endogenous APPL1 under saponin conditions in order to specifically identify 
intact compartments (figure 7. top row).  We observed a significant amount of intact 
vesicles following saponin treatment that did not display any localization with APPL1.  
However, when these cells were treated with the JNK1 inhibitor (+SP) the complete 
opposite localization pattern was observed in which nearly all of the cells positive for 
S58A (+SP) colocalized with APPL1 and also appeared to result in their enlargement 
(figure 7. middle row).  Quantification revealed that S58A colocalized vesicles were 
nearly 3 times larger and had an average area of 4.08 µm
2
 (±0.12) and those only positive 
for APPL1 were determined to have an average area of 1.32 µm
2
 (±0.16) (Appendix 2.  
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Figure 6. Inhibition of ERK1/2 and JNK1 triggers MTMR2 localization to APPL1 
endosomes 
 
HeLa cells were transiently transfected with FLAG-MTMR2 phosphovariants for 42 h 
and analyzed by immunofluorescence microscopy. Cells were treated with various 
inhibitors; U0126 (+U) at 50 µM for 1 h, or combined with SB203580 (+SB) at 20 µM 
for 30 min, and SP600125 (+SP) at 40 µM for 1 h where indicated. Cells were probed for 
endogenous APPL1 (green) and FLAG-MTMR2 (red).  Merged images are shown to 
indicate co-localization. White arrows indicate direct co-localization and purple arrows 
represent vesicles lacking co-localization.  Regions of interest are presented in expanded 
views. Images were collected using 63x objectives. The scale bar represents 15 μm. 
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Figure 7. JNK1 and ERK1/2 inhibition results in enlarged APPL1 endosomes 
 
HeLa cells were transiently transfected with FLAG-MTMR2 or S58A for 42 h and 
analyzed by immunofluorescence microscopy. Cells were left untreated (top panel), 
treated with SP600125 (+SP) at 40 µM for 1 h (middle panel) or combined with U0126 
(+U) at 50 µM for 1 h (lower panel).  Merged images are shown to indicate co-
localization with white arrows indicating direct co-localization and purple arrows 
represent vesicles devoid of co-localization.  Regions of interest are presented in 
expanded views. Images were collected using 40x objectives. The scale bar represents 15 
μm. 
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Table 1).  The C-terminal region of MTMR2 contains Ser
631
 that resides within a similar 
recognition sequence as Ser
58
 (S/T-P) and large scale phospho proteomic studies have 
previously identified Ser
631
 as a phosphorylation site [47-49].  Thus, JNK1 may 
phosphorylate MTMR2 at Ser
631
 and JNK1 inhibition in turn, targets MTMR2 to this 
distinct sub-pool of endosomes.  Overall, these findings suggest that MTMR2 
phosphorylation and targeting to specific pools of early endosomes is dynamically 
regulated, with Ser
58
 phosphorylation mediated by ERK1/2 and Ser
631
 phosphorylation in 
part regulated by JNK1.  
PART II) Characterization of the MTMR2.Ser631 Phosphorylation Site 
3.7 Dephosphorylation of N-terminal Ser
58
 and C-terminal Ser
631
 results in APPL1 
endosomal targeting  
In an effort to determine the relationship with respect to the N-terminal and C-
terminal phosphorylation sites surrounding MTMR2 regulation we generated 
combination variants by site-directed mutagenesis to mimic modifications at Ser
58
 and 
Ser
631
 wherein mutations to an Ala (A) resembles dephosphorylation and mutations to a 
Glu (E) mimic phosphorylated. We then examined their localization by 
immunofluorescence and initially examined co-localization with APPL1 to compliment 
our MAPK inhibitor treatments.   
HeLa cells were transfected with all the FLAG constructs and immunostained for 
endogenous APPL1 (figure 8).  It appears that mutations solely at the C-terminal Ser
631
 
site do not have any effect on MTMR2 subcellular localization as detected by the 
dispersed cytoplasmic staining in both of the single Ser
631
 mutants (figure 8. second and 
bottom row).  Also, the double phosphorylation mutant S58E/S631E displayed a similar 
localization pattern that was present within the cytoplasm (figure 8. third row).  Notably,  
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Figure 8. Dephosphorylation of Ser
58
 and Ser
631
 results in MTMR2 subcellular 
localization to APPL1 endosomes 
 
HeLa cells were transiently transfected with FLAG-MTMR2 phosphovariants for 42 h 
and analyzed by immunofluorescence microscopy. Cells were probed for endogenous 
APPL1 (green) and FLAG-MTMR2 (red).  Merged images are shown to indicate co-
localization (yellow) of enlarge vesicles. White arrows indicate direct regions of co-
localization and purple arrows represent smaller vesicles lacking co-localization.  
Regions of interest are presented in expanded views. Images were collected using 63x 
objectives. The scale bar represents 15 μm. 
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occasionally we observed a subset of vesicles that appeared to have vacuolar-like 
structures (appearance of hollow holes) present within the cytoplasm that were only 
detected with the S58E/S631E mutant.  Vacuolar-like structures have been shown to 
contain higher levels of PI(3,5)P2, the other physiological substrate of MTMR2, most 
prominently at the cell membrane.  These results could be indicative that phosphorylation 
at both sites could influence localization to regions that are predominantly rich in 
PI(3,5)P2 and may provide a mechanism by which MTMR2 is specifically targeted to 
these regions.  However, more in-depth analysis surrounding this localization and 
observations needs to be addressed further.  In all cases, no APPL1 co-localization was 
detected most likely as a result of failure to target MTMR2 to endosomal vesicles by 
modifications at Ser
631
.  Intriguingly, the double phosphorylation-deficient mutant 
(S58A/S631A) displayed a distinct punctate staining pattern that appeared to be localized 
just on the inside of the cell periphery (figure 8. first row).  Moreover, these vesicles 
displayed strong co-localization with APPL1 and also were enlarged compared to 
adjacent vesicles lacking the MTMR2 S58A/S631A mutant (enlarged views).   Size 
measurement quantifications revealed that co-localized vesicles were nearly 2.6 times 
larger and had an average area of ~ 1.14µm
2
 (±0.11) whereas APPL vesicles were ~0.43 
µm
2
 (±0.13) (Appendix 2.Table1). These results indicate that dephosphorylation at both 
sites may mediate targeting to APPL1 endosomes, and in response to PI(3)P depletion at 
Rab5 positive early endosomes, be prolonging receptor containment at these regions. 
Furthermore this result confirms that Ser
58
 is the main phosphorylation site that regulates 
general endosomal targeting and additionally implicates that this may occur as a 
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preliminary step to Ser
631
 dephosphorylation because no change in localization is 
observed when the Ser
631
 site is modified alone. 
To further verify our hypothesis, we examined the co-localization of S58A/S631A 
with Rab5 and compared the localization pattern to APPL1 (figure 9).  It was determined 
that there was a lack of any colocalized regions with Rab5 and most notably, it also 
appeared that the MTMR2 vesicles were further towards the outer cells edge than those 
containing Rab5 both with and without saponin treatment (figure 9. bottom panels).  
What this potentially implicates is that the S58A/S631A mutant is most likely localized 
to vesicles that precede the canonical early endosomes marked by Rab5.  In order to 
confirm this, we again immunostained for endogenous APPL1 and observed the similar 
colocalized staining pattern as previously (figure 9. top panels).  Most notably, following 
saponin treatment we observed that nearly all vesicles were positive for S58A/S631A and 
APPL1.  Also, the colocalized vesicles displayed larger average area in comparison to 
those only positive for APPL1 (enlarged views) similar to that observed previously 
(Appendix 2. Table 1).  
The observed vesicle enlargement could be a result of effects on the endosomal 
PI(3)P levels considering that this mutant still contains catalytic activity.  Therefore, as a 
comparative control we also generated a catalytic inactive double phosphorylation-
deficient mutant protein (S58A/C417S/S631A).  It was determined that the enlargement 
of APPL1 vesicles previously observed was dependent on the phosphatase activity as 
displayed by the lack in vesicle enlargement within our inactive mutant and absence in 
Rab5 localization (Supplemental figure 5). Collectively, these results coupled with the 
MAPK inhibitor treatments suggests that dephosphorylation at Ser
58
 targets MTMR2 to  
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Figure 9. Co-localization of S58A/S631A results in enlarged APPL1 endosomes  
 
HeLa cells were transiently transfected with FLAG-MTMR2 S58A/S631A for 42 h and 
analyzed by immunofluorescence microscopy. Cells were probed for endogenous APPL1 
(green: top panels center), Rab5 (green: lower panels center) and FLAG-MTMR2 (red: 
left panels).  Merged images are shown to indicate co-localization with APPL1 (yellow) 
and absence with Rab5 (green/red). White arrows indicate direct regions of co-
localization and purple arrows represent smaller vesicles lacking co-localization.  
Regions of interest are presented in expanded views. Images were collected using 63x 
objectives. The scale bar represents 15 μm. 
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Rab5 positive early endosomes which is mediated by ERK1/2.  The accompanying 
dephosphorylation at Ser
631
 mediates targeting to APPL1 vesicles and that 
phosphorylation of this C-terminal site could be regulated by JNK1 considering that 
inhibition of both ERK1/2 and JNK1 results in a similar localization pattern as the double 
phosphorylation-deficient mutant (S58A/S631A). 
3.8 Effects on MTMR2 endocytic localization with Ser
631
 phosphorylation 
We have previously determined that dephosphorylation at Ser
58
 results in 
MTMR2 endosomal targeting, however, an additional prominent phosphorylation site 
that resides in the C-terminal region near the coiled-coil and PDZ-binding motifs has yet 
to be fully characterized.  Additionally, considering the important of the N-terminal Ser
58
 
site, this leads us to hypothesize that there may potentially be cross-talk occurring 
between these two sites that governs localization to a particular PI(3)P subcellular 
compartment.  In order to examine the inherent possibility, we generated double mutants 
containing Ser
58
 dephosphorylated and Ser
631
 phosphorylated (S58A/S631E) and vice 
versa (S58E/S631A) by site directed mutagenesis as described under materials and 
methods.  These constructs were transfected in HeLa cells and immunofluorescence 
analysis was performed probing for our FLAG overexpressed proteins and for 
endogenous endosomal proteins APPL1 and Rab5 (figure 10).  It was determined that the 
S58A/S631E mutant displayed the characteristic punctate staining pattern similar to that 
observed with single point mutations at Ser
58
 (S58A) however we did not observe any 
regions of co-localization with APPL1 (figure 10. top panel first row). Additionally, 
when cells were transfected with the S58E/S631A mutant, there was absence of any 
punctate localization and also lack of APPL1 co-localization, fortifying that 
dephosphorylation at Ser
58
 governs general endosomal targeting (figure 10. top panel  
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Figure 10. Rab5 endosome targeting is regulated by dephosphorylation of Ser
58
 and 
phosphorylation of Ser
631 
 
HeLa cells were transfected FLAG-MTMR2 phospho-variants; S58A/S631E and 
S58E/S631A for 42 h and analyzed by immunofluorescence microscopy.  After fixation, 
with cells were incubated with anti-FLAG antibody and Alexa Fluor
®
568 (red).  Cell 
were also probed for endogenous APPL1 (green-top panels) and Rab5 (green-lower 
panels). Boxes indicated regions of interest and are presented in expanded views.  
Merged images show partial co-localization of S58A/S631E with Rab5 (top row-lower 
panel) and are displayed in boxed regions with white arrows.  Images were collected 
using 40xoil and 63x objectives.  The scale bar represents 15 µm. 
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second row).  Moreover, when HeLa cells were probed for endogenous Rab5 with the 
S58A/S631E we observed a subset of vesicles that displayed positive colocalized 
staining, similar to what had previously been observed with single mutations at Ser
58
 
(S58A) (figure 10.bottom panel first row).  Furthermore, it was still observed that there 
existed cytoplasmic localization following phosphorylation at Ser
58
 as displayed by the 
S58E/S631A that shows dispersed cytoplasmic staining and lack of Rab5 co-localization 
(figure 10.bottom panel second row). 
Considering that Rab5 localization to early endosomes is dependent on the correct 
cellular levels of PI(3)P, and that our own results show that overexpression of S58A in 
HeLa cells results in altered Rab5 localization, we therefore addressed whether the 
phosphatase activity was affecting co-localization with Rab5.  We generated the double 
mutant lacking any catalytic activity, represented as S58A/C417S/S631E as previously 
described.  This construct was then overexpressed in HeLa cells and immunofluorescence 
analysis was performed.  The endogenous localization of APPL1 was not affected and the 
mutant displayed lack of any regions of co-localization (figure 11. top panels).  
Furthermore, when cells transfected with S58A/C417S/S631E were probed for 
endogenous Rab5, we observed a significant amount of vesicles displaying positive co-
localization as highlighted in the expanded views (figure 11. bottom panels).  
Accompanying control immunofluorescence images of single point mutations at the 
Ser
631
 (S631A and S631E) phosphorylation site indicate that the punctate pattern and 
Rab5 co-localization is dependent on the dephosphorylation at Ser
58
 (figure 12. first two 
rows).  Likewise, the single catalytically inactive mutant (C417S) and double 
dephosphorylation mutant (S58E/S631E) both displayed the characteristic cytoplasmic  
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Figure 11. Dephosphorylation of catalytically inactive MTMR2 at Ser
58
 localizes to 
Rab5-positive endosomes irrespective of Ser
631
 phosphorylation 
 
HeLa cells were transfected with FLAG-MTMR2 catalytically inactive phospho-variant 
(S58A/C417S/S631E) for 42 h and analyzed by immunofluorescence microscopy (red).  
After fixation, cells were immunostained with anti-FLAG antibody. Cells were probed 
for endogenous APPL1 (green: top panels center), Rab5 (green: lower panels center) and 
FLAG-MTMR2 (red: left panels). Merged images are shown on the right panels with 
yellow vesicles and white arrows indicative of vesicle co-localization. Top panels with 
expanded views indicate lack of vesicle co-localization with APPL1.  Boxes indicate 
regions of interest and are presented in expanded views.  Images were collected using 
40xoil and 63x objectives.  The scale bar represents 15 µm. 
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Figure 12. MTMR2 mutations lacking dephosphorylation of Ser
58
 display dispersed 
cytoplasmic localization  
 
HeLa cells were transiently transfected with FLAG-MTMR2 phospho-variants for 42 h 
and analyzed by immunofluorescence microscopy. Cells were probed for endogenous 
Rab5 (green) and FLAG-MTMR2 (red).  Images were collected using 63x objectives. 
The scale bar represents 15 μm. 
 
 
 
 
 136 
staining as observed with wild-type and lacked any Rab5 co-localization (figure 12. 
bottom  two rows).  Collectively, the strong co-localization of Rab5 and the inactive 
S58A/C417S/S631E mutant combined with the previously reported data of inactive 
S58A/C7417S is highly suggestive of the requirement of Ser
58
 dephosphorylation and 
Ser
631
 phosphorylation for localization to Rab5 positive endosomes [17].  
3.9 Endocytic PI(3)P depletion is dependent on Ser
58
 dephosphorylation and Ser
631
 
phosphorylation 
Because dephosphorylation of Ser
58
 results in PI(3)P depletion at Rab5-positive 
vesicles (Chapter 2. figure 7), it was relevant to evaluate whether dephosphorylation at 
the additional Ser
631
 site could also play a role in this process [17].  As mentioned 
previously, the S58A/S631A mutant was found to localize to and enlarged APPL1 
endosomes presumably as a result of effects on the early endosomal PI(3)P levels.  In 
order to address if this mutant had any large effect on cellular PI(3)P levels, we co-
expressed the S58A/S631A and S58A/S631E mutants with EGFP-2xFYVE in HeLa cells 
and performed immunofluorescence analysis (figure 13).   
Co-expression of the S58A/S631A mutant with EGFP-2xFYVE revealed that 
there was no effect on the localization of the PI(3)P marker as displayed by the punctate 
staining pattern and lack of any co-localization (figure 13. top two rows).  Interestingly, 
when our dephosphorylation Ser
58
 mutant was phosphorylated at Ser
631
 (S58A/S631E), 
we observed a complete loss of the characteristic punctate staining pattern for the PI(3)P 
marker similar to what we had observed previously for S58A (figure 13. bottom two 
panels).  These results suggest that Ser
58
 dephosphorylation and Ser
631
 phosphorylation is 
necessary for efficient PI(3)P depletion at Rab5 positive early endosomes.  
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Figure 13. Dephosphorylation at Ser
58
 and phosphorylation at Ser
631
 induces PI(3)P 
depletion at Rab5 early endosomes  
 
HeLa cells were co-transfected with EGFP-2xFYVE (green) and FLAG-MTMR2 
combination phospho-variants; S58A/S631A (top panels) and S58A/S631E (bottom 
panels) for 42 h and analyzed by immunofluorescence microscopy.  After fixation, cells 
were incubated with anti-FLAG antibody and Alexa Fluor
® 
568 (red).  The punctate 
endosomal pattern of EGFP-2xFYVE remains with S58A/S631A displaying lack of 
vesicle co-localization following saponin (0.01%) treatment.  Images were collected 
using 40x (top panels) and 63x (lower panels) objectives.  The scale bar represents 15 
µm. 
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Figure 14. Inducible PI(3)P depletion at early endosomes is dependent on MTMR2 
catalytic activity  
 
HeLa cells were co-transfected with EGFP-2xFYVE (green) and FLAG-MTMR2 
catalytically inactive phospho-variants (red); S58A/C417S/S631A (top panels) and 
S58A/C417S/S631E (bottom panels) for 42 h and analyzed by immunofluorescence 
microscopy.  After fixation, cells were immunostained with anti-FLAG antibody.  The 
punctate endosomal pattern of EGFP-2xFYVE remains with S58A/C417S/S631A 
displaying partial co-localization of vesicles following saponin (0.01%) treatment. Boxes 
indicate regions of interest and are presented in expanded views.  White arrows indicate 
vesicles displaying co-localization and purple arrow distinguish individual vesicles 
lacking co-localization.  Images were collected using 40x oil objectives.  The scale bar 
represents 15 µm. 
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Figure 15. Modifications at  Ser
631
 does not induce PI(3)P depletion   
 
HeLa cells were co-transfected with EGFP-2xFYVE (green) and FLAG-MTMR2 (red) 
phospho-variants; S58E/S631A, S631A, S58E/S631E and S631E (left panels) for 42 h 
and analyzed by immunofluorescence microscopy.  After fixation, cells were 
immunostained with anti-FLAG antibody.  The punctate endosomal pattern of EGFP-
2xFYVE remains with all constructs implicating lack of endosomal targeting and PI(3)P 
depletion. Images were collected using 63x objectives.  The scale bar represents 15 µm. 
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Furthermore, similar to inactive S58A/C417S, the S58A/C417S/S631E mutant 
displayed nearly complete co-localization with the PI(3)P marker EGFGP-2xFYVE both 
without and following saponin treatment (figure 14. bottom panels).  Intriguingly, 
S58A/C417S/S631A which was shown to localize to APPL1 endosomes displayed partial 
regions of co-localization with the PI(3)P marker (figure 14. top panels).  Initially, it was 
hypothesized that there would not be any regions of co-localization considering that there 
were no effects of the localization of EGFP-2xFYVE observed following co-transfection 
with the active S58A/S631A mutant.  However, APPL1 endosomes are shown to contain 
relatively small amount of the PI(3)P lipid wherein staining for endogenous APPL1 with 
cells transfected with EGFP-2xFYVE displayed a small subset of vesicles that showed 
coalescent regions of co-localization compared to Rab5 (Supplemental figure 6).  
Additionally, co-transfection of EGFP-2xFYVE with inactive MTMR2 (C417S) or single 
and combined modifications at Ser
631
 with did not induce PI(3)P depletion (figure 15).     
3.10 Effects of dephosphorylation at Ser
58
 and Ser
631
 on EGF signaling 
Previously we have determined that endosomal targeting of MTMR2 is mediated 
through dephosphorylation at Ser
58
 and subsequently results in earlier and pronounced 
signaling events particularly with respect to ERK1/2.  Additionally, Zoncu et.al 
demonstrated that prolonged residency of receptors within APPL1 endosomes, resulted in 
extended receptor signaling as monitored by the activation of key signaling pathways 
including ERK1/2 and Akt [1].  Considering that dephosphorylation at Ser
58
 and Ser
631
 
appears to mediate targeting to APPL1 endosomes, we therefore sought to examine the 
potential effects on downstream signaling events following EGF stimulation (figure 16). 
 To test this hypothesis, HEK293 cells were transfected with wild-type, S58A and 
S58A/S631A and activation of signaling pathways were examined by immunoblotting.  
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Figure 16. Dephosphorylation of Ser
58
 and Ser
631
 triggers sustained ERK1/2 
activation 
 
(A) HeLa cells were transfected with wt FLAG-MTMR2, S58A or S58A/S631A and 
serum starved for 30 min then treated with 5 ng/ml EGF for the indicated times. Lysates 
were immunoblotted (IB) for pERK1/2 and pAkt following EGF stimulation using the 
Pathscan
®
 Multiplex antibody. Total ERK1/2 levels served as loading control. Lysates 
were immunostained with anti-FLAG to confirm equal expression. (B) ERK1/2 
phosphorylation levels were quantified by densitometry using Image J, and normalized to 
total ERK1/2 levels. The values indicate the mean ±S.D. (n =3). 
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HEK293 cells were left untreated and additionally treated with EGF stimulation 
following a 30 min serum starvation for various time periods and the downstream 
phosphorylation of accompanied downstream EGFR targets was monitored.  As observed 
previously, a reproducible increase in the phosphorylation of ERK1/2 was observed with 
cells expressing S58A as compared to wild-type which was predominantly enhanced at 
the earlier time point of 5 min (figure 16.A top panel).  Densitometry analysis revealed 
approximately a 40% increase in the relative pERK1/2 expression levels with S58A 
compared to wild-type at the 5 min time period and relative to total ERK1/2 control 
levels (figure 16.B).  Although not as pronounced, we additionally observed a 
reproducible and detectible increase in pAkt with S58A.  In contrast, cells transfected 
with S58A/S631A displayed a large increase in activation of both ERK1/2 and Akt at the 
earlier time period of 5 min post EGF stimulation compared to S58A (figure 16.A).  
Interestingly however, the increase in pERK1/2 was sustained following prolonged EGF 
stimulation for the full length of the study (60 min) while pAkt levels appeared to 
diminish around 30 min.  Accompanying densitometry analysis revealed that there was 
nearly a 50% and 80% difference at the 15-30 and 60 min time periods respectively for 
cells expressing S58A/S631A compared to both wild-type and S58A (figure 16.B).  
Altogether, these results are suggestive that the targeting of MTMR2 to APPL1 
endosomes is mediated by dephosphorylation at Ser
58
 and Ser
631
, which then causes the 
„block‟ of APPL1 endosome maturation and compartment expansion, generated by 
PI(3)P depletion at the early endosomes and collectively leads to increase in EGFR 
receptor signaling.  
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DISCUSSION 
 
PART I) MTMR2 Phosphorylation is mediated by MAPKs 
3.11 ERK1/2 Regulates MTMR2 Phosphorylation at Ser
58
  
An essential requirement for the efficient transmission of extracellular signals 
through correctly modulating signal transduction systems is through the fast cellular 
responses upon the receipt of a particular stimulus.  The MAPKs are a primary route for 
signal activation in response to extracellular signals and through the step-wise activation 
of downstream targets, leads to biological responses affecting growth, proliferation, 
apoptosis, differentiation and survival [18].  In particular, a number of MTMRs have 
been linked to survival and pro-/apoptotic events in which a gene silencing (loss of 
function) approaches were utilized [19,20-22].  The knockdown of MTMR2 lead to a 
dramatic decrease in Schwann cell proliferation and resulted in the activation of caspase-
dependent pro-apoptotic events in Rat Schwann cell cultures [19].  However, the direct 
mechanism(s) through which MTMRs promote cell survival have yet to be identified 
although results implicate that they have important roles in addition to regulating cell 
growth through specifically linked signaling transduction pathways.   
In the current work we have examined the phosphorylation of MTMR2 at Ser
58
 in 
vitro and through the use of activity assays show that ERK1/2 specifically phosphorylates 
Ser
58
 (figure 1).  MTMR2 dephosphorylation at Ser
58
 could lead to greater ERK1/2 
activation as we have previously shown in our signaling experiments [17].  The effects of 
increased and prolonged ERK1/2 activation, may lead to targeted Ser
58
 phosphorylation 
through a type of negative feedback loop as a mechanism to regulate ERK1/2 signaling.  
Our results indicate that ERK1/2 inhibition resulted in endosomal localization of wild-
type MTMR2 as displayed by the punctate distribution similar to S58A (figure 3).  Both 
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ERK1 and ERK2 are nearly indistinguishable, that is they share 85% sequence identity 
and most often utilize the same physiological substrates both in vitro and in vivo [23].  A 
type of mechanism that kinases and in particular MAPKs utilize for precisely maintaining 
signal specificity and efficiency is through the interaction with their substrates and 
regulators through high-affinity docking sites.  Primarily, both ERK1 and ERK2 have 
been shown to phosphorylate substrates containing a consensus MAPK docking sequence 
that consists of a cluster of about two or three basic residues (H/K/R), a short spacer (X), 
and a hydrophobic-X-hydrophobic submotif (Φ) that is usually I/L such as (H/K/R2–3-X1–
6-Φ-X-Φ) [24].  For example, ERK has been shown to phosphorylate PKCα through 
association of the ERK consensus domain (S/T-P) and two docking sites KRGRIYL and 
KRGIIYRDLKL [24].  However, there are no „exact‟ consensus docking sites located in 
full length wild-type MTMR2.  It is notable to mention there are two small regions near 
the C-terminus that moderately resemble the minimal conserved docking site sequence 
391
HIKLIL
396
 and 
571
RHLEL
575
.  These regions could potentially serve as additional 
recognition motifs for the recruitment of ERK1/2, yet in order to fully address the 
significance of these potential MAPK docking regions, further mutational analysis and 
accompanying co-immunoprecipitation experiments are required. The effects of 
increased and prolonged ERK1/2 activation, may lead to targeted Ser
58
 phosphorylation 
through a type of negative feedback loop and as a mechanism to regulated ERK1/2 
signaling.  However, experimental evidence within in vivo systems is an additional 
necessity in order to fortify that the protein of interest is phosphorylated by the suspected 
kinase.  In addition to altered subcellular localization following MAPK inhibition, we 
also examined changes in Ser
58
 phosphorylation following EGF treatments, a known 
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MAPK stimulus.  We found that Ser
58
 phosphorylation was dramatically decreased 
following serum starvation which was then restored to normal levels following ERK1/2 
activation by EGF stimulation (figure 4).  Moreover, following ERK1/2 inhibition and 
subsequent EGF stimulation, there was no change and/or increase in Ser
58
 
phosphorylation levels.  Collectively, these results support our in vitro kinase assays 
implicating ERK1/2 as regulating Ser
58
 phosphorylation. 
Sustained and transient ERK1/2 activation are critical steps in Schwann cell 
development and it is of importance to examine whether ERK1/2 mediated MTMR2 
phosphorylation affects Schwann cell differentiation including myelination events [25].  
The relationship of MTMR2 phosphorylation to ERK1/2 signaling and Schwann cell 
myelination events could be suggested that altered Ser
58
 dephosphorylation would 
prevent endosomal targeting.  Ultimately this could lead to lowered ERK1/2 signaling 
following extracellular stimulation that may lead to downstream effects in myelination 
processes.  Previous research has demonstrated that MTMR2 is highly expressed at the 
onset of myelination, yet the levels of MTMR2.Ser
58
 phosphorylation at these stages is 
not known [25,26].  To fully understand the relationship of MTMR2 phosphorylation and 
myelination, DRG-Schwann cell co-culture experiments can be conducted to analyze the 
levels of Ser
58
 phosphorylation at the differential stages of myelination.  In this way, a 
relationship of MTMR2 phosphorylation with disease relevancy to Schwann cell 
myelination may be unveiled.   
3.12 Inhibition of ERK1/2 and JNK1 Regulates APPL1 Endosomal Targeting               
 
Extracellular stimuli at the plasma membrane transmit biological signals 
throughout the cell via complex systems of highly organized protein-protein interactions 
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and activation of signal cascades, ultimately travelling through cytoplasmic 
compartments to the nucleus where gene transcription is modulated.  The idea that 
receptors can signal in endocytic compartments has only been explored within the last 
few years [1,27].  However, the particular extent to which endosomes participate in signal 
transduction events is not well established [27].  There have been functional connections 
discovered between the small GTPase Rab5 and endocytic flow.  An example which 
highlights this is the Rab5 activation cycle that can additionally be modified by 
extracellular stimuli.  Stimulation by EGF results in an increase in endocytosis through 
activation of the GEF RIN1 which promotes the conversion of Rab5-GDP to its active 
GTP bound state therein controlling the initial fusion events [28].  It has been determined 
that activated Ras functions upstream of Rab5 by influencing RIN1 activity and 
ultimately adding an additional regulatory mode for controlling Rab5 activation [28].  
The small GTPase Ras is an important initial player in signal transduction leading to 
activation of the Ras-Raf-MEK-ERK1/2 pathways resulting in downstream effects on 
growth, differentiation and development [28].  Tall et.al identified that lack of RIN1 
activity lead to a dramatic increase in ERK1/2 phosphorylation providing a link of Ras 
and RIN1 activity to cell signaling events [28].  What these results indicated was that the 
prevention of endocytosis through the inability of Rab5 to become activated by RIN1 was 
resulting in halted progression of endocytosis. It also suggests that these events were 
enhancing the length of receptor containment within endocytic vesicles allowing for 
increased and prolonged receptor signaling.   
Importantly to note is that activated Rab5 localization to early endosomes is 
promoted not only by the activity of GEFs but is also regulated PI(3)P, which is present 
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on these subcellular organelles.  The inter-conversion of different PI species is controlled 
and maintained by PI-kinases and PI-phosphatases.  MTMR2 in particular, has been 
shown to regulate the levels of PI(3)P and more recently, we have determined that it 
preferentially controls the levels of PI(3)P at the early endosomes [17].  Therefore, events 
which promote MTMR2 endosomal targeting such as Ser
58
 dephosphorylation may in 
part play a role in regulating Rab5 localization and signaling events linked to the MAPK 
and more specifically the ERK 1/2 cascade.    
The well characterized MAPK pathways are tightly regulated and controlled in 
such a manner as to modulate the appropriate steps in endocytosis which can in turn, alter 
subcellular localization of proteins in addition to their activity if over stimulated or 
inhibited.  Considering that our data implicates ERK1/2 as regulating Ser
58
 
phosphorylation, it was therefore hypothesized that ERK1/2 inhibition may result in 
MTMR2 localization similar to our observations with S58A.  Intriguingly, MTMR2 
preferentially localized to Rab5 positive endosomes following ERK1/2 inhibition (figure 
5 second row) as opposed to the precursor APPL1 endosomes (figure 6 second row) 
indicating that Ser
58
 dephosphorylation as represented by ERK1/2 inhibition, specifically 
localizes MTMR2 to the early Rab5-endosomes.   
The JNK pathway has been previously shown to augment recycling of the 
Transferrin receptor via direct phosphorylation of the Rab-guanine nucleotide 
dissociation inhibitor (GDI) that is complexed to Rab11a in which Rab11a is stabilized by 
JNK phosphorylation of RabGDI [84].  Inhibition of JNK can alter receptor recycling as 
a result of inactivity of RabGDI and altered subcellular localization in which the Rab11a 
and RabGDI complex can no longer form.  In addition, it has also been shown that p38-
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mediated phosphorylation of RabGDI complexed to Rab5 modulates Rab5 activity 
[29,30].  It has been previously determined that p38 regulates RabGDI activity in the 
cytosolic cycle of Rab5 activation thereby stimulating the formation of the GDI:Rab5 
complex [29,30].  Moreover, p38 activation modulates and increases endocytic rates in 
vivo promoting more efficient receptor internalization [31]. Therefore, it was expected 
that we observe some extent of Rab5 co-localization following dephosphorylation of 
Ser
58
 with ERK1/2 inhibition however when MTMR2 was overexpressed in HeLa cells 
and probed for Rab5 following combined inhibitor treatments for ERK1/2 and/or JNK1 
we did not observed any regions of co-localization which presumably may be a result of 
altered Rab5 localization (figure 5. bottom two rows).  In order to fortify that JNK1 or 
p38 inhibition was affecting the endogenous localization of Rab5, it would be of interest 
to examine the normal localization patterns of both these MAPKs with Rab5 preceding 
and following inhibition. 
APPL1 is an adaptor protein that has been shown to interact through the PTB 
domain with the catalytic subunit of PI3K, phosphoinositide-5-phosphatases and Akt 
[19,32].  It has also been suggested that APPL1 functions as an adaptor that is linked to 
distinct signaling pathways, and has been implicated as a Rab5 effector considering that it 
only interacts with Rab5 in the GTP-bound state [32].  Recently, Chial et.al suggested 
that APPL1 may function as a molecular scaffold contributing to the initial complete 
organization of Rab5 dependent trafficking events and regulation of Rab5 subdomains in 
the early stages of endocytosis [32].  Moreover, APPL1 contains a PH domain that 
mediates interaction with PIs and can simultaneously allow for interaction with other 
proteins through its PTB domain [19,32].  The inter-conversion of APPL1 and the 
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canonical Rab5 early endosomes is highly dependent on the acquisition of PI(3)P.  Zoncu 
et.al (2009) have demonstrated that as the levels of PI(3)P increase, APPL1 is shed from 
the endosomes and FYVE domain containing proteins such as EEA1 are then recruited 
ultimately generating the characteristic Rab5-early endosomes [1].  In hindsight, the loss 
of PI(3)P resulted in the „back-conversion‟ of EEA1 endosomes to generate enlarged 
APPL1 vesicles and prevention of the formation of the early endosomes.  The particular 
reasons for vesicle enlargements are not fully understood although it has been 
hypothesized that the loss of PI(3)P results in the „blockage‟ of endocytosis flow and 
hence prolongs the residency of receptors in these compartments which then accumulate 
[1,33,34].  The results presented here support a critical role of MTMR2 subcellular 
regulation by both JNK1 and ERK1/2.  We show that MTMR2 targeting to APPL1 
vesicles is highly dependent on the inhibition of both ERK1/2 and JNK1 indicating that 
MTMR2 localization is tightly controlled by reversible phosphorylation (figure 6).  
Moreover, the finding that localization to APPL1 endosomes partially resulted in the 
enlargement of colocalized vesicles, suggest that the levels of PI(3)P at the early 
endosomes were affected as a result of MTMR2 targeted depletion, similar to previous 
observed studies with MTM1 [1].  These studies also suggest an alternative role for 
MTMR2 in the earliest stages of endocytosis, which in part may be regulated by 
phosphorylation of an additional C-terminal site (Ser
631
) on MTMR2 that is controlled by 
JNK1.  Therefore, our results are highly suggestive that JNK1 may in part govern the 
phosphorylation of Ser
631
 and regulation of this site may be dependent sequentially on 
Ser
58
 phosphorylation by ERK1/2.  
The shortcoming of utilizing inhibitors is that numerous other targeted systems   
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can also be affected.  Therefore, to eliminate the possibility that combined ERK1/2 and 
JNK inhibition could be affecting APPL1 localization we explored single inhibitor 
treatments using the phosphorylation-deficient mutant S58A.  Under untreated conditions 
S58A displayed the characteristic punctate localization with lack of APPL1 co-
localization as expected.  However JNK1 inhibition resulted in complete APPL1 co-
localization and an increase in vesicle area nearly three times (figure 7. top two panels, 
Appendix 2. Table 1).  Moreover, combined inhibitor treatments of ERK1/2 and JNK1 
resulted in a similar localization pattern and effect on the overall area of colocalized 
vesicles at nearly the same amount (figure 7. bottom panel).  It would be of great interest 
to monitor the localization of both EGF and EGFR to determine if they also reside and/or 
accumulate in these vesicles.  Thus, the precise mechanism underlying the shuttling of 
MTMR2 between Rab5 endosomes (ERK1/2 inhibition) and APPL1 vesicles (ERK1/2 
and JNK1 inhibition) remains to be fully elucidated at this time.   
PART II) Characterization of the MTMR2.Ser
631
 Phosphorylation Site 
3.13 Reversible Phosphorylation at Ser
631
 Targets MTMR2 to Specific PI(3)P Pools 
Because of the effects we observed on MTMR2 localization following ERK1/2 
and JNK1 inhibitor treatments, it was relevant to generate a series of phospho-mutants to 
test our hypotheses.  Expression of single Ser
631
 MTMR2 mutants alone did not result in 
altered MTMR2 subcellular localization nor localization to APPL1 or Rab5 positive 
vesicles (figure 8).  Interestingly, expression of a double phosphorylation deficient 
mutant S58A/S631A resulted in complete loss of cytoplasmic localization and to a 
greater extent, co-localization with and to a partial degree enlargement of APPL1 
endosomes (figure 8 top row).  Moreover, the explicit localization to APPL1 as opposed 
to Rab5 endosomes following the sequential dephosphorylation of Ser
58
 and Ser
631
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implies that reversible phosphorylation governs multiple roles in MTMR2 regulation 
(figure 9).  Further investigations into the potential cross-talk between these two sites 
revealed that targeting to Rab5 endosomes was highly dependent on Ser
58
 
dephosphorylation (S58A) and Ser
631
 phosphorylation (S631E) events, which in turn 
prevented targeting of MTMR2 to APPL1 vesicles (figure 10).  This might provide an 
additional level of regulation in order to control the extent of MAPK signaling by 
regulating MTMR2 localization and trafficking between Rab5 and APPL1 endosomes, 
thereby controlling the flow of endocytosis by modulating the levels of PI(3)P at distinct 
stages.  These results are highly suggestive that dephosphorylation of both Ser
58
 and 
Ser
631
 is necessary to regulate MTMR2 targeting to APPL1 endosomes, and sufficiently 
requires Ser
58
 dephosphorylation for initial vesicle targeting.   
Accumulating evidence suggests that PI(3)P plays a critical role not only in the 
initial fusion events at the early endosomes and the initial receptor sorting, but also 
regulates the bulk transport from the early to late endosomes [1,35,36-38].  Moreover, the 
lack of PI(3)P particularly at the early endosomes prevents the transport of down-
regulated receptors to the late endosomes for degradation and that these receptors then 
remain trapped at the early endosomes [35].  The signaling events related to correct 
PI(3)P levels primarily have been associated with the control of sorting rather than 
receptor transport, meaning that the fate of receptors is in part governed by other factors 
that regulate lipid levels at differential stages in endocytosis.  We have evidence that 
supports the notion in which a subset of APPL1 vesicles contain a modest levels of 
PI(3)P in comparison to Rab5 positive endosomes (Supplemental figure 6).  Although our  
evidence and published data supports this notion, for the direct associated to Rab5- 
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dependet trafficking, further experimental evidence utilizing live cell imaging would be 
required.   
The lack of APPL1 co-localization and positive Rab5 co-localization with the 
S58A/S631E mutant (figure 11), leads us to postulate that the phosphorylation at Ser
631
 
and lack thereof at Ser
58
 may target MTMR2 to PI(3)P rich Rab5 endosomes. 
Additionally this could suggest that conformational changes may occur in the distant 
regions of the protein that potentially allow for greater substrate accessibility and/or 
interaction with accessory proteins that regulate trafficking to and from the early 
endosomes.  Moreover, the lack in Rab5 localization following single modifications 
within the active site Cys residue of MTMR2 and the distant C-terminal Ser
631
 provides 
further justification that dephosphorylation at Ser
58
 is the main event controlling 
subcellular targeting (figure 12).  This implies that MTMR2 structural rearrangements 
occur following post-translational modification by reversible phosphorylation.  Ongoing 
in vitro HDX experiments in our laboratory with these mutants should clarify the 
conformational dynamics in response to MTMR2 phosphorylation. 
Physiological conditions which regulate phosphorylation cross-talk between these 
two sites might be important. Interestingly, under high stress such as hypoosmotic shock 
activate both ERK1/2 and JNK1 pathways. We hypothesize this would result in Ser
58
 and 
Ser
631
 phosphorylation and prevent early endosomal targeting of MTMR2.  Additionally, 
hypoosmotic shock has been shown to boost the levels of PI(3,5)P2 wherein its presence 
in living systems is general present at very low amounts.  We speculate that MAPK 
activation in response to hypoosmotic shock could lead to phosphorylation of MTMR2 
and subsequently release from endocytic vesicles leading to increase in PI(3,5)P2 levels.   
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The phosphatase activity of MTMR2 towards PI(3,5)P2 in vitro is highly compar-  
able to PI(3)P however, there has yet to be identified in vivo, signals that trigger  
localization to compartment(s) rich in this substrate.  In this respect, if two pathways are 
activated which govern MTMR2 phosphorylation those including ERK1/2 and JNK1 
thereby resulting in Ser
58
 and Ser
631
 phosphorylation, this could be indicative of the 
mechanism through which MTMR2 is targeted to regions rich in its other physiological 
substrate PI(3,5)P2.  However, more detailed investigations into the particular 
relationship(s) of dual MTMR2 phosphorylation at Ser
58
 and Ser
631
 which could 
potentially be involved in the receptor and/or protein degradation pathway by regulating 
the levels of PI(3,5)P2 in the cellular stress response system are required. 
3.14 Early Endosomal PI(3)P Depletion is Mediated by Reversible Ser
58
 and Ser
631
 
Phosphorylation  
 
The dissociation of APPL1 from endosomes correlates with accumulation of 
PI(3)P and in turn the recruitment of FYVE domain containing proteins including EEA1 
and WDFY2 [1].  It has also been implicated that the generation of PI(3)P thereby 
functions as the molecular switch that controls the maturation into the canonical early 
endosomes.  It is suggested that PI(3)P and APPL1 may compete for a limited number of 
binding sites on Rab5 positive endosomes.  When PI(3)P was depleted, binding of 
APPL1 to Rab5 positive endosomes was dramatically increased at the sites that had lost 
PI(3)P.  More specifically, the study by Zoncu et.al (2009) utilized wortmanin to inhibit 
PI(3)P production and also targeted MTM1 to PI(3)P rich endosomes in order to 
effectively deplete massive cellular levels of PI(3)P [1].  Moreover, it was determined 
that attenuating APPL1 binding on endosomes by PI(3)P generation, allowed for the 
proficient and stabilization of EEA1 binding to Rab5 endosomes.  In this competition-
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type of scenario it can be suggested that both kinases and phosphatases that regulate 
PI(3)P, ultimately could control the signaling and maturation properties of endocytosis 
events following through these particular stages.  In this respect, dephosphorylation of 
MTMR2 at Ser
58
 and Ser
631
 which we have shown targets this lipid phosphatase 
specifically to APPL1 endosomes, could in turn also regulate the inter-conversion and/or 
intermediate processes en route to the early endosomes.  Therefore, the catalytic activity 
of MTMR2 would be required in order to successfully deplete PI(3)P. The localization of 
the PI(3)P rich marker EGFP-2xFYVE is not affected when MTMR2 is 
dephosphorylated at both these site however only when Ser
631
 is phosphorylated can 
MTMR2 directly localize to Rab5 endosomes and effectively deplete PI(3)P (figure 13).  
This implicates that the C-terminal Ser
631
 site functions as an additionally regulatory 
mechanism that controls MTMR2 regulation and potentially serves as the prime switch 
that governs targeting to APPL1 endosomes and in turn, trafficking into and between the 
early endosomes.  While this direct link cannot be completely vindicated from these 
results and would require further validations including experiments such as live-cell 
imaging, the significance of these findings cannot be underscored.   
Only recently has it been determined how MTMR2 regulates and controls the 
levels of PI(3)P and how this is associated with endocytic events, yet in eukaryotic 
systems there can be suspected to be a more complex underlying regulation to avoid 
repercussions [17].  Additionally, the question arises as to what consequence would be 
derived following loss of this regulation particularly by loss of MTMR2 catalytic 
function?  The lipid phosphates activity of MTMR2 has been shown in numerous systems 
to be critical, yet how this alters its function is not fully understood.  Our observations 
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indicate that when MTMR2 is dephosphorylated at Ser
58
 and Ser
631
 it results in targeting 
to APPL1 endosomes, yet the loss of activity in this respect, only partially resulted in 
localization to PI(3)P containing regions as opposed to those highly rich in its substrate 
(figure 14).  This partial localization and previously determined lack of effect on PI(3)P 
marker distribution, implicates that the additional regulatory features surrounding 
reversible Ser
631
 phosphorylation are more strictly regulated than initially anticipated.  It 
was surprising to observe co-localization between S58A/C417S/S631A and  the PI(3)P 
marker EGFP-2xFYVE because we did not observe any PI(3)P attenuation with 
expression of active MTMR2 (S58A/S631A).  The subset of vesicles observed that 
displayed direct co-localization with the marker when MTMR2 was dephosphorylated at 
both sites; suggest that MTMR2 could potentially have a function in the intermediate 
stages of conversion between APPL1 and Rab5 endosomes and result in the accumulation 
of PI(3)P in these compartments.  Moreover, it was again determined that only once 
Ser
631
 was phosphorylated (S58A/S631E) would MTMR2 then localize to compartments 
that were highly rich in PI(3)P.  Conversely, the Ser
631
 single mutant (S631E) or in the 
case that Ser
58
 was phosphorylated (S58E, wt) did not affect localization and/or PI(3)P 
levels (figure 15).  This supports the observation that the endosomal targeting of MTMR2 
is regulated by dephosphorylation at Ser
58
.  Taken together, these results implicate that 
the N-terminal Ser
58
 and C-terminal Ser
631
 function co-ordinately to mediate the 
appropriate MTMR2 subcellular targeting and effectively, the specific dephosphorylation 
of the lipid substrate.   
3.15 Dephosphorylation of MTMR2 Ser
58
 and Ser
631
 results in sustained ERK1/2 
activation 
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The long held concept of endocytosis is primarily that it is used as a mechanism 
to regulate receptor signaling by degrading these receptors following their internalization 
thereby perpetuating the corresponding signals [45,46].  Moreover, it has been 
accustomed that following receptor internalization, their bound ligands/stimuli become 
dissociated and hence, these receptors are no longer capable of signaling.  More recent 
evidence however oppose this theory and suggest that once receptors become activated 
and in turn internalized, they can continue to signal via distinct endosomal compartments 
following their internalization [1,45].  In particular, the Akt and MAPK pathways have 
been linked to the signaling capacity of EGFRs and the neuronal growth factor receptor 
TrkA,  particularly through interactions with the adaptor protein APPL1 [44].  The 
signaling strength however, varies within different systems in addition to extent of the 
stimulus.  More specifically, there has been evidence determined that has linked the 
formation of the APPL1 compartments and the residency time of these receptor within 
these sub-organelles, directly to the signaling capacity of these newly defined endosome 
subpopulations [1].   
Activation of the Akt and MAPK signaling pathways are critical in a number of 
biological processes and it has been shown that the loss of APPL1 on endosomes is 
mediated primarily in a PI(3)P dependent fashion and is also associated with decreased 
receptor signaling which in turn lowers the activation of corresponding cascades [1].  In 
our system, we identified that dephosphorylation of both Ser
58
 and Ser
631
 resulted in 
APPL1 endosomal targeting and sustained ERK1/2 activation and to a lesser extent 
prolonged Akt activation (figure 16).  These data support the hypothesis that the 
reversible phosphorylation of MTMR2 at these two critical sites, targets MTMR2 to 
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APPL1 endosomes thereby prolonging the residency time of receptors within these 
compartments and hence, extending receptor signaling.  However, a question to ask is 
what are the structural feature(s) of the C-terminal Ser
631
 that particularly governs 
MTMR2 targeting to this unique and small endosome subpopulation?  As an example, 
PDZ-binding motifs have previously been shown to be important in anchoring proteins to 
the actin cytoskeleton in addition to holding together key signaling complexes [41-43].  
MTMR2 Ser
631
 resides near the C-terminal PDZ binding motif.  Considering that our lab 
has evidence indicating that dephosphorylation at Ser
58
 allows for greater solvent 
accessibility (i.e. a greater open-complex), it can be hypothesized that dephosphorylation 
at Ser
631
 may function in a similar manner.  That is, allow for greater access of MTMR2 
to other interacting proteins that assist in stabilizing these signaling complexes.  On the 
other hand, it may also provide additional docking sites for the recruitment of adaptor 
proteins that are dependent on and/or sensitive to PI(3)P levels on APPL1 endosomes.  
Similar HDX experiments in vitro would assist in identifying a structural relationship to 
reinforce this hypothesis.  Additionally, it would be of great interest to monitor EGFR 
trafficking following EGF stimulation with these mutants in order to definitively identify 
the localization of the active receptors with respect to particular stage of endocytosis. 
Although the direct relationship of MTMR2 endosomal targeting to ERK1/2 
signaling and activation cannot be definitively concluded from these studies, recent 
evidence surrounding ERK1/2 regulation can assist in comprehending how MTMR2 may 
play a functional role.  Under basal conditions, ERK1/2 activation triggers 
phosphorylation of the MKP-1 protein phosphatase at two Ser residues in the extreme C-
terminus thereby stabilizing MKP-1 which in turn, functions via a negative feedback 
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mechanism to transiently dephosphorylate and inactivate ERK1/2 [18].  However, MKP-
1 can also be phosphorylated at other sites within its C-terminus which then results in 
targeted ubiquitination and degradation [18].  Lin et.al (2003) have demonstrated that 
overexpression of the upstream kinase MEK1/2 which governs ERK1/2 phosphorylation, 
results in extended and increased strength of ERK1/2 activation [18].  The question arises 
as to how ERK1/2 can maintain signaling if its activation triggers MKP-1 stabilization 
and ultimately ERK1/2 inactivation?  It has been proposed that sustained ERK1/2 
activation may result in phosphorylation of other sites on MKP-1 that trigger down-
regulation thereby allowing prolonged ERK1/2 activation [18].  MTMR2 Ser
58
 
dephosphorylation mediates earlier ERK1/2 activation and accompanying 
dephosphorylation of Ser
631
 allows for sustained activation and signaling.  Thus we are 
interested in examining if dephosphorylated MTMR2 increases receptor residency that 
results in increase in MEK1/2 activation, or if it results in activation of a signaling 
cascade that targets MKP-1 stability. 
 Collectively, these results lead us to revise our initial proposed model of MTMR2 
regulation by reversible phosphorylation (figure 17_Proposed Model 2).  As previously 
stated, it is hypothesized that phosphorylation at Ser
58
 sequesters MTMR2 in the 
cytoplasm and that extracellular signal(s) are required to trigger dephosphorylation and in 
turn, endosomal targeting.  The efficient localization of MTMR2 to endocytic vesicles 
results in targeted PI(3)P depletion with resultant effects on endosomal maturation and 
signaling events.  Our recent evidence leads us to suggest that dephosphorylation of 
Ser
631
 is required for localization to APPL1 endosomes.  In contrast, regulation of Ser
631
 
phosphorylation may be regulated through the antagonistic action of JNK1 in order to 
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modulate the extent of receptor signaling in a transient fashion.  Conversely, APPL1 
endosomal targeting of MTMR2 results in extended ERK1/2 activation that in part, is 
controlled via a negative feedback mechanism in which sustained ERK1/2 signaling then 
results in the phosphorylation of Ser
58
 and hence, perpetuates and regulates the extent of 
receptor-endosome signaling events.  Zoncu et.al (2009) determined that the conversion 
of APPL1 endosomes that are en route to the classical Rab5-EEA1 early endosomes is 
mediated by the accumulation in the levels of PI(3)P [1].  Therefore consistent with this 
notion, the reversible phosphorylation of MTMR2 can be implicated to be a critical 
regulatory event controlling not only its subcellular localization, but ultimately regulate 
the flow of endocytosis and signaling events directly through controlling the levels of its 
substrate.  
  In addition to ERK1/2 activation, it will also be necessary to monitor pERK1/2 
localization following reversible MTMR2 phosphorylation.  The data presented here 
supports the hypothesis that MTMR2 dephosphorylation at both Ser
58
 and Ser
631
 triggers 
sustained ERK1/2 activation however, more recent data may also suggest that MTMR2 
could in fact additionally regulate pERK1/2 localization.  According to recent evidence 
by Liu et.al (2010) they have shown that repeated stimulation in cell culture using human 
lung epithelial cells (BEAS-2B) with cytokines such as Interleukin 13 (IL-13) resulted in  
sustained pERK1/2 activation leading to compartmentalization of pERK1/2 to Rab5 
endosomes [39].  Additionally, pERK1/2 was also excluded from the characteristic 
nuclear translocation wherein ERK1/2 is essentially sequestered into the cytosol and only 
following a priming stimulation can it then be translocated to the nucleus [39].  This is 
suggestive that prolonged and sustained pERK1/2 could prevent nuclear translocation and  
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in turn have transcriptional consequences that prevents the induced expression of a 
number of ERK1/2 target genes [39].  Furthermore, it can be postulated that other cellular 
events modulating ERK1/2 activation and signaling could potentially govern not only its 
localization, but also the transcription of down-stream regulatory genes.   
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Figure 17. Endosomal Targeting of MTMR2 is mediated by MAPKs 
 
Phosphorylation of Ser
58
 by ERK1/2 sequesters MTMR2 in the cytoplasm, thereby 
preventing PI(3)P depletion and promoting endosome maturation events. 
Dephosphorylation at Ser
58
 thus mediates endosomal targeting and PI(3)P depletion 
wherein subsequent Ser
631
 dephosphorylation targets MTMR2 to APPL1 endosomes and 
effectively determines the particular substrate lipid pool.  Prolonged residency of 
MTMR2 at APPL1 endosomes results in sustained ERK1/2 activation and endosomal 
signaling.  Phosphorylation at Ser
631
 by JNK1 prevents APPL1 targeting as a mechanism 
to control receptor signaling. 
 162 
CHAPTER 4 
Concluding Remarks and Future Directions 
MTMR2 is a highly conserved lipid phosphatase ranging from yeast to complex 
eukaryotes, yet the unique cellular functions that govern its regulation and how it is 
specifically linked to its biological substrates remains scarce.  Remarkably though, little 
is understood into the vast biological consequences of substrate dephosphorylation 
relatable to MTMR2 targeting and associated effects on signal transduction, in addition to 
its main role in regulating cellular mechanisms.  While MTMR2 seems to play a critical 
role in endocytosis events primarily due to the location of its substrates, it remains 
unclear as to the definitive role of MTMR2 in associative biological processes.  
The current study has provided significant insights into the regulation of MTMR2 
by reversible phosphorylation and how these events are linked to substrate targeting.  
Considering that MTMR2 shares high sequence similarity and function with several 
MTM family members particularly with respect to the phosphorylation sites examined in 
this study, it is possible that other MTM members may also be regulated in a similar 
manner.  Much emphasis can now be addressed into exploring the possibility that 
reversible phosphorylation may be the link between MTM substrate targeting and 
compartmental regulation.  Furthermore, our results point to a mechanism by which 
differential phosphorylation can not only govern MTMR2 subcellular localization, but 
also control the extent to which substrate pools are targeted.  This function likely entails 
highly mediated cross-talk between the two phosphorylation sites under study, through 
which their regulation may in turn, be controlled through uniform negative feedback 
loops with the associated kinases. 
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The aims of this study were to gain further understanding into the cellular 
mechanisms that govern MTMR2 biology particularly with respect to regulation by 
reversible phosphorylation.  More recently, Christopher Bonham from our lab has 
identified in vitro by HDX-MS that dephosphorylation at Ser
58
 results in greater solvent 
accessibility.  Presumably this suggests a mechanism by which dephosphorylation 
triggers conformational changes that ultimately lead to an open three-dimensional protein 
conformation thereby allowing greater access to the endosomal binding surface.  
Collectively, there is still a great deal of information to be elucidated, ultimately in future 
hopes of identifying the specific MTMR2 malfunctions that ultimately results in the 
prevalent and devastating CMT4B1 disease. 
Our next tasks will be to examine the in vivo alterations in Ser
58
 phosphorylation 
stoichiometry with various kinase inhibitors using MS and the pSer
58
 antibody 
accompanied by siRNA depletion of MAPKs in order to asses changes relatable to living 
systems.  Moreover, the importance of gaining further understanding into regulation by 
phosphorylation and how these mechanism can be relatable to associated CMT4B1 
features, it will be valuable to utilize Schwann cells in order to examine changes in the 
stoichiometry of Ser
58
 phosphorylation during different myelination stages.  Considering 
that MTMR2 has been determined to be highly expressed at the onset of myelination 
coupled to our results indicating that the definitive subcellular is controlled by differential 
phosphorylation, it would be of great interest to monitor changes in MTMR2 
phosphorylation at both Ser
58
 and Ser
631
 under various stimuli in addition to MTMR2 
CMT4B1 associated mutations.  It is likely that CMT4B1 mutations may inadvertently 
affect MTMR2 phosphorylation through a number of yet to be identified mechanism, as 
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research has previously shown that MTMR2 phosphorylation decreases with PH-GRAM 
domain mutations [40].  Ultimately, the goal is to examine the levels of MTMR2 
phosphorylation in patients affected with CMT in attempts to fully understand how 
MTMR2 regulation in this respect may potentially be associated with disease 
manifestations. 
Abnormalities in PI synthesis and turnover could potentially affect both cell 
survival factors and those mediating cell deaths.  Therefore, it could be proposed that 
decreased Schwann cell proliferation which is a characteristic feature of CMT4B1 could 
substantially be connected to impaired endocytosis leading to prolonged or over 
activation of receptors responsible for governing specific growth factor signaling 
cascades.  To better understand the mechanisms of action of MTMR2 and the relationship 
between the various proposed biological roles in vesicular trafficking, it is important to 
elucidate the structural features that are a consequence of dephosphorylation and how 
these could in turn, affect protein function and particularly localization.  Future 
experiments aimed at investigating structural changes that could occur, may yield 
valuable insights into the compartmentalization that accompanies Ser
58
 
dephosphorylation and the recumbent effects associated with changes in PI(3)P.  
Moreover, further investigations regarding the prolonged biological effects associated 
with sustained ERK1/2 activation and how this in particular is associated with 
myelination defects is of extreme importance and may provide the link between lack of 
functional MTMR2 and disease characteristics.     
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Supplemental Figure 1.  Sample preparation for analysis by MALDI-TOF 
 
HEK293 cells were transfected with wild-type MTMR2, immunoprecipitated and 
separated by SDS-PAGE.  The bands corresponding to the protein of interest were 
excised, and control samples were additional taken (C1: Control, C2: Gel control, E1: 
Experimental).  The gel pieces excised were subjected to in gel-trypsin digestion and 
analyzed by MADL-TOF. 
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Supplemental Figure 2.  Purification of Recombinant MTMR2 and Phospho-
variants 
 
IPTG induction was used to induced protein expression in BL21 cells transfected with 
PET-His6 vectors containing wt-MTMR2, S58A or S58E.  Cells were collected before 
addition of IPTG (uninduced) and following 16 h IPTG induction (induced). Protein 
purification was achieved by immobilization to HIS-select Ni
2+-
affinity resin followed by 
elution and collection of the supernatant containing the purified protein of interest 
(elution 1). 
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Supplemental Figure 3. S58A co-localizes with Rab5 and not with wild-type or S58E  
 
HeLa cells were transiently transfected with FLAG-wild-type-MTMR2 (A-C),  FLAG-
S58A (D-F), and FLAG-S58E (G-I). Following 42 h transfection, cells transfected with 
FLAG-S58A were pre-treated with 0.01 % saponin and all samples analyzed by 
immunofluorescence..  Expanded views of marked areas demonstrate Rab5 localization 
with S58A at distinct subcellular organelles.  Colocalized regions are indicated by open 
arrows and yellow in color merge.  Images were collected using 63x (top/lower panel) 
and 40x oil (middle panel) objectives.  The scale bar represents 15 µm. (shown 10 µm in 
expanded views) 
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Supplemental Figure 4.  MTMR2  dephosphorylation at Ser
58
 does not trigger late 
endosome targeting  
 
HeLa cells were transiently transfected with FLAG-wild-type-MTMR2 (A-C), FLAG-
S58A (D-F), or FLAG-S58E (G-I). Expanded views of positively transfected S58A HeLa 
cells following a 0.01 % saponin treatment with marked areas demonstrating absence of 
Rab7 localization and are indicated by closed arrows and in merge.  Images were 
collected using 63x (top and lower panel) and 40xoil (middle panel) objectives.  The 
scale bar represents 15 µm. (shown 10 µm in expanded views) 
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Supplemental Figure 5. Vesicle enlargement is dependent on MTMR2 S58A/S631A 
catalytic activity 
 
HeLa cells were transiently transfected with FLAG-MTMR2 S58A/C417S/S631A for 42 
h and analyzed by immunofluorescence microscopy.  After fixation, cells were incubated 
with anti-FLAG antibody and Alexa Fluor
® 
568 (red) and additionally stained 
endogenous Rab5 or APPL1 (green).  The lack of APPL1 vesicle enlargement is due to 
the loss of MTMR2 catalytic activity.  Images were collected using 63x objectives.  The 
scale bar represents 15 µm. 
 176 
 
 
Supplemental Figure 6. Subcellular localization of PI(3)P at endosomes 
 
HeLa cells were transfected with EGFP-2xFYVE (green) for 24 h and analyzed by 
immunofluorescence.  Following fixation, cells were immunostained for endogenous 
Rab5 or APPL1 (red).  Merged images are displayed to show regions of co-localization 
and are presented in expanded views.  Yellow indicates co-localization of endogenous 
markers to vesicles rich in PI(3)P. Images were collected using 63x objectives. Scale bar 
represents 15 µm.   
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Table 1. Summarization of Vesicle Size Measurements and Quantification 
 
The quantitative analysis of size measurements from individual cells reveals co-
localization with APPL1 results in increased vesicle area due to MTMR2 targeting and 
PI(3)P depletion.  Loss of activity with S58A/C417S/S631A indicate the requirement of 
phosphatase activity for vesicle enlargement.  The data is representative of the average 
area (μm2) each of 10 independently measured vesicles spanning 3 independent 
experiments.  The standard deviations (μm) were determined for each measured vesicle 
and is represented as the average from 3 separate trials.  Vesicle area determination was 
quantified using Image J with an analyze set scale to 15 μm based on image micrometer 
bars. 
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